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Abstract 
 
Burkholderia pseudomallei is a Gram negative bacterial pathogen and the causative agent 
of melioidosis, which is the third most frequent cause of death from infectious disease in 
Northeastern Thailand and also highly endemic in Southeast Asia and Northern Australia. 
Problems of melioidosis management include misdiagnosis and the increasing resistance 
of the bacteria to the current anti-infective treatment, resulting in high mortality and 
having a global impact as a potential bioweapon. Little is known about the ambiguous 
pathogenesis and virulence mechanisms of B. pseudomallei infection. One way to gain 
understanding is through the investigation of the structure/function relationships of 
potential target proteins, as a starting point for a rational drug discovery programme. 
Structural studies on the target proteins of B. pseudomallei can shed light on their 
biological functions at the molecular level. 
 
This thesis presents the structural studies on immunogenic proteins of B. pseudomallei as 
part of a targeted structural genomics programme on B. pseudomallei. Seven target genes 
were selected from lists of putative essential genes and also identified B. pseudomallei 
proteins that elicit an immuno cross reactivity to the sera of infected humans, which may 
be involved in virulence and/or pathogenicity of B. pseudomallei. Of those, BPSL0606, 
an uncharacterised protein, was cloned, over-expressed, purified, and crystallised. The 
first crystal structure of BPSL0606 was determined and revealed that it is structurally 
similar to the GCN5-related N-acetyltransferase (GNAT) superfamily. Dimer formation 
in the crystal packing agreed with gel filtration analysis and the interface of BPSL0606 
was similar to many GNAT members. Structure-based alignment of BPSL0606 against 
known structures of GNATs showed that BPSL0606 has conserved residues that are 
involved in the binding of acetyl coenzyme A in members of GNATs, suggesting that 
BPSL0606 may bind the acetyl coenzyme A. Although co-crystallization of BPSL0606 
and acetyl coenzyme A and ligand observation by nuclear magnetic resonance suggested 
that BPSL0606 did not bind to the acetyl coenzyme A. Analysis of the aminoglycoside 
binding site indicated that BPSL0606 could possibly bind to this substrate. The 
BPSL0606 structure with acetyl coenzyme A and kanamycin was modelled, proposing a 
possible clue related to the antibiotic resistance. The findings in this PhD thesis provide 
the molecular and structural information of B. pseudomallei proteins, which could 
contribute to further investigations.   
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Chapter 1: Introduction 
 
 
Despite the prevalence of antibiotics and immunisation regimes, infectious 
diseases retain their ability to kill and thus understanding their pathogenicity has 
important implications for human health. Melioidosis is one such infectious 
disease and is endemic in Southeast Asia and northern Australia (Currie et al, 
2008). The mortality of melioidosis is about 50% and 19% in northeast Thailand 
and northern Australia, respectively (Peacock, 2006). In northeast Thailand, 
melioidosis is currently the third most common cause of death from infectious 
diseases after HIV/AIDS and tuberculosis (Limmathurotsakul et al, 2010). The 
causative agent of melioidosis is a Gram-negative bacterial pathogen, 
Burkholderia pseudomallei (White, 2003).   
 
 
In addition, an anthrax attack in the United States in 2001, caused by 
contamination by bacterial spores of Bacillus anthracis, has raised public 
awareness of health security, and in particular the threat of bioterrorism (Pfeiffer, 
2009). Due to the high mortality of B. pseudomallei infections and its persistence 
in soil and ground water, the bacteria has the potential to be used as a bioweapon. 
Harmful and serious disease causing microorganisms have been categorised by 
the Centers for Disease Control and Prevention (CDC) and B. pseudomallei is 
listed as a category B bioterrorism agent (Rotz et al, 2002). Indeed, the closely 
related bacteria, B. mallei, which causes the disease glanders, primarily found in 
horses and also affecting other animals and humans, was successfully used as a 
biological weapon during World War I by infecting livestock for export to Allied 
forces (Hawley & Eitzen, 2001). 
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1.1. Microbiological aspect of B. pseudomallei 
B. pseudomallei is a non spore forming, bacillus-like, motile, aerobic bacterium. It 
is also a soil-dwelling saprophyte and frequently found in drenched rice paddy 
fields in endemic regions of melioidosis (White, 2003). Unlike other Burkholderia 
species, it is oxidase positive and capable of arabinose assimilation (Cheng & 
Currie, 2005).  Ashdown’s selective agar (Ashdown, 1979) is typically used in 
order to isolate and grow B. pseudomallei from clinical specimens (Cheng et al, 
2006). Various types of colony morphology of B. pseudomallei have been 
observed and the association of morphotype and phenotype changes was 
demonstrated by Chantratita et al (2007a). Seven unique colony morphotypes 
have been identified according to its surface texture of the colony center, outer 
edge of colony, surface roughness in outer half of colony, colony diameter and 
colony color (Figure 1.1). 
 
 
 
Figure 1.1 Photographs showing the variation of colony morphotypes of B. 
pseudomallei grown on Ashdown’s selective media. Approximately 75% of 
clinical samples from melioidodsis patients are found as type I colonies, which 
has a rough texture at the center and is irregular in the outer edge, with a pale 
purple colour. This figure is adapted from Stone (2007). 
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B. pseudomallei has the ability to survive in different harsh environmental 
conditions including low moisture content soil, acidic environments, the presence 
of detergents (Cheng & Currie, 2005) and even a lack of nutrients (Wuthiekanun 
et al, 1995). It can also survive in distilled water for at least 16 years (Pumpuang 
et al, 2011). A study of B. pseudomallei survival in water showed that a putative 
membrane protein, BPSL0721, which was up regulated, may be involved in the 
adaptation for surviving in an aqueous environment. However, this gene is not 
essential for survival as the BPSL0721 deficient mutant was still able to survive in 
water (Moore et al, 2008). The effect of chemical and physical environments on 
B. pseudomallei survival and persistence has been reviewed by Inglis & 
Sagripanti (2006). B. pseudomallei can survive in various conditions of  high 
water content, pH changes, osmotic pressure and chemical stress, but is less 
tolerant to ultra-violet light exposure. Another factor that influences disease 
outbreaks is the weather conditions, with many cases of melioidosis occurring in 
the rainy season (Wiersinga et al, 2006). As B. pseudomallei is susceptible to 
ultraviolet light (Sagripanti et al, 2009), this may explain the relatively low 
incidence of melioidosis during the dry season when natural sunlight levels are 
very high. 
 
 
1.2. Geographical distribution of melioidosis 
The traditionally recognised endemic areas of melioidosis are approximately the 
tropical latitudes between 20°N and 20°S (Cheng & Currie, 2005). The hyper-
endemic region includes northeast Thailand, northern Australia, Singapore and 
parts of Malaysia (Figure 1.2). Recently, the endemic zone has been extended to 
cover Papua New Guinea, the Indian subcontinent, southern China, Hong Kong 
and Taiwan. In addition, sporadic cases have been reported from both the 
Americas and Africa (Currie et al, 2008). International travel makes B. 
pseudomallei infection and melioidosis an increasing global concern. 
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Figure 1.2 The worldwide distribution map of B. pseudomallei and melioidosis. 
Major zones of endemic disease are colored in red, whereas yellow areas 
represent the spread of melioidosis. This figure is taken from Currie et al (2008).  
 
 
1.3. Clinical presentation 
Melioidosis can be acquired by percutaneous inoculation, inhalation or ingestion, 
with inoculation thought to be the major route for disease infection (Wiersinga et 
al, 2006). The latency period can last from a few days to up to 62 years and 
clinical features may vary from an asymptomatic state, to acute or chronic lung 
infection, or to overwhelming septicemia (Woods et al, 1999). Apart from the 
lung, which is the most commonly affected organ, skin infections, bone and join 
infections, liver and spleen abscesses, genio-urinary infection and brain abscess 
can be found as clinical symptoms of melioidosis (Figure 1.3). A variation in the 
clinical pattern of melioidosis in Australia, Thailand, Singapore and Malaysia has 
been observed (Cheng & Currie, 2005). Misdiagnosis of this disease frequently 
occurs due to its polymorphic symptoms, which are similar to other lung 
infections, and B. pseudomallei is recognised as “the great mimicker” (Stone, 
2007). 
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Figure 1.3 An illustration of clinical presentations of melioidosis: Melioidosis 
sepsis is associated with the bacterial dissemination to principle organs such as 
the lungs, liver and spleen, as well as the central nervous system (CNS). This 
figure is taken from Wiersinga et al (2006). 
 
 
If the primary infection is survived, a major cause of morbidity and mortality is 
recurring melioidosis. The re-occurrence is about 6% in the first year and 13% 
throughout 10 years of medical follow-up (Peacock, 2006). Interestingly, 25% of 
recurrent cases were re-infection by different strains, which could imply differing 
levels of response to antibiotics within the strains (Maharjan et al, 2005). A study 
of clinical risk factors showed that 12-16 weeks of antibiotic treatment in 
melioidosis patients decreased risk of relapse, compared to those who were 
treated for 8 weeks or less (Limmathurotsakul et al, 2006). Different proteins 
expressed from B. pseudomallei isolated during primary and relapsing melioidosis 
have been identified using proteomic analyses (Velapatino et al, 2012). Up-
regulation of B. pseudomallei proteins, including the HSP20/alpha crystalline 
family protein (BPSS2288) and flagellin (BPSL3319) in the relapsing isolate, 
compared to the initial isolate has been observed. These proteins could be 
determinants of melioidosis relapse and may be involved in melioidosis latency 
and virulence.   
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In addition, immunosuppressive people are at risk to the disease, especially those 
suffering from diabetes mellitus (Suputtamongkol et al, 1999). Between 37% and 
60% of melioidosis patients are also diabetic. Exposure to soil or water by rice 
farmers in Thailand, and Aborigines in Australia, is also associated with 
contracting melioidosis. Other clinical risk factors for developing melioidosis 
such as excess alcohol consumption, chronic lung disease and renal disease have 
also been reported (Cheng & Currie, 2005), as well as heart disease, malignancy 
and age ≥ 50 years (Currie et al, 2010). 
 
 
1.4. B. pseudomallei genome 
To date, the completely sequenced genomes of four strains of B. pseudomallei are 
available in published databases, while another 19 have been drafted (Holden, 
2009). The genome of B. pseudomallei strain K96243 (Figure 1.4) consists of two 
chromosomes of 4.07 megabase pairs and 3.17 megabase pairs (Holden et al, 
2004). Many core genes involved in essential cellular functions, for example cell 
growth and metabolism, are found in the large chromosome whereas accessory 
genes associated with adaptation and survival in various environmental niches are 
found in the smaller chromosome.  
 
 
Figure 1.4 Schematic diagrams of two chromosomes in the B. pseudomallei strain 
K96243 genome:  3,460 coding sequences are encoded by chromosome 1 whereas 
2,395 coding sequences are encoded by chromosome 2. This figure is taken from 
Holden et al (2004).   
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Interestingly, only 86% of the genome of B. pseudomallei strain K96243 (4619 
genes) have been found in all strains, with 14% of the genome varying across 
different strains (Sim et al, 2008). This plasticity of the B. pseudomallei genome 
has been studied and genomic islands related to horizontal gene transfer have 
been identified as one of the crucial source of genomic diversity within B. 
pseudomallei (Tuanyok et al, 2008). In addition, the genomic variation of 
different B. pseudomallei isolates and gene loss in genomic islands of B. 
pseudomallei genomes have been observed (Lye et al, 2010). However, from a 
comparative study between the clinical and environmental isolates of B. 
pseudomallei, there is no evidence to confirm the association of genomic islands 
with the mechanism of virulence (Bartpho et al, 2010).  
 
Since the completely sequenced first genome of B. pseudomallei strain K96243 
was published (Holden et al, 2004), there has been a considerable emphasis on 
molecular based research to make insights into the pathogenicity and virulence 
mechanisms of B. pseudomallei. However, the ambiguous system of B. 
pseudomallei infection is still a key challenging research question.  
 
 
1.5. Pathogenesis and virulence 
1.5.1. Pathogenesis 
A key element of the pathogenesis of B. pseudomallei is its ability to invade, 
survive and replicate within both phagocytic and non-phagocytic cells of the host 
(Allwood et al, 2011). Adhesion to the external surface of host cells is considered 
the first step in the pathogenesis of B. pseudomallei prior to an intracellular 
invasion. The initial attachment of B. pseudomallei to host cells is mediated by a 
bacterial capsule (Galyov et al, 2010). Subsequently, an intracellular invasion of 
B. pseudomallei occurs either in macrophages or epithelial cell lines. It is likely 
that the type III secretion system (T3SS) plays an important role in the bacterial 
invasion as well as escaping from endocytic vesicles (Stevens & Galyov, 2004). 
Once inside the host cell cytoplasm, the ability to survive intracellularly is a key 
for developing the infection while avoiding host immune surveillance. Strategies 
of evasion of the host immune response by B. pseudomallei include escaping from 
the endosome to the cytosol, inducing macrophage cell death and cell-to-cell 
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spreading through actin polymerization (Gan, 2005). B. pseudomallei can form 
actin based membrane protrusions by continuous nucleation of actin at one pole of 
the bacterial cell, allowing intracellular motility (Figure 1.5).  The bacterial 
movement to adjacent cells leads to cell fusion and the formation of multinuclear 
giant cells (MNGC), which indicates the progression of infection (Adler et al, 
2009).  
 
 
 
Figure 1.5 A schematic diagram of the B. pseudomallei intracellular lifestyle: An 
initial attachment to host cells involves the bacterial capsular polysaccharide, pili 
and adhesins. Molecular syringes like T3SS facilitate bacterial invasion. B. 
pseudomallei possesses intracellular survival mechanisms against host immune 
responses. Actin based mobility of the pathogen allows cell-to-cell spread and 
MNGC formation. This figure is adapted from Allwood et al (2011). 
 
 
 
1.5.2. Virulence determinants 
Some putative virulence factors of B. pseudomallei have been identified on the 
basis of existing evidence from a known virulent role in other pathogens. Quorum 
sensing, a communication system that depends on cell density in Gram-negative 
bacteria using N-acyl-homoserine lactones (AHLs) for coordinating gene 
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expression, is one such potential putative virulence factor. It plays a role in 
regulating a multidrug efflux pump responsible for antibiotic resistance in B. 
pseudomallei (Popat et al, 2008). Another recognised virulence determinant is the 
type III secretion system (T3SS). Proteins encoded from some T3SS gene clusters 
in B. pseudomallei are similar to those produced from Salmonella typhimurium 
and Shigella flexneri that are involved in pathogenesis (Troisfontaines & Cornelis, 
2005). In addition, B. pseudomallei can produce an extracellular capsular 
polysaccharide that is related to virulence as well as lipopolysaccharide, flagella, 
pili and other secreted proteins including haemolysin lipases and proteases 
(Wiersinga et al, 2006). Recently, the type VI secretion system (T6SS) has been 
considered important in the intracellular lifestyle in B. pseudomallei (Galyov et al, 
2010). 
 
 
1.5.2.1. Capsular polysaccharide 
A homopolymer of -3)-2-O-acetyl-6-deoxy-β-D-manno-heptopyranose(1- 
forming an extracellular capsular polysaccharide in B. pseudomallei has been 
identified as a possible virulence determinant (Reckseidler et al, 2001). The 
capsular polysaccharide may block the access of complement receptor-1 on 
phagocytes to C3b deposited on the bacterial surface, resulting in host immune 
response failure and thus B. pseudomallei survival in serum (Reckseidler-Zenteno 
et al, 2005). Capsule mutants of B. pseudomallei, prepared by the deletion of wcb, 
a capsular polysaccharide encoded gene operon, have revealed an attenuation in 
mice (Warawa et al, 2009).  
 
 
1.5.2.2. Lipopolysaccharide 
A comparative study of the lipopolysaccharide profiles of B. pseudomallei 
(pathogenic) and B. thailandensis (non-pathogenic) suggests that 
lipopolysaccharide may not be involved in virulence in B. pseudomallei 
(Wiersinga et al, 2006). However, a knockout of one of the genes encoding 
lipopolysaccharide in B. pseudomallei exhibits an attenuation in hamsters, and 
serum killing (DeShazer et al, 1998).  
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1.5.2.3. Quorum sensing 
An intrinsic bacterial resistance to antibiotics is associated with efflux pumps such 
as AMrAB-OprA, BpeAB-OprB and BpEF-OprC, which secrete the signaling 
molecules, N-acyl-homoserine lactones (AHLs). In B. pseudomallei, there are up 
to six different types of AHLs, the composition of which may vary slightly from 
strain to strain (Chan et al, 2007). The presence of AHLs in B. pseudomallei 
cultures has been reported with an involvement of the LuxI protein and LuxR 
transcriptional regulators in AHL biosynthesis (Wiersinga et al, 2006). LuxIR 
quorum sensing homologue mutants of B. pseudomallei show a decreasing 
virulence in hamsters and mice, compared to the wild type strain (Ulrich et al, 
2004). 
 
 
1.5.2.4. Type III secretion system (T3SS) 
The T3SS is a bacterial machinery that allows direct communication between 
bacteria and host cells and injects effector proteins into the host cytosol across the 
cellular membrane in the presence of translocator proteins. The T3SS of B. 
pseudomallei belongs to the Inv-Mxi-Spa family, which is known as a key 
virulence determinant in S. enterica and S. flexneri (Troisfontaines & Cornelis, 
2005). In B. pseudomallei, T3SS is encoded by the Burkholderia secretion 
apparatus (bsa) gene cluster. Compared to the wild type strain, the deficient T3SS 
mutants exhibit a reduction of replication in J774.2 macrophage cells, a lack of 
ability to escape from endocytic vacuoles and an absence of membrane protrusion 
and actin tail formation (Stevens et al, 2002).  
 
 
1.5.2.5. Type VI secretion system (T6SS) 
In the B. pseudomallei genome, fourteen T6SS orthologs have been found and 
they are similar to those present in B. mallei (Shrivastava & Mande, 2008). Six 
gene clusters of T6SS are encoded in the B. pseudomallei K96243 genome. They 
have been assigned as T6SS-1 (BPSS1496 to BPSS1511), T6SS-2 (BPSS0515 to 
BPSS0533), T6SS-3 (BPSS2090 to BPSS2109), T6SS-4 (BPSS0166 to 
BPSS0185), T6SS-5 (BPSS0091 to BPSS0117), and T6SS-6 (BPSL3096 to 
BPSL3111) according to the T6SS of B. mallei described by Schell et al (2007). 
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The T6SS-1 cluster genes were inducible following B. pseudomallei invasion of 
macrophages, but they were not involved in bacterial survival and growth inside 
macrophages (Shalom et al, 2007). A deficiency of multinucleated giant cell 
(MNGC) formation was observed in B. pseudomallei T6SS-1 mutants. In 
addition, Δhcp1 mutants decreased B. pseudomallei intracellular growth and 
cytotoxicity in RAW 264.7 macrophages (Burtnick et al, 2011). Furthermore, in a 
Syrian hamster model of virulence, the T6SS-1 was shown to be a crucial 
determinant of virulence, based on the LD50 against the relevant mutants of B. 
pseudomallei, whereas the other five T6SS gene clusters did not. These results 
suggest that the T6SS-1 is involved in virulence and plays a significant role in the 
intracellular lifestyle of B. pseudomallei. 
 
1.5.2.6. Flagella 
B. pseudomallei is motile and flagellated. The difference between the flagellin 
gene fliC in B. pseudomallei and B. thailandensis, a closely relative non-
pathogenic strain may be related to virulence. A B. pseudomallei flic knockout 
mutant exhibits less invasive abilities into a mouse macrophage cell line, RAW 
264.7, and a human lung epithelial cell line, A549, compared to the wild type 
strain, but higher than that of B. thailandensis (Chuaygud et al, 2008). These 
results suggest that the flagella in B. pseudomallei facilitate bacterial invasion in 
both phagocyte and non-phagocyte cells. Based on the LD50, the flagella defective 
mutant, which was non-motile and aflagellate, was less virulent during intranasal 
infection of BALB/c mice comparing to the wild type B. pseudomallei (Chua et 
al, 2003), which suggests that flagella are a virulence determinant of B. 
pseudomallei infection in this mouse model. 
 
1.5.2.7. Pili 
Type IV pili associated with adherence in B. pseudomallei has been suggested to 
play a role in virulence. A deletion mutant of the gene encoding the putative pilus 
structural protein (PilA) has exhibited a reduction of adherence to human 
epithelial cells, resulting in a delay of death in nematodes. Infection by this 
mutated strain was also attenuated in BALB/c mice following intranasal infection 
in comparison with the wild type B. pseudomallei (Essex-Lopresti et al, 2005). 
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1.6. Host-pathogen interaction 
1.6.1. Pathogen recognition 
When a pathogen strikes, the host’s innate immune system is a surveillance 
system which recognises microorganisms via a limited set of germline-encoded 
pattern-recognition receptors (PRRs) (Akira et al, 2006). PRRs have an ability to 
recognise microbial components, called pathogen-associated molecular patterns 
(PAMPs), which are essential for their survival and are difficult to alter. Different 
PRRs interact with specific PAMPs, regardless of the pathogen life-cycle stage. A 
family of commonly known PRRs is the toll-like receptors (TLRs) which are type 
I integral membrane glycoproteins. Extracellular domains of TLRs contain 
varying numbers of leucine-rich-repeat (LRR) motifs. The cytoplasmic domain of 
TLRs is known as the Toll-IL-1R domain, which is homologous to the 
cytoplasmic region of the interleukin 1 receptor (IL-1R) (Cook et al, 2004). TLRs 
are classified into several subfamilies based on their primary sequences. Each of 
these subfamilies recognises related PAMPs. In B. pseudomallei infection, 
PAMPs that are present on the bacterial surface interact with the corresponding 
TLRs of the host cell, for example, CD14-TLR4, peptidoglycans-TLR2, flagellin-
TLR5 and bacterial DNA or CpG-TLR9 (Wiersinga et al, 2006).  
       
1.6.2. Bacterial intracellular survival 
The initial host defense against B. pseudomallei includes natural antibiotic 
peptides, the complement system and phagocyte cells. Antimicrobial peptides 
called defensins are naturally produced to kill bacteria attacking host cells. It is 
unfortunate that B. pseudomallei is resistant to the natural immunity (Jones et al, 
1996). In addition, B. pseudomallei can produce an extracellular polysaccharide 
capsule that prevents complement attack. This polysaccharide capsule reduces the 
deposition of complement factor C3b, resulting in anti-phagocytosis (Reckseidler-
Zenteno et al, 2005).   
 
Macrophages are well-known phagocyte cells, whose functions are to ingest and 
destroy bacteria. Responses of macrophages to B. pseudomallei are different from 
other bacteria. An inducible nitric oxide synthase (iNOS), which directs the 
clearance of bacterial pathogens, is suppressed when the macrophages are infected 
with B. pseudomallei. This can explain why this bacteria can survive and multiply 
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inside host macrophage cells. In addition, IFN-γ, that has an important role in the 
host immune system, is produced at a lower level in the host’s resistance to B. 
pseudomallei infection, compared to other bacterial infections, resulting in 
increased bacterial loads in melioidosis patients (Panomket, 2011). 
 
 
1.7. Melioidosis management 
The difficulties of melioidosis management include a limitation in diagnostic 
approaches and the increasing resistance of the bacteria to the current anti-
infective treatments.  
 
1.7.1. Diagnosis 
Although a number of techniques have been developed for the rapid detection of 
B. pseudomallei in patient fluids, bacterial culture using selective media (e.g. 
Ashdown’s agar and B. pseudomallei selective agar, BPSA) are still the gold 
standard for melioidosis case confirmation (Peacock, 2006). Although this 
traditional diagnostic method is a time-consuming process, it has the advantage of 
identifying high risk of death patients in terms of a quantitative culture 
(Wuthiekanun et al, 2010). Alternatives to this culture-based method, include 
serological diagnosis using antibody and antigen detection. An indirect 
haemagglutination assay (IHA) is commonly performed, although it has a poor 
sensitivity and specificity. This particular diagnostic method is problematic in 
Thailand, where there is a high rate of background seropositive population (Cheng 
& Currie, 2005). As an improvement to the serological tests for melioidosis 
diagnosis, it has been reported that a crude B. pseudomallei antigen enzyme-
linked immunosorbent assay (ELISA) had an advantage over IHA observations 
(Chantratita et al, 2007b; Limmathurotsakul et al, 2011). 
 
During 20 years of observation of melioidosis in Northern Australia, the mortality 
of melioidosis has decreased from 30% at the beginning to 9% in the last five 
years, which is attributed to earlier diagnosis and enhancements in intensive care 
management (Currie et al, 2010).  
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1.7.2. Antibiotic resistance 
Burkholderia species are known to be one of the most antibiotic resistant bacteria. 
Predominantly, drug resistance mechanisms of bacteria involve enzymatic 
inactivation of antibiotics, drug target alteration and limited drug permeability 
into the bacterial cell (Poole, 2002). The latter plays a key role in antibiotic 
resistance mode of action in Burkholderia.  
 
 
There are three mechanisms of action that limit antibiotic penetration into 
bacterial cells. Firstly, lipopolysaccharide (LPS), a unique component of Gram-
negative bacterial cell walls, restricts the binding of cationic antibiotics, including 
aminoglycosides and polymyxins. Also, it renders the bacteria resistant to cationic 
peptides of the human innate immune system. Secondly, low cell membrane porin 
protein content may affect the permeability of water-soluble antibiotics into the 
bacterial cell due to an abnormal function. Thirdly, transport proteins, namely 
efflux pumps, are involved in antibiotic resistance. Antibiotics can be removed 
from the bacterial cell by the specific efflux pumps before being delivered to their 
cellular targets (LiPuma, 2007). In addition, biofilm formation may cause the 
bacteria to resist an antimicrobial agent. Possible resistant mechanisms in the 
biofilm include reduced drug diffusion through the biofilm, drug inactivation 
within the biofilm, the presence of less susceptible stationary-phase organisms, 
and the up-regulation of biofilm associated antibiotic resistance genes (LiPuma, 
2007).  
 
 
Commercially available antibiotics can be categorised into several classes, 
depending on their modes of action. β-lactams, including penicillins, carbapenem 
and cephalosporins are related to an inhibition of bacterial cell wall synthesis.  
Aminoglycosides, macrolides, tetracyclines and chloramphenicol are involved in 
the binding of the ribosome subunit, resulting in the inhibition of protein 
synthesis. Fluoroquinolones disrupt DNA replication as a result of DNA gyrase 
inhibition (Kohanski et al, 2010). On the whole, B. pseudomallei is intrinsically 
resistant to many antibiotics. A susceptibility of B. pseudomallei to 35 
antimicrobial agents in terms of the minimum inhibitory concentration (MIC), 
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determined by agar dilution in Mueller–Hinton medium, has been studied by 
Thibault et al (2004). The results indicate that B. pseudomallei is extremely 
resistant to penicillins (amoxicillin, ticarcillin), aminoglycosides (gentamicin, 
tobramycin, netilmicin, amikacin), macrolides (erythromycin), cephalosporins 
(cefoxitin), fluoroquinone (norfloxacin), fosfomycin, and clindamycin. The 
mechanism of resistance to aminoglycosides and macrolides can be explained by 
the presence of a multidrug efflux system in B. pseudomallei (Van Bambeke et al, 
2000).  The BpeAB-OprB pump in B. pseudomallei was accountable for the 
efflux of the aminoglycosides gentamicin and streptomycin, the macrolide 
erythromycin and the dye acriflavine (Chan et al, 2004). 
 
 
In addition, further antibiotics that B. pseudomallei is moderately resistant to 
include fluoroquinones (nalidixic acid, pefloxacin, ciprofloxacin, gatifloxacin and 
levofloxacin), co-trimoxazole and rifampicin. These antimicrobial agents are 
involved in the disruption of DNA replication and RNA synthesis. On the other 
hand, carbapenems like imipenem, the third generation of cepharosporins 
(ceftazidime and cefotaxime), other β-lactams (piperacillin and 
piperacillin/tazobactam and co-amoxiclav) tetracyclines (minoxycycline and 
doxycycline), and chloramphenicol, are efficient for killing this pathogen.   
 
 
Recently, resistance to ceftazidime during antimicrobial therapy, which is 
currently used as the first line treatment for melioidosis, has been reported 
(Chantratita et al, 2010). These observations mean that finding new therapeutic 
drugs for developing melioidosis treatments are an urgent need. 
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1.8. Identification of potential therapeutic target proteins 
In attempts to identify proteins involved in infection and virulence mechanisms of 
B. pseudomallei, that may be targeted by novel therapies, many studies have been 
carried out using different techniques. 312 putative essential genes of B. 
pseudomallei have been identified by a computational bioinformatics approach 
(Chong et al, 2006). B. pseudomallei protein sequences were compared with 
known essential genes encoding proteins from other bacterial pathogens, and also 
against human protein sequences to identify targets that did not have human 
homologues. The subset of genes thus identified have been annotated as vital 
genes for B. pseudomallei survival, and possible potential candidates for 
antimicrobial drug target development. In addition, the relative levels of protein 
expression in B. pseudomallei and the non-pathogenic B. thailandensis have been 
observed by proteomic analysis (Wongtrakoongate et al, 2007). Several proteins 
in B. pseudomallei that are up regulated compared to B. thailandensis have thus 
also been identified as potential markers of pathogenicity and virulence. They 
may play a key role in virulence as they were highly expressed in the virulent 
species but missing in the avirulent species.  
 
Su et al (2008) have identified a set of B. pseudomallei target proteins that raise 
the human immune response in infected patients. The genomic expression library 
of a clinical strain of B. pseudomallei D286 was constructed and immunologically 
screened with pooled melioidosis infected human sera. 109 expressed 
polypeptides reacted with melioidosis positive sera and the coding sequence of 
sero-positive clones were analysed for sequence identification. These identified 
proteins are involved in cell envelope biogenesis, cell mobility and secretion, 
transcription, metabolism, transportation and also include many uncharacterised 
proteins. Many of these proteins (30%) are found in the cytoplasm. With an 
assumption that the cytoplasmic localised proteins are exposed after destruction of 
bacterial cells by the host immune defense, the results suggest that these identified 
immunogenic proteins may be induced and up-regulated during human infection. 
These immunogens could be further investigated for anti-infective targets, and a 
number of them have been investigated in this thesis.  
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1.9. Structural genomics 
A fundamental of structural genomics of proteins with unknown function is to 
start from the gene sequence, produce protein and determine its three-dimensional 
structure, which could provide useful biological information of the protein 
(Thornton et al, 2000). Structural genomics requires techniques such as protein 
crystallography and nuclear magnetic resonance (NMR) to determine the structure 
of biologically interesting molecules from model organisms and those with 
medical importance, aiming to derive function from the structures (Brenner, 
2001). From the determined structure, the organization of the protein chain in 
three dimensions is revealed and the residues which are buried in the core or 
involved solvent exposure on the protein surface can be identified as well as the 
overall shape and electrostatic properties of the protein. The protein structure can 
also reveal the quaternary structure in the crystal conditions or in solution at high 
concentration, which may indicate its biological multimeric state. In addition, 
biochemical and functional information can be extracted from the structure of 
protein-ligand complexes, that provide a crucial clue to their catalytic 
mechanisms. The similarity of the protein folds and structural motifs of an 
uncharacterised protein compared to the structural information of characterised 
proteins in the available databases may be used to infer its biochemical and 
biological functions.  
 
 
In one such study, the structure determination of BPSL1549, an uncharacterised 
protein from B. pseudomallei has led to the discovery that it is a novel toxin 
(Cruz-Migoni et al, 2011). According to proteomic profiles, BPSL1549 has been 
identified as a putative virulence factor since the protein is expressed in B. 
pseudomallei but absent in B. thailandensis, a non-pathogenic strain 
(Wongtrakoongate et al, 2007). At the protein sequence level, BPSL1549 has no 
sequence similarity to any protein excluding other Burkholderia species. The 
crystal structure of BPSL1549 has been determined and analysed (Cruz-Migoni, 
2011). By comparison to available structures deposited in the protein data bank, 
the fold recognition revealed that BPSL1549 is structurally similar to the catalytic 
domain of the cytotoxic necrotizing factor 1 (CNF1-C) from Escherichia coli 
(Figure 1.6a). And, indeed, the three crucial catalytic residues of CNF1-C are 
! 18!
present in BPSL1549 and are virtually the only conserved residues between these 
two proteins (Figure 1.6b). CNF1-C is an enzyme that catalyses the deamidation 
of a specific glutamine residue into a glutamic acid in the Rho protein family, 
which regulates the GTPase involved in actin cytoskeleton assembly. This 
comparative structure information suggested that BPSL1549 could also have a 
toxic role similar to CNF1-C. Further investigations have shown that BPSL1549 
specifically deamidates glutamine-339 of the eukaryotic transcription factor 
eIF4A, rendering it inactive and thus inhibiting protein translation, ultimately 
resulting in cell death (Cruz-Migoni et al, 2011). These results support the 
proposal that BPSL1549 could play important roles in pathogenesis and virulence 
in B. pseudomallei. This study shows that structural analysis of a protein of 
unknown function can lead to important insights into its biological function and 
can shed light on pathogenicity and virulence mechanisms.   
 
 
Structural genomics also has an impact on drug discovery. The availability of the 
three-dimensional structure of drug targets facilitates pharmaceutical 
development, especially for structure-based drug design (Dry et al, 2000). 
Structure data allow an identification of active sites or ligand binding sites and the 
optimization of lead compounds to reveal the selectivity and specificity 
preferences of druggable molecules at atomic resolution. DrugBank targets by 
structural genomics centers have been listed in Weigelt et al (2008). Together 
with a bioinformatics approach, structural information extracted from the 
determined protein-ligand complex structure can be inferred and contributes to the 
development of drug candidates (Congreve et al, 2005). 
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a)  
b)  
Figure 1.6 From structure to function: a) Superposition of BPSL1549 (blue) and 
CNF1-C (red) structures shows their structural similarity. b) Catalytic residues of 
CNF1-C are identical to equivalent residues in BPSL1549, leading to the 
biological function discovery of BPSL1549. This figure was taken from Cruz-
Migoni et al (2011).   
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1.10. Aims of the study and thesis outline 
This thesis describes the instigation of structural studies on several potential target 
proteins of B. pseudomallei for drug discovery and use of structural genomics, 
with an attempt to gain more understanding of the molecular mechanisms 
underlying the disease. The proteins that form the subject of this thesis are 
BPSL3022 (cell division protein FtsQ), BPSS0945 (subfamily M23 unassigned 
peptidase), BPSS0238 (putative penicillin binding protein) and the proteins of 
unknown function BPSS1416, BPSS0603, BPSS0683 and BPSL0606. The 
rationale behind this target selection is given in the introduction to Chapter 4. 
 
The aims of this study are as followings.  
• to create a list of potential target proteins of B. pseudomallei 
• to clone the genes encoding these proteins 
• to produce the proteins in Escherichia coli  
• to purify the soluble proteins 
• to crystallise the protein 
• to determine the three dimensional structure of the proteins  
• to analyse the structures obtained.  
 
 
In this thesis, a brief description of protein crystallography theory involved in this 
study is summarised in Chapter 2. The materials and methods used through out 
this work are detailed in Chapter 3. Target selection, gene amplification and 
cloning, protein over expression and protein purification are described in Chapter 
4. The crystallisation and structure determination of BPSL0606 is discussed in 
Chapter 5. Structure analysis of BPSL0606 is detailed in Chapter 6. Functional 
analysis of BPSL0606 is discussed in Chapter 7. Finally, conclusions and future 
works are included in Chapter 8.  
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Chapter 2: Protein Crystallography !
X-ray crystallography is a powerful technique for determining the three-
dimensional structure of proteins and biological macromolecules. 88% of the 
entire biomolecular structures publicly deposited in the protein data bank (PDB) 
December 2012 release have been determined by X-ray crystallography. Although 
protein crystallography has advantages in terms of providing accurate models of 
protein structure at atomic resolution, with no limitation in the size of protein 
samples, it is dependent on obtaining protein crystals as a starting point. 
Crystallographic theory is covered in a number of textbooks (Blow, 2002; 
Rhodes, 2006; Rupp, 2010). This chapter will briefly introduce the processes in 
the experiments described in this thesis including crystallisation of the protein 
sample, crystal manipulation, X-ray data collection and processing, structure 
determination, structure refinement and validation of the structure. 
 
2.1. Protein crystallisation 
If a purified and homogeneous protein of interest can be produced, crystals of the 
protein can be obtained as the protein solution moves toward a metastable 
supersaturated state. The crystallisation trials are subjected to multi-dimensional 
conditions to induce the nucleation. According to the thermodynamics of 
crystallisation, molecular collisions in the supersaturated protein solution drive 
phase separation and the nucleation event occurs when the physicochemical 
reaction reaches the critical free energy and overcomes the kinetic barrier in 
which crystals form, and the system proceeds to binary phase equilibrium (Figure 
2.1a). This process involves protein solubility, which is affected by several 
parameters including pH, ionic strength, temperature and concentration of salts, 
organic precipitants and additives. An initial optimization of these variables for an 
individual protein to be crystallised is accomplished by combinatorial screening. 
Commercially available screens facilitate the coverage of crystallisation space 
conditions. In addition, programmed robots are commonly set up for automated 
crystallisation, where the experiments are miniaturised to nano-scale volumes 
reducing the protein requirements. 
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a)  
b)  
Figure 2.1 Crystallisation diagrams: a) A free energy diagram for crystallisation 
showing that nucleation requires free energy from the physicochemical reaction to 
overcome the kinetic barrier in order to form crystals. The figure is taken from 
McCoy (2010) and b) A schematic illustration of a phase diagram of protein 
crystallisation using the vapour diffusion method. As a result of water vapour 
diffusion in the closed system, protein and precipitant concentrations increase 
toward the supersaturation condition, allowing nucleation and thus crystal 
formation. The protein concentration drops as the crystals sequester the protein. 
The figure is adapted from Chayen & Saridakis (2008). 
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2.1.1. Vapour diffusion techniques 
Vapour diffusion is a conventional method for protein crystallisation. It involves 
mixing a small amount of the protein solution with the precipitant solution, 
usually in a 1:1 ratio. The technique provides a closed system allowing the protein 
mixture drop to equilibrate against a larger volume of reservoir solution that may 
contain buffer, salt and/or precipitant. The vapour diffusion of water and volatile 
compounds in the closed system occurs slowly. Water vapour from the protein 
mixture drop diffuses into the reservoir solution, resulting in a proportional 
increment of both the protein and precipitant concentrations in the drop. This 
process leads into a supersaturated state and enables crystallisation. If successful 
crystallisation is achieved, the protein concentration in the drop decreases as the 
crystals sequester the protein (Figure 2.1b).      
  
 2.1.1.1.  Sitting drop vapour diffusion 
A drop of protein solution mixed with crystallisation solution from the reservoir is 
placed on a microbridge over the reservoir, which is sealed with a greased rim and 
a cover slide (Figure 2.2a). This technique can be adapted to an automated 
crystallisation set up, with a robotic dispenser, allowing for miniaturization and 
using very small quantities of protein, approximately 200 nanolitres. Thus, sitting 
drop vapour diffusion is commonly used for the initial screening in 96-well plates. 
 
 2.1.1.2.  Hanging drop vapour diffusion 
Unlike the sitting drop technique, the protein mixture drop is placed on a 
siliconised cover slide that is inverted to face the reservoir, and again grease is 
used to seal the well (Figure 2.2b). This technique requires manual set up, and is 
often used for an optimization of crystal growth conditions. Drops of up to 10 
microlitres can be easily used, and thus large crystals, which are easier to 
manipulate can sometimes be grown.  
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Figure 2.2 Illustrations showing the vapour diffusion experiments: a) Sitting drop 
technique- crystals are growing in the drop on the microbridge.  b) Hanging drop 
technique- crystals are growing in the drop facing the reservoir. 
 
2.1.2. Protein crystals 2.1.2.1.  Crystal assembly 
Protein crystals are assemblies of translatingly repeating identical units, called 
unit cells. These unit cells are parallelepipeds defined by lengths a, b, c and inter-
axial angles α, β, γ. The unit cell is characterised by its space group, which 
defines the internal symmetry. There are 230 space groups, but as proteins are 
chiral, symmetry operators such as mirror planes cannot be used and there are 
thus only 65 possible space groups. The space group is defined by the lattice type 
and crystal system. There are five different lattice types, describing the position of 
the lattice points on the unit cell, where a lattice point is a point that is in exactly 
the same environment in all unit cells in the crystal. The primitive lattice (P) is a 
simplest type containing one lattice point at each vertex of the unit cell. An 
additional lattice point at the center of the unit cell generates the internal lattice 
(I). A centered lattice (C) has an additional point on one face and the face-
centered lattice (F) has lattice points at the center of each face.  
 2.1.2.2.  Crystal system 
There are 7 crystal systems which are based on different rotational symmetries. 
Only 2-fold, 3-fold, 4-fold and 6-fold axes are allowed and each of these systems 
has different unit cell shape and dimensions. The simplest crystal system is 
triclinic with the unit cell a ≠ b ≠ c and α ≠ β ≠ γ. The cell in which α = γ = 90° 
and β > 90° is called monoclinic, whereas the orthorhombic system has α = β = γ 
= 90°. For unit cells with all three angles equal to 90°, if a = b = c, the system is 
b) a) 
Cover slip 
Grease 
Crystals 
Protein and precipitant drop 
Microbridge 
Precipitant reservoir 
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cubic and when a = b ≠ c, it is tetragonal. In addition, if the unit cell has a = b = c 
and α = β = γ ≠ 90°, it is rhombohedral, whereas the hexagonal unit cell has a = b 
= c and α = β = 90° γ = 120°. Together with centrosymmetry operators, these 
crystal systems create 14 Bravais lattices as shown in Figure 2.3.  The 
combination of the lattice type, the crystal system and the presence of any screw 
axes (a combination of rotation and translation) gives the space group of the 
crystal. 
 
 
Figure 2.3 The 14 Bravais lattices: P = primitive, C = one face centered, I = body 
centered, F = face centered. This figure is taken from http://www.xtal.iqfr.csic.es/ 
Cristalografia/index-en.html. 
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2.1.2.3.  Mounting crystals  
In order to harvest crystals from crystallisation trays, the protein crystals need 
careful manipulation. Because the crystal is in equilibrium with the surrounding 
mother liquor in the drop, it should be handled with the remaining mother liquor. 
Under a light microscope, the fragile crystal is gently fished out by a standard 
fiber loop with an appropriate size to the crystal and then transferred into a 
suitable cryobuffer, which is made from the solutions present in the mother liquor 
plus a cryoprotectant. The crystal is held in the loop by surface tension of the 
cryobuffer and ready to either plunged into liquid nitrogen or mounted onto the 
diffractometer. In this step, rapid transfer is preferred to avoid dehydration. 
 
 
2.2. X-ray diffraction 
X-ray diffraction data measurement from macromolecular crystals has lead to the 
determination of atomic structures. When a molecule is struck by an X-ray beam, 
the X-rays interact with the electrons in the molecule and diffraction occurs. 
However, this diffraction is very weak. A crystal of the molecule can be used to 
amplify the diffraction signal. The crystal contains many molecules in the same 
orientation and the diffracted rays from all the molecules have a cumulative 
effect, enabling the signal to be observed. The crystal diffracts the X-ray beam in 
many directions, resulting in a diffraction pattern. The electron density map 
derived from the diffraction pattern can be depicted by mathematical means of a 
three-dimensional periodic function.      
 
 
2.2.1. Principles: Bragg’s law 
W.L. Bragg proposed an interpretation of X-ray diffraction as reflection on 
individual lattice planes hkl. In a crystal, a set of parallel planes, having Miller 
indices hkl, acts as a mirror resulting in a reflection. Each set of planes is an 
independent diffractor producing a single reflection. As Bragg’s law defines 
(Figure 2.4), the condition to obtain the scattered X-ray in phase from parallel 
planes is  
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2dhkl sin θ = nλ     
 
where  dhkl is a lattice space between two parallel planes 
 θ is an angle of diffraction 
 λ is a wavelength of an incident X-ray 
and n is an integer  
 
Figure 2.4 Bragg’s law: A representation of the reflection of incident X-rays with 
an angle θ from a set of parallel planes (separated by a distance d) in the crystal to 
achieve the scattered X-ray in phase. The figure is taken from McCoy (2010). 
 
Each spot in the diffraction pattern collected during the diffraction experiment 
represents a reflection related to the set of parallel planes with indices (hkl). h, k 
and l are defined as the numbers that the plane divides the unit cell edges (a, b and 
c), respectively.  
 
 
2.2.2. Fourier Transform 
A Fourier transform describes the relationship between molecules in the crystal 
and its diffraction pattern. A reflection can be depicted by a structure factor 
equation representing a diffracted X-ray. For a unit cell with n atoms, the structure 
factor for the reflection Fhkl can be expressed as a Fourier sum of all the atomic 
diffracting contributions: 
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!!"# != ! f!!!!! e!"!!(!"!!!"!!!"!) 
 
fj is the scattering factor of atom j, dependent on the atomic number, and hence 
electrons, of the atom and is treated as a simple sphere of electron density. xj, yj 
and zj represent the coordinates of atom j in real space, and h, k and l are the 
lattice indices of a specific reflection in reciprocal space. The contribution of 
individual atom j to Fhkl depends on both the atomic element, which determines 
the amplitude of the contribution (fj), and the atomic position in the unit cell (xj, 
yj, zj), which designates the phase of the contribution. 
 
Alternatively, Fhkl can be expressed in terms of the volume element of electron 
density in the unit cell, ρ(x,y,z).  
 
 !!"# = ! ρ(x, y, z)! e!"!(!"!!"!!")!dV 
 
Each volume element contributes to Fhkl derived from the integral over the unit 
cell volume, V denoted for all values of x, y and z. This equation shows that Fhkl 
is the Fourier transform of ρ(x,y,z) on the set of hkl planes. Therefore, all of the 
structure factor Fhkls constitute the transform of ρ(x,y,z) on all sets of parallel 
planes for the whole unit cell. 
 
Due to the reversible nature of the Fourier transform, the electron density can also 
be described as the transformation of the structure factors as follows: 
 ρ(x, y, z) != !1V ! !!"#! !e!!"!(!"!!"!!")!! %
 
The calculation of electron density at a position (x,y,z) in the unit cell is 
performed by the summation over all the hkl planes. The structure factor Fhkl is a 
periodic wave function with amplitude, frequency and phase. It can also be 
represented by a complex vector and decomposed into its amplitude, |Fhkl| and 
phase, αhkl. The electron density equation can then be expressed as follows:%
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ρ(x, y, z) != !1V ! |!!"#|! !e!!e!!"!(!"!!"!!")!!  
 
The amplitude of a wave scattered from a particular plane hkl, |Fhkl| is directly 
quantifiable by the measurement of reflection intensities, Ihkl, as |Fhkl| is 
proportional to the square root of Ihkl. However, the phase αhkl can not be 
measured during the experiment. To achieve the phase information, phasing 
methods will be explained later in this chapter.     
 
 
2.3. Data collection 
To measure the intensities of all the diffracting rays, a number of images are 
recorded in which the crystal is rotated through a small angle, perpendicular to the 
X-ray beam. This method is called the rotation method of data collection (Dauter, 
1999) and allows all the data to be measured without individual reflections 
overlapping with one another.  
 
The radiation of the X-ray that has wavelength λ can be represented by the Ewald 
sphere with radius 1/ λ centered on the X-ray beam. When reciprocal lattice points 
with indices (hkl), representing the crystal, lies at the surface of the Ewald sphere, 
the interference of X-ray scattered for that particular reflection satisfies Bragg’s 
Law in three dimensions. The diffracted beam is directed along the line joining 
the sphere with the reciprocal lattice point at the surface (Figure 2.5a). To obtain 
different reflections from other reciprocal lattice points, the reciprocal lattice 
points need to be moved to the surface of the Ewald sphere. The crystal has 
therefore to be rotated about a single axis to bring a number of successive 
reflections into the diffracting position. When the crystal is rotated and the 
reciprocal plane intersects with the sphere, an ellipse of the diffraction is created 
by the projection on the detector. The orientation of the plane at the beginning and 
the ending of the rotation forms two intersecting ellipses with all reflections 
recorded between them as a lune (Figure 2.5b). There will be a family of 
concentric lunes displayed on the detector as reflections are arrayed in sets of 
parallel planes. Diffraction spots are arranged along lines with in each lune, 
indicating the regularity of the reciprocal lattice. Their pattern is distorted to a 
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different extent as a result of the mapping of the curved Ewald sphere on the flat 
detector surface. 
   
a)   
 
b)  
 
Figure 2.5 a) The Ewald construction: 1/d = (1/ λ)sinθ is fulfilled when the 
reciprocal lattice point is on the surface of the Ewald sphere. b) A lune is formed 
from reflections from the same plane in the reciprocal lattice, corresponding to the 
start and end positions when the crystal is rotated. This figure was taken from 
Dauter (1999). 
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2.3.1. Data collection strategies 
In order to carry out an X-ray diffraction experiment, it is necessary to clarify the 
objectives for each individual crystal. These purposes include sample 
characterization, structure determination, resolution extension, and ligand 
identification. Different experimental objectives require different criteria to 
achieve a good data set. Preliminary X-ray experiments are crucial to analyse the 
unit cell parameters, diffraction strength and resolution range, as well as to 
determine space group, however, the complete data collection is not necessarily 
required at this stage. Different strategies can be used to measure the X-ray 
diffraction intensities for structure determination, depending on the structure 
solution method, whether molecular replacement or experimental phasing. 
Completeness of the data set is prioritised for molecular replacement since the 
reflection amplitudes at low-resolution ranges are used to calculate Patterson 
functions. On the other hand, anomalous diffraction phasing requires an accuracy 
of intensity measurement as well as the data completeness in order to measure the 
small anomalous signals. A high-resolution data set may be required when atomic 
structure refinement is performed. In addition, when searching for bound ligands, 
a modest resolution data set (2.5 Å or better) is sufficient to identify binding 
without ambiguity.  
 
To obtain the desired data sets, some strategic parameters of data collection are 
taken into account. A selection of a rotation range and rotation start point is a key 
to data completeness as the minimum rotation range is required to cover the whole 
asymmetric unit of reciprocal space which is limited by the resolution sphere and 
the Laue symmetry group. The orientation of the crystal to the X-ray beam 
determines where the rotation start point is. Equally, It is important to adjust the 
rotation per image of the crystal to avoid excessive reflection overlap. Δφ is 
generally set to a small increment between 0.1° and 1.5°. The distance between 
crystal and detector sets the limit of the resolution at the edge of the detector, 
whilst allowing individual reflections to be separated. Another factor that could 
affect the data quality is an X-ray exposure time. Long exposure times may lead 
to overloaded reflections at low resolution as well as radiation damage. For 
anomalous diffraction experiments, appropriate wavelength(s) used in the 
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experiment should be selected from the absorption edge of anomalous scatterers, 
based on the fluorescence spectra. 
 
At present, the strategy generation for data collection is fully automated. 
However, experimenters need to be able to judge the diffraction quality and 
decide the practical strategy for meaningful data to be collected.   
 
 
2.3.2. Radiation damage 
During X-ray exposure, more than 90% of the X-ray beam does not interact with 
the sample at all. A small amount of the X-rays physically interacts with the 
crystal, defined as diffraction and absorption. Only approximately 8% of these 
interacting photons are diffracted by the crystal, whereas the other 92% are 
predominantly absorbed and contribute to the damage of the crystal sample 
(Garman, 2010). The latter phenomenon involves an energy loss due to either the 
photoelectric effect or Compton scattering. The photoelectric effect is the total 
absorption of photons, resulting in an ejection of an inner shell electron of an 
interacting atom. A primary photoelectron can induce up to 500 ionization 
incidents which relate to the formation of radical species in the crystal. The 
excited atom can then release a characteristic X-ray or an Auger electron as it 
returns to its ground state. Compton scattering represents an inelastic scattering of 
the photon whose energy is partially transferred to an atomic electron, resulting in 
lower energy that has higher wavelength. The effect of the ionization of an atom 
owing to either photoelectric absorption or Compton scattering includes a 
disruption of crystalline order and specific structural damage. A loss of reflection 
intensities at high resolution, an expansion of unit cell, an increase in values of the 
measured internal consistency of data (Rmerge) and an increase in scaling B-factors 
values can be observed as a consequence of this global damage. To monitor the 
global damage during X-ray exposure, the ratio of the summed mean intensity and 
the mean intensity of the first data set (ID/I1) is employed as well as the pairwise R 
factor between identical and symmetry-related reflections occurring on different 
images (Rd plot). On the other hand, the specific structural damage is difficult to 
monitor during the experiment since refined structures are required. Specific 
structural damage that has been observed in protein structures includes disulfide 
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bridges broken, the decarboxylation of glutamate and aspartate residues, loss of 
hydroxyl group of tyrosine residues, C-S bond cleavage in methionine residues 
plus other covalent bond breakage. Radiation damage often leads to incomplete 
data collection and failure of structure determination, and must therefore be 
considered carefully in the design of the experiment. 
 
 
2.3.3. Tools for data collection 
A diffractometer is an instrument designed for collecting X-ray diffraction data. 
The integral elements of a diffractometer are detailed below: 
   2.3.3.1.  X-ray sources and optics 
The two most common ways of producing X-rays for protein crystallography are 
either by electron bombardment at a target anode or by synchrotron facilities. The 
generation of X-ray relies on an emission of characteristic radiation which can be 
selected by a monochromator. The approaching X-ray is diffracted by the crystal 
monochromator and the desirable wavelength is selected. Focusing optics then 
allows the X-rays to be focused, into a parallel and intense beam for diffraction 
experiments. 
 
2.3.3.1.1. Rotating anode 
A rotating-anode X-ray generator is commonly set up in many crystallography 
laboratories. Initially, electrons are accelerated from a heated tungsten filament 
(cathode) across an electrical potential of several tens of kV towards the target 
anode. The high energy electron beam strikes the anode and ejects an electron 
from an inner shell of the target element. An electron from a higher energy shell 
falls back to fill the empty inner orbital releasing its excess energy as an X-ray 
photon. The characteristic X-ray radiation from the K shell of a copper anode has 
an approximate wavelength of 1.54 Å, whereas a shorter wavelength is obtained 
from molybdenum-based anode (0.71 Å). Due to the large quantity of heat 
generated by electron attack, the target anode requires sufficient cooling, by 
rotating the anode. More heat can be dissipated to the water coolant allowing 
more X-rays to be produced. 
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2.3.3.1.2. Synchrotron 
X-rays can also be generated using a synchrotron and the X-ray beam from 
synchrotron sources is much more intense and brilliant than the in-house X-ray 
source. As the energy is tunable, a synchrotron X-ray source has a significant 
impact on collecting data for some techniques used for determining 
macromolecular structures. In a synchrotron, electrons are produced in an electron 
gun, or injector, by thermionic emission and these electrons are then accelerated 
in a linear accelerator (LINAC) to obtain an extremely high energy. The electron 
stream then travels to a booster synchrotron in which a radio frequency voltage is 
used to accelerate the electron energy, whilst being maintained by magnetic field. 
The final energy obtained is of the order of a few giga electron volts (GeV). The 
powerful electron beam then travels with a high speed in the storage ring where 
large electromagnets are installed to bend and keep the electron beam orbit stable 
in a high vacuum beam tube. Every time the beam is bent, the angular velocity 
changes and the X-rays are emitted at a tangent to the curved path. The beams 
thus produced are called bending magnet beams. Alternatively, insertion devices 
such as wigglers or undulators can be placed in the straight sections of the storage 
ring. These insertion devices are a series of powerful magnets which oscillate the 
beam, rapidly produce even more brilliant X-rays. The X-ray beams pass through 
a front end, to a beam-line where an experimental hutch is established for carrying 
out the X-ray diffraction experiment.   
 2.3.3.2.  Detectors 
Nowadays, the use of conventional X-ray film for collecting X-ray diffraction 
images has been replaced by imaging plate and charged coupled device (CCD) 
detectors greatly increasing the speed of data collection (Smyth & Martin, 2000).  
 
Imaging plate detectors consist of a layer of phosphor BaFBr doped with Eu2+ 
based material. The incident X-ray stimulates the Europium ions to their excited 
state (Eu3+). After scanning by a He-Ne laser, phosphor-luminescence is induced 
and photons are released. The emitted light intensities are recorded by a photo 
multiplier tube and thus an image of the diffraction pattern can be reconstructed. 
The image plate is erased after each exposure by visible light exposure after 
readout. 
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Unlike imaging detectors, CCD detectors are technologically advanced and more 
favourable in terms of fast readout time, therefore they are predominately 
established in many synchrotron macromolecular crystallography beamlines. 
CCD detectors are made of CCD semiconductor array chips. X-ray photons are 
absorbed in a thin fluorescent screen coated with phosphor Gd2O2S doped with Tb 
which converts X-ray to visible light photons and generates scintillation. The 
screen is attached to fiber optic taper next to a CCD semiconductor in which 
electrons are accumulated proportional to the number of photons before being 
relocated into the readout row and producing electronic diffraction pattern images.  
 
Recently, solid state detectors, such as the hybrid pixel detector PILATUS 1M 
have been introduced. These detectors record the X-rays directly onto each pixel, 
allowing continuous read out and very fast data collection times. 
 2.3.3.3.  Goniometer 
To be able to rotate the crystal, the apparatus called goniometer or goniostat is 
employed. A loop with a cryoprotected crystal is mounted on a goniometer head 
that allows the crystal movement and automatic adjustment. A rotation of the 
goniometer, φ-angle, is assigned the crystal orientation with reference to the X-ray 
beam and the detector while maintaining the crystal centering. In addition, heating 
the goniometer head is required in order to prevent ice formation from the crystal 
cooling system.  
 
As the majority of the incident X-rays are not scattered by the electrons in the 
crystal, a beam stop, made from a tiny lead piece is placed between the mounted 
crystal and the detector. This object prevents an overexposure on the detector 
from the intense direct beam which may otherwise damage it. 
 2.3.3.4.  Cryocooler 
The cryocooling system provides a cryogenic nitrogen stream over the crystal 
during an X-ray exposure to reduce radiation damage. In the cryocooler, liquid 
nitrogen from a dewar is first evaporated and the subsequent cooling of the gas to 
100K is undertaken by heat exchange with the liquid nitrogen. The cold stream of 
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cryogenic nitrogen gas is gently blown out over the crystal via the nozzle and is 
surrounded by a dry air stream which counteracts the formation of frost on the 
crystal. 
 
 
2.4. Data processing 
All reflections produced from a diffracting single crystal need to be processed in 
order to obtain a useful dataset for subsequent phasing and electron density 
reconstruction. This stage involves the determination of unit cell dimensions, 
crystal system and space group, data integration, intensity measurement, scaling 
and averaging intensities and calculating structure factor amplitudes. The data 
processing is done automatically by software packages and program suites.  
 
2.4.1. Autoindexing 
Using a couple of diffraction images, usually 90° apart from each other, the 
program Mosflm (Leslie & Powell, 2007) will find diffraction spots that have 
higher intensity pixels than background. The identification of these reflections 
enables the program to index the crystal and obtain unit cell dimensions by 
measuring the reflection spacings which are proportional to reciprocal lattice 
spacings and geometrically related to real lattice spacings. To determine the unit 
cell dimensions, the crystal-to-detector distance must be known as well as the 
direct beam position and the incident wavelength. Therefore, the unit cell 
dimensions, crystal system and lattice type can be computed and a list of possible 
solutions with their degrees of penalty is produced.   
 
2.4.2. Integration 
In order to obtain a single data set, all images collected from the X-ray diffraction 
experiment are integrated. This process involves predicting the position of the 
reflections and estimating the reflection intensities with associated standard 
deviations. The intensities calculated by a summation integration and a 
subsequent profile fitting. The pixel values of all intensity pixels are summed and 
the sum of background values are subtracted. The standard deviation is based on 
Poisson statistics. During the integration of the complete dataset, the unit cell 
parameters are typically fixed but the detector parameters, crystal orientation and 
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mosaic spread are refined to establish the best prediction of spot positions. The 
data integration results are written in a single MTZ file including the indices of all 
reflections (h,k,l) and estimated intensities (Ihkl) and error σ(I).   
 
2.4.3. Data reduction 
To reduce lists of reflections to a unique list, the integrated raw data are scaled 
and the multiple measurements of identical reflections are merged. Scaling is 
required to account for variations in incident beam intensity, crystal shape and 
absorption. The average signal to noise ratio over all N reflections in a resolution 
shell can be expressed as: 
 Iσ(!) = ! 1N ! |I ! |σ(!(!))!  
 
Symmetry-related reflections are merged into a unique data set representing the 
asymmetric unit of the reciprocal space. Merging statistics are computed to 
indicate the data quality in terms of the reliability factor. The linear merging R-
value is commonly used to describe the merging of N redundant observations of 
reflections h within the desired resolution range. 
 R!"#$" = ! |I ! ! − Ī(!)|!!!!! I ! !!!!!!  
 
where Ī(h) is the average intensity of each reflection 
 
As the number of equivalent measurements increases, so does R-merge and so a 
redundancy-independent merging R-value can also be calculated. 
 
R!"#!or!R!"#$ = ! ( NN− 1)!!! ! |I ! ! − Ī(!)|!!!!I ! !!!!!!  
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Introducing a term of 1/(N-1)1/2 to the linear merging R-value can improve the 
precision of merging intensities, yielding the precision-indicating merging R-
value.  
R!"# = ! ( 1N− 1)!!! ! |I ! ! − Ī(!)|!!!!I ! !!!!!!  
 
 
2.4.4. Determining data quality 
At this stage, a unique dataset has been obtained and an initial analysis of the 
quality of diffraction data is carried out. There are several criteria to assess the 
data quality. Signal-to-noise ratio (SNR) is one of data quality indicators, either 
the overall SNR of the data or the SNR in the highest resolution shell. 1 < I/σ(I) < 
2 is typically defined as a SNR threshold for the resolution cut-off. The 
completeness of good data is expected to be close to 100% across the entire 
resolution range. Merging statistics are other important indicators to describe the 
internal consistency of the data as well as indicate the level of random error and 
residual systematic error in the data (Evans et al, 2011). 
 
 
2.5. Structure determination 
At this stage, the intensity of every reflection has been measured (Ihkl), which is 
proportional to |Fhkl|2, the remaining unknown is the phase αhkl. As this phase 
information has been lost during the X-ray diffraction experiment, solving the 
phase problem is required in order to fulfill the electron density reconstruction 
according to the equation: 
 !(!,!, !) != ! 1! ! |!!!"|! !!!"!!!!"(!!!!"!!")!!  
 
There are two possible ways for phasing that are molecular replacement and 
experimental phasing. Providing that there are closely related protein structures 
available in the databases, molecular replacement can be simply employed. If this 
is not the case, then experimental phases must be obtained. This method involves 
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finding the substructure of either heavy atoms or anomalous scattering atoms 
existing in the protein molecules with different techniques subsequently used to 
derive the phase angle. The common methods used to determine the phase angle 
are described below, and both rely on the Patterson function to determine the 
heavy atom substructure.    
 
 
2.5.1. Patterson function 
As the phase of an atomic structure factor depends on the position of the atom in 
the unit cell, to find the coordinates of the heavy atom in the unit cell, the 
Patterson method is employed. The Patterson function P (u,v,w) is a Fourier sum 
of the square of the structure factor amplitude with its frequencies h in the u-
direction, k in the v-direction and l in the w-direction, in the absence of phases.  
 P(u, v,w) != !1V ! |!!"#|!! !e!!"!(!"!!"!!")!!  
 
The amplitude contribution of the heavy atom in the derivative crystal can be 
obtained from the difference between the structure-factor amplitudes of the native 
and the derivative. 
 ∆! ! = |!!"|!– !|!!| ! 
 
A difference Patterson function can be derived as the equation below 
 ∆P(u, v,w) != !1V ! ∆!!"# !! !e!!"!(!"!!"!!")!!  
 
A Patterson map shows peaks at the locations corresponding to vectors between 
atoms and allows location of the atom(s) in the unit cell.   
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2.5.2. Isomorphous replacement 
Due to the isomorphism of native and heavy-atom derivative crystals, structure 
factors of a single reflection from native and the corresponding derivative 
reflection can be used to find out the heavy atom contribution. In vector terms, the 
structure factor for the heavy atom derivative (FPH) is the sum of those for the 
native protein (FP) and the heavy atom alone (FH) as the following: 
 
FPH = FP + FH 
or 
FP = FPH - FH  
 
The structure factor amplitude of the heavy atoms can be estimated from the 
isomorphous difference. !! ≃ |!!"|!– !|!!|  
 
If the substructure of the heavy atoms can be determined using the Patterson 
function, then FH can be calculated and |FH| and αH are thus known. 
  
This vector equation can be solved for FP using a Harker diagram which 
represents the relative vectors in the complex plane (Figure 2.6a). From the 
measured reflection intensities of the protein and heavy atom derivative crystals, 
their structure factor amplitudes |FP| and |FPH| can be calculated as the length of 
the vectors FP and FPH without their direction or phase angles. In the Harker 
diagram, a circle of radius |FPH| centered on the head of the vector –FH is drawn, 
representing the vector sum |FPH| - FH and together with a circle of radius |FP| 
centered at the origin. Therefore, the possible vector solutions can be drawn at the 
intersection points of these two circles (Figure 2.6b). To break the phase 
ambiguity, the second heavy atom derivative is used to obtaining the more likely 
phase angle from the overlapping of three circles (Figure2.6c). The phase of the 
native protein αP can be calculated from the following equation. 
 α! = !α! !± !cos!! !!"! − !!!! − !!!!2!!!!  
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a)  
b)  
c)  
Figure 2.6 Isomorphous replacement a) A representation of structure factor 
vectors of a native protein FP with phase αP (black) and its heavy atom derivative 
FPH with phase αPH (blue) is shown in an Argand diagram. b) Harker construction 
of single isomorphous replacement with phase ambiguity: two possible phases 
(αP) can be calculated. c) Harker construction of multiple isomorphous 
replacement: two or more heavy atom derivatives are used to resolve the phase 
ambiguity. The illustrations are taken from Taylor (2010). 
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2.5.3. Multi-wavelength anomalous dispersion (MAD) 
A different way to obtain phases is to use the anomalous scattering signal from 
certain atoms in the structure. In terms of X-ray absorption, a group of particular 
atoms can exhibit anomalous scattering when the incident wavelength is near to 
their absorption edges in which the absorption dramatically changes. The 
anomalous differences can be employed to locate the anomalous scatterers. 
 
Selenium is the most widely used as an anomalous scattering atom for MAD 
phasing approach. A fluorescence scan close to the absorption of the Se K-edge 
(0.9795 Å) where the f’ and f’’ are greatest allows the identification of energies to 
be used in MAD data collection (Figure 2.7). Three wavelengths are selected 
based on the absorption curve.  λ1 is at the peak of the anomalous signal f”. λ2 is at 
the point of inflection where the dispersive signal f’ reaches its minimum. λ3 is a 
remote wavelength that maximises the dispersive difference to λ2.  
 
!  
Figure 2.7 Typical absorption curve showing anomalous scattering signal in 
electrons for MAD phasing: The selection of wavelengths used in MAD is based 
on the real and imaginary anomalous scattering contributions, f’ (purple) and f” 
(red). This illustration is taken from Taylor (2010). 
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An atomic scattering factor relating to the anomalous contributions can be 
described as: 
 ! !,! = !! !! + !!′ ! + ! ∙ !′′ !  
 
The atomic scattering factor involves three different terms in which f0 represents a 
normal scattering depending on the Bragg angle whereas the dispersive 
component f’ and the absorption component f’’ represent anomalous scattering 
occurring at the absorption edge depending on the wavelength. The normal 
scattering factor is modified by f’ while f’’ is 90° advanced in phase. This 
anomalous effect leads to the breakdown of the Friedel’s law (Figure 2.8). As a 
result, the structure factor amplitude and intensity of reflection hkl is not equal to 
-h-k-l. The Bijvoet pair F+ and F- can be expressed in the following equations. 
 !! ! = |!!|! + !a|!!|! + b !! |!!| cosα!+ !b|!!||!!| sinα 
and 
 !! ! = |!!|! + !a|!!|! + b !! !! cosα!− !b|!!||!!| sinα 
 
where |FT| is the total structure factor amplitude of the protein without anomalous 
contributions and |FA| is the structure factor amplitudes of the anomalous marker. 
The constants a, b and c are dependent on the anomalous scattering contributions 
as described below. ! = !!′! + !!′′!!!! !!!!!!!!!!! = !2!′!! !!!!!!!!!!! = !2!′′!!  
The phase angle α is the phase difference between the true protein phase φT and 
the phase of the anomalous scattering contributions φA (Figure 2.9). 
 α = !φ! − !φ! 
 
When data collected at more than one wavelength are available, these unknown 
variables can be determined and FA, FT and α can be computed. 
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From the broken Friedel’s law, the Bijvoet difference can be calculated as: 
 ∆!± = !!"! − |!!"! | 
 
To locate anomalous scattering atoms, the Bijvoet difference coefficients ΔF2  are 
used to calculate a Patterson map that should  contain only peaks corresponding to 
the interatomic vectors between pairs of anomalous scattering atoms.  
 
  
Figure 2.8 Breakdown of Friedel’s law: When an anomalous scatterer is present, 
the structure factor amplitudes of Bijvoet mates are different, |FPA| ≠  |F-PA|. The 
vector FP (blue) represents the contributions from all of non-anomalous atoms and 
the vector FA (red) is the contributions from the anomalous scattering atom, 
consisting f0+f’ (green) and f” (orange) components.  
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a)  
b)   
Figure 2.9 Argand diagrams involved in MAD phasing: a) The structure factor of 
the protein with the anomalous scattering atom F+ (black) is made of the 
contribution of the protein FT (purple) and the anomalous scattering contributions 
FA (red). b) The phase shift (α) is described as the difference between the protein 
phase without anomalous contributions (φT) and the phase of the anomalous 
scattering contributions (φA).  
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2.5.4. Molecular replacement 
If the protein of interest has a structurally similar model available, phasing can be 
achieved by using the phase from its structure homologue. Typically, more than 
25% sequence identity and less than 2.0 Å rmsd between Cα atoms of the known 
models and unknown structured protein are considered to be required for this 
technique to work. The principle of molecular replacement based structure 
solution relies on the Patterson function. A Patterson map is calculated using a 
Fourier transform of the reflection intensities, resulting in an interatomic vector 
map. A Patterson map is also generated using calculated structure factor 
amplitudes from the atomic coordinates of the known structure model. In order to 
solve the unknown structure, the Patterson functions of the model and the 
unknown protein structures are aligned. The Patterson map of the known structure 
model is rotated over the other to obtain the relative orientation of the search 
model in the new unit cell. A new Patterson is then calculated on the related 
search model and the translation of the correctly oriented model is obtained by 
searching similar Patterson vectors between symmetry-related molecules in the 
unit cell. Therefore, an initial electron density map of the target protein structure 
can be reconstructed using its own measured amplitudes and phases taken from 
the correctly oriented search model.     
 
 
2.6. Structure refinement 
After an initial model of the protein has been built into the electron density map, 
model refinement is carried out to make the best agreement between the model 
and the X-ray data. A local real space refinement is approached by fitting 
individual residues into the electron density. To get more favorable geometry, the 
atomic positions are adjusted using real space regularization tools. After the local 
real space refinement, stereochemical and conformational errors remain. The 
model is therefore subjected to global reciprocal space restrained refinement. 
Stereochemical restraints including bond length, bond angle, torsion angle, 
chirality and planarity are taken into account during refinement, which has the 
effect of improving the observation-to-parameter ratio of the refinement. A 
number of repeating cycles of refinement are performed to adjust the atomic 
parameters of the model and optimise the fit between observed and calculated 
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structure factor amplitudes until the shifts reach convergence. An overall fitness 
between diffraction data and the model structure is described as a global linear 
residual, R-value. 
 R = ! |!!"#!– !!!"#!|! !!"#!  
 
The agreement between the experimental data and fitted model can be computed 
separately for the working data set and the excluded cross validation data set, 
designated as Rwork and Rfree, respectively. A small subset of randomly selected 
reflections set aside and not involved in the refinement is used for cross-validation 
technique to represent how well the model predicts experimental observations that 
are not themselves used to fit the model. Thus, Rfree is used to evaluate the model 
quality as well as the phase accuracy (Brunger, 1992).   
 
2.6.1. Maximum likelihood 
Maximum likelihood is statistical inference technique that declares that the best 
model on the evidence of the data is the one that explain what has actually been 
observed with the highest probability (McCoy, 2004). The maximum likelihood 
methods play an important role in crystallographic programme algorithms 
involving in data processing, electron density reconstruction and structure 
refinement. In protein crystallography, an experimental data refers to the observed 
structure factor amplitude for each reflection in reciprocal space (|Fobs|) and a 
model means the calculated structure factor of the structure in real space (Fcal). A 
solution is the most likely model with the Fcal that has the highest probability of 
generating the Fobs. A reflection likelihood function can be written as: 
 Ρ− !"#$ = !Ρ !"#";!"#$% = !Ρ(|!!"#|; |!!"#|) 
  
As the assumption of an independence of all reflections, an approximation of total 
likelihood is the product of the reflection likelihoods.  
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! − !"#$!"!!" = Ρ |!!"#|; |!!"#| =!! !Ρ |!!"#|; |!!"#|! ! 
 
Since the probability distributions are continuous, the sum in this equation is 
converted into an integral with all angles. 
 
! − !"#$!"!#$ = ! !Ρ( !!"# ; |!!"#|)!!!!!!  
 
The likelihood function is given by integrating out the nuisance phase between 
Fobs and Fcal, α. 
Ρ( !!"# ; |!!"#|) = ! !Ρ( !!"# ,!; |!!"#|)!!"!!!  
 
The errors in the phased structure factors in reciprocal space that arises from 
errors in the atomic model in real space can be described by the central limit 
theorem. The probability distribution for Fobs given Fcal is a two dimensional 
Guassian in reciprocal space with variance σ2Δ centered on Fcal. 
 
Ρ !!"#;!!"# = ! 1!!∆! !!!|!!"#! !!!"#|!!∆!  
 
From the relationship, Ρ(|Fobs|,α;|Fcal|) = Fobs x Ρ(Fobs;Fcal), it is therefore, 
 Ρ |!!"#|; |!!"#|
= !2|!!"#|!!∆! exp − |!!"#|! + |!!"#|!!∆! exp 2|!!"#||!!"#|!∆! !!"#$!!! !" 
 
The equation is thus simplified to the Rice distribution equation, 
 Ρ |!!"#|; |!!"#| = !2|!!"#|!∆! exp − |!!"#|! + |!!"#|!!∆! !! 2|!!"#||!!"#|!∆!  
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When |Fcal| is equal to zero, the Wilson distribution equation is therefore 
introduced, 
 Ρ |!!"#|; !!"# = 0 = !2|!!"#|!∆! exp |!!"#|!!∆!  
  
Usually, the log-likelihood (LL) is calculated instead of the likelihood. The LL 
gain value, which is the difference between LLs, can be used to determine the 
success of a procedure in maximum likelihood-based programmes.   
 
 
2.7. Structure validation 
Structure validation is an assessment of geometry and electron density to ensure 
the reliability of the structure model. The model can be checked automatically 
using structure validation tools such as PROCHECK (Laskowski et al, 1993) and 
MolProbity (Chen et al, 2010). The stereochemical parameters of the protein 
structure are verified in terms of an overall goodness of stereochemistry G-factor. 
G-factors should be scored greater than -0.5. The Ramachandran plot is used to 
evaluate the backbone conformation of the protein (Ramachandran et al, 1963). 
All residues should be in the allowed regions of the Ramachandran plot. If there is 
wrong conformation within the structure, it will have Ramachandran outiers. The 
distribution plot of B-factors can reveal an incorrection of model building either 
main chains or side chains with an observation of high B-factor values. 
 
As refinement proceeds, the model is validated using these tools, and corrections 
are made to areas with bad geometry, high B-factors, incorrect torsion angles and 
Ramachandran outliers. These tools are also useful to check that the final model 
contains no errors and is of a sufficient quality for deposition in the protein data 
bank. 
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Chapter 3: Materials and Methods 
 
This chapter describes the materials, methods and strategies used throughout the 
research project. Target selection, the amplification of the protein encoded genes, 
cloning of these genes, protein expression and purification, protein crystallisation, 
X-ray data collection, data processing, structure determination and ligand 
observation by nuclear magnetic resonance (NMR) are included.  
 
 
3.1. Target selection 
All target genes in this project were selected from lists of identified potential 
targets based on literature reviews (see section 1.8). As there is increasing 
attention on the development of rational drug design and biomarkers, putative 
essential genes and also immunogenic proteins of B. pseudomallei were taken into 
account in preparing the target list. Seven B. pseudomallei genes of interest are 
described in section 4.1. 
 
 
3.2. DNA manipulation 
3.2.1. Gene amplification 
The genes encoding target proteins were amplified from the genomic DNA of B. 
pseudomallei strain D286 isolated from a melioidosis-suffering patient in 
Malaysia. Oligonucleotide primers were designed using nucleotide sequences of 
the completely sequenced genome of B. pseudomallei strain K96243 as a 
reference. They were chemically synthesised by commercial company services 
(Eurofins MWG Operon and Sigma-Aldrich) for subsequent polymerase chain 
reaction (PCR) according to published guidelines (Dieffenbach et al, 1993). The 
standard 3-step PCR was carried out using a thermal cycler TC-312 (Techne). The 
reaction was made up of B. pseudomallei genomic DNA template, primers, 
polymerase enzyme, buffer and deoxyribonucleotides (dNTPs). Two different 
protocols were employed depending on the cloning strategies (see Table 3.1). 
Protocol A was used with BiomixTM Red (Bioline) for TA cloning whereas 
DyNAzymeTM EXT DNA polymerase (Finnzymes) was used together with its 
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optimised buffer and dNTPs for restriction enzyme cloning (protocol B). To make 
the DNA template accessible, the initial denaturation at 94˚C was performed for 5 
minutes. In each cycle, denaturation at 94˚C for 1 minute was carried out and the 
reaction was then cooled down to the annealing temperature calculated on the 
basis of the melting temperatures of the oligonucleotide primers (Tm) for 1 
minute. Subsequently, the extension of DNA fragments was followed at 72˚C for 
3 minutes. 25 cycles were repeated and the final extension occurred at 72 ˚C for 5 
minutes as the final step. 
 
 
Table 3.1 Recipe for PCR 
 Protocol A 
(µl) 
Protocol B 
(µl) 
Genomic DNA of B. pseudomallei 1 1 
100 µM forward primer 0.5 0.5 
100 µM reverse primer 0.5 0.5 
2x Biomix Red 25 - 
DyNAzymeTM EXT DNA Polymerase - 1 
10x DyNAzymeTM EXT Buffer - 5 
10 mM dNTP mix - 1 
Optional DMSO ranging from 0-1 µl (up to 10% v/v) 
Sterile deionised water to give final volume of 50 µl 
 
 
3.2.2. Agarose gel electrophoresis 
To analyse DNA fragments including PCR products and digestion products, 1% 
(W/V) agarose gels were prepared in 50 ml 1x TAE buffer and 4 µl GelRedTM 
(Biotium). 5-10 µl DNA samples with an addition of 6x gel loading dye (NEB) 
were run on the gel in TAE buffer at 100 Volts for 40 minutes. To estimate the 
size of the DNA fragments, an appropriate molecular weight DNA marker 
(HyperLadderTM I, Bioline) was used on the same gel. The gel containing DNA 
samples was visualised under ultra-violet light. 
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3.2.3. PCR purification and gel extraction 
After PCR, the PCR products were monitored on a 1% agarose gel and if the 
specific PCR product had been obtained, then it was separated from the rest of the 
reaction mixture using the QIAquick PCR Purification Kit (QIAGEN) according 
to the manufacturer’s instructions. When non-specific PCR products had been 
seen on the agarose gel, the rest of the PCR mixture was then loaded and run on 
another agarose gel electrophoresis. The specific DNA band with an expected size 
of the gene was cut off and recovered from the gel using a QIAquick Gel 
Extraction Kit (QIAGEN) following the manufacturer’s instructions.  
 
3.2.4. Gene cloning 
After PCR purification or gel extraction, PCR products were cloned into pET 
vectors following the manufacturers’ protocols. 
 
3.2.4.1. TA cloning 
Most of target genes (including BPSS0945, BPSS0238, BPSS1416, BPSS0603 
and BPSS0683) in this project were engineered into the pETBlue-1TM AccepTor 
vector (Novagen) which provides a high copy number of the screening vector for 
cloning and also facilitates protein expression (Figure 3.1 in Appendix). As a 
result of PCR, the target genes were synthesised with 3’-deoxyadenosine 
triphosphate overhangs, which were ligated to 3’-deoxyuridine triphosphate 
overhangs present in the linearised vector. With the AccepTor vector kit 
(Novagen), the PCR product was gently mixed with the commercially linearised 
vector, which was then ligated by the ligase provided in the ClonablesTM ligation 
premix. The recipe for ligation is shown in Table 3.2. The ligation reaction was 
performed at 16°C for 2 hours. 
 
Table 3.2 A ligation protocol for the pETBlue-1TM AccepTor vector (Novagen) 
 µl 
PCR product 4 
ClonablesTM 2x Ligation Premix 5 
50 ng/µl AccepTorTM Vector 1 
Total reaction volume 10 
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3.2.4.2. Restriction enzyme cloning 
Some of target genes in this work (including truncated BPSL3022 and 
BPSL0606) were cloned into the pET24-a vector (Figure 3.2 in Appendix) using 
restriction enzymes. Firstly, the gene sequences were analysed for potential 
cleavage sites using NEBcutter (Vincze et al, 2003), according to the recognition 
sequences of the commercially available restriction enzymes. Restriction enzymes 
that would not digest the gene targets were considered to be used for cloning, 
corresponding to the restriction map of the vector. 
 
The vector was digested with two different restriction enzymes for example NdeI 
and BamHI (EcoRI or XhoI are used instead of BamHI for cloning BPSL3022). 
To prepare the linearised vector ready to be used for cloning, the digestion 
mixture is shown below (Table 3.3). 
 
 
Table 3.3 Restriction enzyme digestion 
 µl 
pET24-a vector 10 
NdeI 1 
BamHI 1 
10x buffer* 2 
Sterile deionised water 6 
Total reaction volume 20 
*The selection of buffer depends on individual enzyme activity efficiency. The 
compatible buffer for both enzymes is recommended by the manufacturer (NEB). 
 
 
The digestion was carried out at 37 °C, which is an optimal temperature for 
enzyme activity, for 1 hour. Then, the linearised vector was recovered by the PCR 
purification kit (QIAGEN). The gene fragment from the PCR reaction was 
prepared to be an overhang-provided insert. The digestion was performed in the 
same way as the vector preparation.  
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 Digested vector and insert were mixed together with T4 ligase to join each other 
with compatible sticky ends as the recipe in Table 3.4. The ligation reaction was 
incubated at 16 °C for 3 hours or overnight for enhancing recombinant clones. 
 
Table 3.4 Ligation for recombinant pET24-a 
 µl 
Digested pET24-a 5 
Digested gene insert 12 
T4 Ligase 1 
10x T4 ligase buffer 2 
Total reaction volume 20 
 
 
3.2.5. Transformation of E. coli competent cells 
After cloning, the engineered pETBlue-1 vectors were transformed into NovaBlue 
(Novagen), a derived K12 strain of E. coli recommended for the pETBlue-1 
system.  
 
1 µl of ligation mixture was added to 50 µl of competent cells and placed on ice 
for 30 minutes. Using heat shock to allow physical changes in the bacterial cell 
membrane and plasmids to pass into the cell, the pre-chilled eppendorf tube 
containing the mixture of competent cells and plasmids was incubated in a 42˚C 
water bath for 30 seconds. Then, the reaction was rapidly cooled on ice for 2 
minutes. 250 µl of room temperature SOC medium (Novagen) was added into the 
reaction tube which was shaked at 250 rpm at 37°C for 30-60 minutes prior to 
plating. 50 µl and 100 µl of the transformation mixture was spread on LB media 
agar (Table 3.5) containing 50 µg/ml carbenicillin, 15 µg/ml tetracycline, 70 
µg/ml X-gal and 80 µM IPTG. The plates were inverted and incubated overnight. 
The recombinant clones were screened using suitable antibiotic markers as well as 
blue-white colony screening.  
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The recombinant pET24-a plasmids were transformed into E. coli DH5α cells 
(Novagen), using the above protocol except that the LB agar contained 15 µg/ml 
kanamycin as the antibiotic selective maker. 
 
3.2.6. Screening of recombinant clones by colony PCR 
In order to select the correctly orientated insert clones of the white colonies of 
pETBlue-1 transformants, colony PCR was undertaken, using a vector-specific 
primer and one target gene primer. A colony from an agar plate was picked using 
a sterile pipette tip and transferred to a PCR tube containing 10 µl of sterile water. 
The reaction was heated up to 99 °C for 5 minutes to lyse the cells using the PCR 
machine with heated lid lock on a cap, preventing the tube from opening. It was 
then centrifuge at 12000 g for a minute to remove the cell debris. The supernatant 
was transferred to a new PCR tube as a solution of DNA template for the standard 
PCR. pETBlueUP-primer (TCACGACGTTGTAAAACGAC) was used together 
with a reverse primer of the target gene. Alternatively, pETBlueDOWN-primer 
(GTTAAATTGCTAACGCAGTCA) can be used together with a forward primer 
of the target gene. The standard PCR was carried out following the protocol A in 
Table 3.1. To sub-culture investigating clones for further experiments, the same 
colony was picked and streaked on an agar plate containing 50 µg/ml carbenicillin 
and 15 µg/ml tetracycline. 
 
Table 3.5 Lysogeny broth (LB) media and LB agar recipes 
 g/L 
Tryptone 10 
Yeast extract 5 
Sodium chloride (NaCl) 5 
Agar* 15 
* Agar was added for preparing 1.5% w/v LB agar 
 
3.2.7. Plasmid DNA extraction 
After getting transformants, the recombinant plasmids were propagated in E. coli 
by growing up a selective single colony in 10 ml aliquots of LB media (Table 3.5) 
with appropriate antibiotics at 37°C, 250 rpm for overnight. The bacterial cells 
were harvested using a Sigma 3-16K table-top centrifuge at 5000 rpm for 5-10 
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minutes. After making copies of the recombinant clones in E. coli, the constructed 
DNA plasmids were extracted using the QIAprep Spin Miniprep Kit (QIAGEN) 
following the technical protocols provided by the manufacturer. 
 
3.2.8. Analysis of DNA sequencing 
The recombinant clones were verified by DNA sequencing with universal T7 
promoter primers. The automated fluorescent DNA sequencing was carried out by 
external services (Genetic Core Facility, University of Sheffield and Source 
Bioscience). The chromatogram data were analysed using Finch TV (Geospiza, 
Inc.; Seattle, WA, USA). 
 
3.3. Protein expression 
After the sequence of the recombinant clones was confirmed, the correct clones 
were further used for producing the recombinant proteins. To produce the 
proteins, the recombinant genes encoding B. pseudomallei target proteins were 
expressed in E. coli.  
 
3.3.1. Transformation of Tuner (DE3) pLacI 
pETBlue-1 recombinant plasmids were transformed into a suitable expression 
host that was Tuner (DE3) pLacI (Novagen), which provides an additional source 
of Lac repressor. 
 
1 µl of the pETBlue-1 recombinant plasmids was added to a 20 µl aliquot of 
thawed competent cells and was incubated on ice for 5 minutes. Then, it was 
heated in a 42 °C water bath for exactly 30 seconds and back on ice for 2 minutes. 
80 µl of room temperature SOC medium (Novagen) was added and the mixture 
was incubated at 37°C while shaking at 250 rpm for 60 minutes. 5-50 µl of the 
cell suspension was spread on LB agar containing 50 µg/ml carbenicillin and 34 
µg/ml chloramphenicol and the plates were incubated at 37°C overnight. 
 
3.3.2. Transformation of BL21 (DE3) 
pET24-a recombinant plasmids were transformed into E. coli BL21(DE3) 
competent cells (Novagen). The procedure of transformation was carried out as 
described in section 3.3.1 with an exception of using LB agar containing 15 µg/ml 
kanamycin. 
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3.3.3. Protein over-expression   
An over expression test was initially performed in a 50 ml culture. Transformant 
colonies were initially inoculated in 10 ml of LB media containing the appropriate 
antibiotics (50 µg/ml carbenicillin and 34 µg/ml chloramphenicol were used for 
growing Tuner (DE3) pLacI with pETBlue-1 recombinants whereas 15 µg/ml 
kanamycin was used for growing BL21 (DE3) with pET24-a recombinants) and 
the bacteria were grown at 37°C, 250 rpm overnight after inoculation. 1% 
inoculum was added to 50 ml LB media containing suitable antibiotics as above 
and the culture was incubated at 37°C while shaking at 250 rpm until an OD600 of 
0.6 was reached. Then, 50 µl of 1M IPTG (1 mM IPTG at final concentration) 
was added to an exponential phase growth culture and was incubated at the same 
temperature and shaking conditions for an additional 4 hours. The cell suspension 
was then transferred into 50 ml Falcon tubes. Bacterial cells were harvested using 
a Sigma 3-16K table-top centrifuge at 5000 rpm for 10-15 minutes. After draining 
off the liquid media, cell pastes were kept in -20°C for further analysis of protein 
expression. 
 
In order to optimise the growing conditions for obtaining soluble protein 
production, the final concentration of IPTG added and incubation temperature 
after induction were varied if the initial conditions did not yield soluble protein.  
 
 
To scale up the protein production, 5 ml of overnight pre-culture (1% inoculum) 
was added into 500 ml LB media containing suitable antibiotics. The culture was 
incubated at 37°C while shaking at 250 rpm until an OD600 of 0.6 was reached. 
0.5 ml of 1 M IPTG (1 mM IPTG at final concentration) was added and the 
culture was incubated at 37°C (20°C for BPSS0945 production) while shaking at 
250 rpm for an additional 4 hours prior to harvesting the cells. The culture was 
transferred into 250 ml centrifuge tubes and centrifuged at 10,000 rpm for 15-20 
minutes in a Beckman Avanti J25i centrifuge. Cell pastes were collected in 50 ml 
Falcon tubes and kept in the -20°C freezer for subsequent purification. 
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3.3.4. Selenium-methionine (Se-Met) incorporated protein 
production 
For BPSL0606, a Se-Met substituted protein was required for experimental 
phasing. To produce the Se-Met protein, the recombinant E. coli BL21 (DE3) 
carrying BPSL0606 in pET24-a was grown in LB media containing 15 µg/ml 
kanamycin at 37°C while shaking 250 rpm until OD600 ~ 0.6. The bacterial cells 
were harvested by centrifugation at 10000 rpm for 15-20 minutes at 4 °C and the 
liquid media were drained off. The cells were resuspended in minimal media M9 
(Table 3.6) and the cell suspension was then transferred into new flasks 
containing 500 ml minimal media M9 with Se-Met and all other supplements plus 
15 µg/ml kanamycin (Table3.6). When the OD600 of the bacterial culture in 
minimal media reached 0.6, 0.5 ml of 1 M IPTG (1 mM IPTG at final 
concentration) was added for induction and the culture was incubated at 37°C 
while shaking at 250 rpm for an additional 4 hours prior to harvesting. 
 
Table 3.6 Minimal media preparation for Se-Met substituted protein production 
M9 media   per litre 
Na2HPO4 6.78 g 
KH2PO4 3 g 
NaCl 0.5 g 
NH4Cl  1 g 
Glycerol 5 ml 
Supplements Final concentration 
CaCl2 0.1 mM  
MgSO4 2 mM  
Thiamine hydrochloride 2 µg/ml  
L-lysine 100 µg/ml  
L-threonine 100 µg/ml  
L-phenylalanine 100 µg/ml  
L-isoleucine 100 µg/ml  
L-valine 100 µg/ml  
L-leucine 100 µg/ml  
Se-Met  50 µg/ml 
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M9 minimal media was prepared and sterilised by autoclaving. All supplements 
were prepared in stock solutions, which were sterilised by a 0.2 µm pore size 
syringe filter and the required amounts of sterilised stock solutions were added to 
the autoclaved minimal media before use.  
 
 
3.3.5. Protein expression analysis 
In order to analyse the small-scale over-expression of the recombinant proteins, 
1.5 ml of samples were taken from the culture before and after induction of IPTG. 
Bacterial cells were pelleted by a bench-top centrifuge at 13,000 rpm for 5 
minutes. Proteins from the cell pellets were extracted and analysed by sodium 
dodecyl sulfate polyacrylamide gel electrophoresis (SDS PAGE).   
 
3.3.5.1. Cell disruption using BugbusterTM 
BugbusterTM (Novagen) was used to extract proteins in the cells by cell lysis. Cell 
pellets from 1.5 ml of bacterial culture were resuspended with a mixture of 4 µl 
BugbusterTM nuclease and 100 µl BugbusterTM protein extraction reagent. The 
reaction was mixed gently by pipetting the mixture and incubated on a rocking 
platform for 15 minutes at room temperature. The supernatant was then separated 
by centrifugation at 13,000 rpm for 5 minutes using a top bench centrifuge. The 
pellets containing the insoluble fraction of the protein were resuspended with 100 
µl 50 mM Tris-HCl pH 8. The soluble fraction and the insoluble fraction were 
further analysed by SDS PAGE. 
 
3.3.5.2. Cell disruption by ultra-sonication 
Cell pastes were resuspended in 50 mM Tris-HCl pH 8 with a ratio of 1:10 (1 g of 
cell pastes : 10 ml of buffer). The cell suspension was transferred to plastic bottles 
on ice and the bacterial cells were disrupted by ultra-sonication on ice. The ultra-
sonication was performed 3 cycles of 20 seconds each cycle with maximum 
amplitude and the samples were allowed to cool down between each cycle. Cell 
debris was separated from supernatant using in a Beckman Avanti J25i centrifuge 
at 24500 rpm for 10-15 minutes at 4 °C. The supernatant was subsequently 
analysed for protein concentration and proceeded to purification trials. 
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3.3.5.3. Bio-Rad protein assay 
To determine the protein concentration by the Bradford method (Bradford, 1976), 
1-20 µl of protein solution was added into a 1 ml plastic cuvette. 0.8 ml MilliQ 
water and 0.2 ml Bio-Rad reagent were added and the sample was mixed by 
inversion. The sample was then put into a spectrophotometer and the absorbance 
of the sample at 595 nm (A595) was measured against the reference set to zero 
with the solution of MilliQ water and Bio-Rad reagent. A read out value between 
0.1-0.7 was recommended for reliability. An estimated protein concentration was 
calculated from the following formula: 
 !"#$%&'!!"#!$#%&'%("#! (!" !") = ! !!"!×!15!!ℎ!!!"#$%&!!"!!ℎ!!!"#$%&'!!"#$%&!(!") 
 
where 15 is an estimated coefficient based on a calibration curve using a standard 
protein. 
 
 
3.3.5.4. Sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS PAGE). 
To visualise proteins for size approximation, about 20 µg protein sample was 
added with 10x reducing agent, 4x NuPAGE sample buffer (Invitrogen) and 
MilliQ water, if required, to a final volume of 20 µl. The mixture was heated in a 
100 °C heating block prior to loading and running on SDS polyacrylamide gel 
consisting of 12% resolving gel and 6% stacking gel (Table 3.7). All samples to 
be analysed were loaded on to the vertical gel with an additional lane of 
Mark12TM unstained standard (Invitrogen) as a protein ladder. The gel was run 
against 1x SDS buffer (diluted from 10x stock solution, Table 3.8) at 200 Volts 
for 50 minutes. Then, the gel was removed from the gel cassette and rinsed with 
water before staining. The gel was soaked in to staining solution (0.1% (w/v) 
Coomassie Brilliant Blue in 20% (v/v) methanol plus 10% (v/v) acetic acid 
solution) until the gel colour was saturated and sufficient to visualise. Then, it was 
destained in destaining solution (20% (v/v) methanol plus 10% (v/v) acetic acid 
solution) until its background was clear.   
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Table 3.7 SDS polyacrylamide gel recipe 
12% resolving gel  
30% Acrylamide/bisacrylamide (29:1) 2.5 ml 
1M Tris-HCl buffer, pH 8.8 2.35 ml 
10% SDS solution 62.5 µl 
10% Ammonium persulphate solution 62.5 µl 
TEMED 6.25 µl 
MilliQ water 1.28 ml 
6% stacking gel  
30% Acrylamide/bisacrylamide (29:1) 0.75 ml 
1M Tris-HCl buffer, pH 6.8 0.47 ml 
10% SDS solution 37.5 µl 
10% Ammonium persulphate solution 37.5 µl 
TEMED 3.75 µl 
MilliQ water 2.46 ml 
 
Table 3.8 10x SDS buffer recipe 
 Per liter 
Glycine 144 g 
Tris 30g 
SDS 10g 
 
 
3.4. Protein purification, crystallisation and data collection 
For each of the proteins studied, purification was undertaken using a combination 
of ion exchange chromatography and gel filtration chromatography. Crystals were 
grown using commercial screens (QIAGEN) using a Hydra II Plus One robot. 
Data collection was collected using both an in-house Rigaku MicroMax 007 
micro-focus copper rotating anode generator and Diamond synchrotron radiation. 
! 63!
Details for each protein are given in the following chapters; section 4.4.4 
(BPSS0945), section 4.6.3.3, 5.1 and 5.2 (BPSL0606). 
 
3.5. Data processing 
All X-ray diffraction images were autoindexed and integrated by Mosflm (Leslie, 
2006). The diffraction data were scaled and merged by SCALA (Evans, 2006) . 
At the Diamond beamlines, diffraction data were automatically processed using 
XDS in the xia2 pipeline (Winter, 2010). The Matthews_coeff program in the 
CCP4 suite (Collaborative Computational Project, 1994) was used to analyse the 
unit cell contents on a basis of the unit cell volume and protein size (Matthews, 
1968).  
 
3.6. Structure determination 
The software suite Phenix (Adams et al, 2010) was used to determine the protein 
structure using molecular replacement and the MAD method. The best structure 
solution was obtained and the protein chains were re-built using the CCP4 suite 
(Collaborative Computational Project, 1994) and Coot (Emsley et al, 2010). 
REFMAC5 was used for structure refinement (Murshudov et al, 2011). Structure 
validation was carried out using RAMPAGE in the CCP4 suite (Lovell et al, 
2003). 
 
3.7. Ligand observation by nuclear magnetic resonance (NMR) 
Freshly purified BPSL0606 protein was prepared in 20 mM Na-phosphate buffer 
pH 6.5 plus 0.1 M NaCl for 1H-NMR experiment. The concentration was 
calculated using the measured absorbance at 280 nm divided by an extinction 
coefficient predicted from ProtParam tool. Acetyl coenzyme A solution was 
prepared at the same molar concentration of the protein. A mixture of purified 
protein and acetyl coenzyme A was prepared in a 1:1 molar ratio. All samples 
were loaded into NMR tubes and added with 50 µl heavy water (D2O) prior to 
loading the samples to a Bruker Avance 600MHz NMR spectrometer equipped 
with a 5mm TXI 13C/15N Z-gradient probe. 1H NMR spectra of samples were 
observed. 
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Chapter 4: Target Selection, Cloning, 
Protein Expression and Purification 
 
This chapter describes target selection, gene amplification, cloning of target 
genes, protein over-expression and protein purification. Although the desired 
outcome of this project would be a molecular structure of each target protein, it is 
unrealistic to assume that this will occur, with failures possible at any 
experimental step. Thus, the gene amplification and cloning of BPSL3022, 
BPSS0945, BPSS0603, BPSS0683, BPSL0606, BPSS0238 and BPSS1416 are 
described. The protein expression of BPSL3022, BPSS0945, BPSS0603, 
BPSS0683 and BPSL0606 are detailed and the protein purification of BPSS0945 
and BPSL0606 are discussed. 
 
 
4.1. Target selection 
A list of target genes in this study was created from a selection of potential drug 
targets, which are detailed below.  
 
Su et al (2008) have experimentally identified 109 immunogenic proteins by 
western blotting a B. pseudomallei D286 genomic expression library against the 
pooled sera of melioidosis patients, as a primary antibody screening. The proteins 
that reacted with the serum of the melioidosis patients may thus be involved in the 
pathogenesis and virulence of a B. pseudomallei infection. Based on a database of 
conserved domains (Marchler-Bauer et al, 2011), these immunogenic proteins 
have been classified into different functional groups, including cell envelope 
biogenesis (13%), cell mobility and secretion (6%), transcription (6%), amino 
acid transport and metabolism (11%), inorganic ion transport and metabolism 
(3%), protein metabolism (8%), energy production and conversion (8%), nucleic 
acid metabolism and repair (5%), miscellaneous metabolic proteins (16%), other 
transporters (7%) and uncharacterised hypothetical proteins (17%).  
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In conjunction, 312 putative essential genes of B. pseudomallei have been 
identified computationally (Chong et al, 2006). The B. pseudomallei genome was 
compared with the human genome sequence to identify those B. pseudomallei 
genes that do not have a homologue in humans. These genes were further 
compared with known essential gene sequences in the database of bacterial 
essential genes (Zhang et al, 2004) to obtain a list of putative essential genes in B. 
pseudomallei. These genes were classified into different functional classes 
according to the Wellcome Trust Sanger Institute annotation naming strategies, 
including regulator proteins (21.2%), inner membrane/outer membrane/secreted/ 
surface structure (20.8%), information transfer (transcription/translation/DNA/ 
RNA modification) (17.9%), central/intermediate/miscellaneous metabolism 
(18.6%), energy metabolism (3.5%), degradation of small and large molecules 
(1.3%), pathogenicity/adaptation/ chaperones (4.5%), some information but no 
function (4.8%) and conserved hypothetical proteins (7.4%).        
 
To make a list of a potential drug candidates in this study, the 109 immunogenic 
proteins from the study of Su et al (2008) were compared with the 312 putative 
essential genes of the study of Chong et al (2006) using the B. pseudomallei locus 
tag identity (BPS_XXXX). The intersection between these two identified groups 
gave a list of four proteins that elicit an immune response in infected individuals, 
and are also predicted to be essential for B. pseudomallei survival (Figure 4.1). 
These proteins (BPSL3022, BPSS0945, BPSS0238 and BPSS1416), which may 
play a role in pathogenesis or virulence and are also attractive drug targets, were 
thus selected as the first four proteins to be characterised (Table 4.1) 
 
A further three uncharacterised proteins, BPSS0603, BPSS0683 and BPSL0606, 
which were also immunogenic proteins but were not putative essential genes, 
were selected and added to the list after failing to obtain crystals from any of the 
first four proteins for crystallographic studies. 
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b)
 
21% 
21% 
19% 
18% 
7% 
5% 
4% 4% 1% 
Distribution of 312 B. pseudomallei putative essential genes classified by 
the Wellcome Trust Sanger Institute annotation naming scheme  
Regulator 
IM, OM, secreted, surface structure 
Central/intermediate/miscellaneous metabolism 
Information transfer 
Conserved hypothetical protein 
Some information but no function 
Pathogenecity, adaptation, chaperones 
Energy metabolism 
Degradation of small and large molecules 
13% 
11% 
8% 
8% 
6% 
6% 5% 
3% 
7% 
16% 
17% 
Distribution of 109 identified B. pseudomallei immunogenic proteins 
classified according to the conserved domain database  
Cell envelope biogenesis 
Amino acid transport and metabolism 
Protein metabolism 
Energy production and conversion 
Cell motility and secretion 
Transcription 
Nucleic acid metabolism and repair 
Inorganic ion transport and 
metabolism 
Other transporter 
Other metabolic protein 
Uncharacterized and hypothetical 
protein 
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c)
 
 
Figure 4.1 An initial target selection:  
a) 312 putative essential genes identified for potential drug target were grouped 
by their relative functions (Chong et al, 2006).  
b) The experimentally identified 109 immunogenic proteins were classified into 
their conserved domain related groups (Su et al, 2008). 
c) A Venn diagram showed the intersection between these two identified targets, 
which includes BPSL3022, BPSS0945, BPSS0238 and BPSS1416.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
109 identified immunogenic 
proteins 312 putative essential genes 
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Table 4.1 A list of selected targets 
Locus tag Annotation Gene size 
(base pair) 
No. of 
Amino acid 
Molecular 
weight 
(kDa) 
BPSL3022 Cell division protein 
FtsQ 
753 250 27.93 
BPSS0945 Subfamily M23B 
unassigned peptidase 
948 315 32.03 
BPSS0238 Penicillin binding 
protein 
2163 720 76.75 
BPSS1416 Hypothetical protein 1404 467 47.72 
BPSS0603 Hypothetical protein 303 100 10.99 
BPSS0683 Hypothetical protein 357 118 12.99 
BPSL0606 Hypothetical protein 651 216 23.49 
 
 
4.2. Gene amplification 
Oligonucleotide primers for target gene amplification were designed according to 
their open reading frames of their individual nucleotide sequence based on the 
completely sequenced genome of B. pseudomallei strain K96423.  
 
4.2.1. Primer design 
PCR primers were designed compatible to vectors used for subsequent cloning. 
Two different cloning methods were used in this study.  
 
The first method is TA cloning using the pETBlue-1 vector, which facilitates 
cloning and enables high-level recombinant protein expression in E.coli 
(Novagen). This system requires the insert to start with an ATG start codon so 
that translation initiation occurs, with an optimal spacing of 8 base pairs between 
the ribosome binding site and the start codon. Therefore, the forward primers 
were designed to start with ATG and the reverse primers were designed 
complementary to their own sequence. This method was used for cloning of 
BPSL3022, BPSS0945, BPSS0238, BPSS1416, BPSS0603 and BPSS0683. 
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The second method of cloning used in this project, was restriction enzyme 
cloning, with pET24-a vector, which is a cloning/expression vector that provides a 
C-terminal His tag fusion (Novagen). For the restriction enzyme cloning, primers 
were designed with the additional recognition sequence of restriction enzymes 
used in the cloning. The target sequences were firstly analysed using NEB cutter 
(Vincze et al, 2003) to identify restriction sites present in the target sequences. 
The primers were then designed to contain restriction sites not present in the 
target gene. The forward primer of BPSL3022, BPSS0238, BPSS1416 and 
BPSL0606 contained NdeI (CATATG). The reverse primers for different 
constructs of BPSL3022 either had EcoRI (GAATTC) or XhoI (CTCGAG) sites, 
whereas the reverse primers for BPSS0238, BPSS1416 and BPSL0606 contained 
BamHI (GGATCC). A list of primers used in this study is shown in Table 4.2. 
 
Table 4.2 A list of primers used in this work (underline-restriction site) 
Locus tag 
Annotation 
Cloning 
method 
5’-3’ Oligonucleotides 
Forward primer Reverse primer 
BPSL3022 
Cell division 
protein FtsQ 
   
BPSL3022_1 TA ATGCGGGAAATCCGCATCG 
19 bp 
Tm 60 °C, %GC 57.9 
GCTTACATGCCCGCCGC 
17 bp 
Tm 58 °C, %GC 70.6 
BPSL3022_2 TA  TTACTTCTTGCCCTTGTCGGT  
21 bp 
Tm 62 °C, %GC 47.6 
BPSL3022_1 RE GCGTTCCATATGCGGGAAATC 
21 bp 
Tm 64 °C, %GC 52.4 
GGTGAATTCTTACATGCCCGC 
21 bp 
Tm 64 °C, %GC 52.4 
BPSL3022_2 RE  TGATGAATTCTTACTTCTTGCCCT 
24 bp 
Tm 64 °C, %GC 37.5 
BPSL3022_3 RE  GTCCTCGAGCTTCTTGCCCT 
20 bp 
Tm 64 °C, %GC 60 
BPSS0945 
Subfamily 
M23B 
unassigned 
peptidase 
TA ATGAGCAAGAGCGAGATCGA 
20 bp 
Tm 60 °C, %GC 50 
CTAGCCCTGCTGCCGGC  
17 bp 
Tm 60 °C, %GC 76.5 
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Table 4.2 A list of primers used in this work (underline-restriction site) 
(continued) 
Locus tag 
Annotation 
Cloning 
method 
5’-3’ Oligonucleotides 
Forward primer Reverse primer 
BPSS0238 
Penicillin 
binding 
protein 
TA ATGCCAACGAAGGATTTCGAC 
21 bp 
Tm 62 °C, %GC 47.6 
TCAGTCTTCGGTGCGAAACA  
20 bp 
Tm 60 °C, %GC 50 
 RE GTACGCCGCATATGCCAAC 
19 bp 
Tm 60 °C, %GC 57.9 
GGATCCCCGCTCAGTCTTC 
19 bp 
Tm 62 °C, %GC 63.2 
BPSS1416 
Hypothetical 
protein 
TA ATGCCTGCCTCCATGAGC  
18 bp 
Tm 58 °C, %GC 61.1 
TCATGCGGCGCCCTCCA 
17 bp 
Tm 58 °C, %GC 70.6 
 RE CCGCATATGCCTGCCTCCAT 
20 bp 
Tm 64 °C, %GC 60 
AGGATCCTCATGCGGCGCCC 
20 bp 
Tm 68 °C, %GC 70  
BPSS0603 
Hypothetical 
protein 
TA ATGATAATGGAGGCAAGCATGT  
22 bp 
Tm 62 °C, %GC 40.9 
GTTACGTGCTCGCCGC 
16 bp 
Tm 54 °C, %GC 68.8 
BPSS0683 
Hypothetical 
protein 
TA ATGCGCCTCACCATTCGAAT 
20 bp 
Tm 60 °C, %GC 50 
TCAGCGCACGATGGTGAAT 
19 bp 
Tm 58 °C, %GC 52.6 
BPSL0606 
Hypothetical 
protein 
RE GAATCTCCCATATGGACTGG 
20 bp 
Tm 60 °C, %GC 50 
GGATCCTCATCGGTTCATTC 
20 bp 
Tm 60 °C, %GC 50 
NB:  TA = TA cloning 
 RE = Restriction enzyme cloning 
 
 
4.2.2. Polymerase chain reaction (PCR) 
The amplification of these target genes was carried out using the polymerase 
chain reaction (PCR). The genomic DNA of B. pseudomallei strain D286, kindly 
provided by the Universiti Kebangsaan Malaysia, was used as a template. The 
optimization of PCR was carried out for individual gene amplification by varying 
the annealing temperature and the percentage of dimethyl sulfoxide (DMSO). As 
the B. pseudomallei genome contains high GC levels (68%), the addition of 
DMSO was used in the PCR in order to facilitate base pairing disruption between 
double stranded DNA with high GC contents (Kang et al, 2005; Musso et al, 
2006). The PCR conditions for each gene are shown in Table 4.3.  
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Table 4.3 PCR conditions for target gene amplification 
 Annealing 
temperature (°C) 
DMSO (% V/V) 
BPSL3022_1/TA 56 - 
BPSL3022_2/TA 56 - 
BPSL3022_1/RE 60 - 
BPSL3022_2/RE 56 5 
BPSL3022_3 58 2 
BPSS0945 56 5 
BPSS0238 56 10 
BPSS1416 56 5 
BPSS0603 53 - 
BPSS0683 60 - 
BPSL0606 56 2 
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4.3. BPSL3022-Cell division protein FtsQ 
BPSL3022 truncation: periplasmic protein constructs  
In the B. pseudomallei genome, BPSL3022 has been annotated as the cell division 
protein FtsQ (Winsor et al, 2008). The ftsQ gene in E. coli is found in a cell 
division gene cluster that is involved in septum formation and synthesis of cell 
wall components. The FtsQ protein (31 kDa) consists of a 24 N-terminal amino 
acid residue cytoplasmic tail, residues 25-49 embedded in the cytoplasmic 
membrane and the remainder forming a C-terminal periplasmic domain of 226 
residues (Carson et al, 1991). The structures of FtsQ from E. coli and Yersinia 
enterocolitica have been successfully determined (Van den Ent et al, 2008). Both 
these proteins are composed of two domains. The topology of the α-domain close 
to the membrane is β-α-α-β-β and the C-terminal β-domain consists of nine β-
strands with two long α-helices (Figure 4.2). The constructs for expressing the 
proteins, that crystallised into these two structures of the periplasmic domain of 
FtsQ in E. coli and Y. enterocolitica, contain residues 58-276 and residues 59-285 
for E. coli and Y. enterocolitica FtsQ, respectively, each lacking the N-terminal 
hydrophobic region.  
 
Figure 4.2 Crystal structures of periplasmic FtsQ in E. coli and Y. entericolitica:  
E.coli and Y.entericolitica FtsQ have 56% sequence identity and the rmsd of their 
superposed structures (Cα) is 1.63 Å. This figure is taken from Van den Ent et al 
(2008). 
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The protein sequence of FtsQ in B. pseudomallei (BPSL3022) was analysed using 
hydropathy plot, which showed that the protein contains a N-terminal 
hydrophobic part, which is likely to be a membrane anchor (Figure 4.3). Kyte-
Doolittle scale plots show the distribution of hydrophobic and hydrophilic 
residues on the protein sequence and positive values represent the hydrophobic 
character of the protein. A score of more than 1.6 indicates a potential 
hydrophobic membrane-spanning domain. This corresponds to a prediction of 
transmembrane helices, based on a hidden Markov model by the TMHMM server 
v.2.0 (Krogh et al, 2001). The TMHMM annotation probabilities for the sequence 
of BPSL3022 are shown in Figure 4.4.  
 
 
 
Figure 4.3 A hydropathy plot for BPSL3022, showing the N-terminal 
hydrophobic region (residues 1-24) of this protein. This figure was produced 
using the hydropathy plot server (http://www.vivo.colostate.edu/molkit/ 
hydropathy/index.html). 
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Figure 4.4 Transmembrane prediction of BPSL3022: Residues 10 to 32 of 
BPSL3022 are likely to form a transmembrane helix. This figure was produced 
using TMHMM server (Krogh et al, 2001). 
  
When the secondary structure of BPSL3022 was predicted using 
mGenTHREADER PREDICTION (McGuffin et al, 2000), the top hits had 
approximately 30% identity to the crystal structures of E. coli and Y. 
enterocolitica. Thus, the protein sequence of BPSL3022 was aligned with the 
sequences of the crystal structures of periplasmic FtsQ in E. coli and Y. 
enterocolitica using ClustalW (Thompson et al, 1994), as shown in Figure 4.5.  
 
Using this alignment, two constructs of BPSL3022 were designed, in an attempt 
to optimise the probability of crystallisation. According to the BPSL3022 
sequence, one truncated form of BPSL3022 (named BPSL3022_1) was 
constructed from residue 40 (arginine, R) to residue 239 (methionine, M), where 
the sequence similarity to the FtsQ homologue structures ends, and the other 
construct (named BPSL3022_2) started from residue 40 to the C-terminus, residue 
250 (lysine, K) (Figure 4.5). Therefore, the oligonucleotide primers of the 
truncated BPSL0606 were designed corresponding to the open reading frame 
from the residue 40 with additional start codon ATG to amplify these gene 
fragments.     
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Figure 4.5 Protein sequence alignment of the crystal structures of the periplasmic 
FtsQ protein from E. coli (second line) and Y. enterocolitica (first line) and FtsQ 
from B. pseudomallei (third line); The constructs that crystallised for FtsQ in      
E. coli and Y. enterocolitica were considered in order to design a construct of 
periplasmic FtsQ in B. pseudomallei, on the basis of sequence similarity. 
Completely conserved residues are shown in green, identical residues are in 
yellow and similar residues are shown in cyan. This figure was created using 
Boxshade (Hofmann & Baron). 
 
The protein sequences of the two BPSL3022 truncates were analysed by 
ProtParam (ExPASy server). The short truncated FtsQ consists of 201 amino 
acids with a molecular weight of 22.6 kDa and a theoretical pI of 5.3, whereas the 
long truncated FtsQ is 212 amino acids long and has a molecular weight of 23.9 
kDa with a theoretical pI of 5.7 (Figure 4.6). 
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a)  
b)  
Figure 4.6 Protein sequence analysis of BPSL3022 constructs by ProtParam: a) 
Characteristics of the short truncated BPSL3022 (residues 40-239); b) 
Characteristics of the long truncated BPSL3022 (residues 40-250) 
 
ProtParam: BPSL3022s 
MREIRIDGDT EHINAPTVRA GVVGRLKGNF FTVDLDLARV AFEQMPWVRH ASVRRVWPNA  
LAVTLEEYKP LGTWGNDQLV SVDGELFTAN QGELDAELPS FDGPEGSAKE VVARYRDFAK  
WFAPIHATPE EVTLSPRYAW TVKLSNGMQV ELGRERNSDT LPDRIQRLVA AWPSVTQRWG  
GDIEYADLRY PNGFAIRAAG M  
 
Number of amino acids: 201 Molecular weight: 22584.4 Theoretical pI: 5.30 
 
Amino acid composition:  
Ala (A)  21  10.4% 
Arg (R)  18   9.0% 
Asn (N)   8   4.0% 
Asp (D)  13   6.5% 
Cys (C)   0   0.0% 
Gln (Q)   6   3.0% 
Glu (E)  15   7.5% 
Gly (G)  16   8.0% 
His (H)   3   1.5% 
Ile (I)   7   3.5% 
Leu (L)  16   8.0% 
Lys (K)   5   2.5% 
Met (M)   4   2.0% 
Phe (F)   8   4.0% 
Pro (P)  12   6.0% 
Ser (S)   8   4.0% 
Thr (T)  11   5.5% 
Trp (W)   7   3.5% 
Tyr (Y)   5   2.5% 
Val (V)  18   9.0% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
 (B)   0   0.0% 
 (Z)   0   0.0% 
 (X)   0   0.0% 
 
 
Total number of negatively charged residues (Asp + Glu): 28 
Total number of positively charged residues (Arg + Lys): 23 
 
Atomic composition: 
Carbon      C       1010 
Hydrogen    H       1557 
Nitrogen    N        287 
Oxygen      O        296 
Sulfur      S          4 
 
Formula: C1010H1557N287O296S4 
Total number of atoms: 3154 
 
Extinction coefficients: 
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in water. 
Ext. coefficient    45950 
Abs 0.1% (=1 g/l)   2.035, assuming ALL Cys residues appear as half cystines 
 
 
Estimated half-life: 
 
The N-terminal of the sequence considered is M (Met). 
 
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro). 
                            >20 hours (yeast, in vivo). 
                            >10 hours (Escherichia coli, in vivo). 
 
 
Instability index: 
 
The instability index (II) is computed to be 25.37 
This classifies the protein as stable. 
 
ProtParam: FtsQ (BPSL3022L) 
MREIRIDGDT EHINAPTVRA GVVGRLKGNF FTVDLDLARV AFEQMPWVRH ASVRRVWPNA  
LAVTLEEYKP LGTWGNDQLV SVDGELFTAN QGELDAELPS FDGPEGSAKE VVARYRDFAK  
WFAPIHATPE EVTLSPRYAW TVKLSNGMQV ELGRERNSDT LPDRIQRLVA AWPSVTQRWG  
GDIEYADLRY PNGFAIRAAG MRFLTDTDKG KK  
 
Number of amino acids: 212  Molecular weight: 23874.9  Theoretical pI: 5.71 
 
Amino acid composition:  
Ala (A)  21   9.9% 
Arg (R)  19   9.0% 
Asn (N)   8   3.8% 
Asp (D)  15   7.1% 
Cys (C)   0   0.0% 
Gln (Q)   6   2.8% 
Glu (E)  15   7.1% 
Gly (G)  17   8.0% 
His (H)   3   1.4% 
Ile (I)   7   3.3% 
Leu (L)  17   8.0% 
Lys (K)   8   3.8% 
Met (M)   4   1.9% 
Phe (F)   9   4.2% 
Pro (P)  12   5.7% 
Ser (S)   8   3.8% 
Thr (T)  13   6.1% 
Trp (W)   7   3.3% 
Tyr (Y)   5   2.4% 
Val (V)  18   8.5% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
 (B)   0   0.0% 
 (Z)   0   0.0% 
 (X)   0   0.0% 
 
 
Total number of negatively charged residues (Asp + Glu): 30 
Total number of positively charged residues (Arg + Lys): 27 
 
Atomic composition: 
Carbon      C       1067 
Hydrogen    H       1652 
Nitrogen    N        304 
Oxygen      O        313 
Sulfur      S          4 
 
Formula: C1067H1652N304O313S4 
Total number of atoms: 3340 
 
Extinction coefficients: 
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in water. 
Ext. coefficient    45950 
Abs 0.1% (=1 g/l)   1.925, assuming ALL Cys residues appear as half cystines 
 
 
Estimated half-life: 
 
The N-terminal of the sequence considered is M (Met). 
 
The estimated half-life is: 30 hours (mammalian reticulocytes, in 
vitro). 
                            >20 hours (yeast, in vivo). 
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4.3.1. Gene amplification 
The target genes encoding the periplasmic part of B. pseudomallei FtsQ were 
amplified from the genomic DNA of B. pseudomallei strain D286 using the 
oligonucleotide primers designed according to the open reading frame that 
encodes from residue 40 of the full-length protein with additional start codon 
(ATG) to fulfill the requirement of pETBlue-1 vector system. The forward primer 
(5’-ATGCGGGAAATCCGCATCG-3’) and reverse primer (5’- GCTTACATG 
CCCGCCGC-3’) were used in a standard PCR to obtain the short truncated FtsQ, 
while the same forward primer was used together with the reverse primer (5’-
TTACTTCTTGCCCTTGTCGGT-3’) for obtaining the long truncated construct. 
The PCR products for both gene fragments amplification were achieved using an 
annealing temperature of 56 °C with an expected size of approximately 600 base 
pairs (Figure 4.7). 
 
Figure 4.7. PCR products of truncated BPSL3022 gene amplification on a 1% 
agarose gel: The expected size of the PCR products obtained was in the region of 
600 base pairs. 
 
4.3.2. Cloning of BPSL3022_1 and BPSL3022_2 
The PCR products of BPSL3022_1 and BPSL3022_2 were cloned into the 
pETBlue-1 vector by joining the given 3’-dU overhang of the linearised pETBlue-
1TM AccepTor vector and the 3’-dA overhangs of the PCR products. The 
linearised pETBlue-1TM AccepTor vector provides single 3’-dU overhangs that 
can be ligated with an insert with 3’-dA overhangs, generated during PCR with a 
DNA polymerase lacking 3’->5’exonuclease activity. After ligation, the 
recombinant plasmids were transformed into E.coli NovaBlue, which enables 
blue/white screening. White colonies obtained are the bacteria carrying the 
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recombinant plasmids, as the insert interferes with a lacZ α-peptide open reading 
frame in the vector, resulting in the disruption of β-galactosidase production, 
which disables the cleavage of the chromogenic substrate, X-gal, on the agar 
plate. 
 
Recombinant clones of BPSL3022 were selected by the blue white colony 
method. The recombinant plasmids can carry the insert either correctly oriented or 
the wrong way round. To determine the correct orientation of the insert, the white 
colonies were further screened by colony PCR. The use of a vector specific 
primer together with an insert primer for amplifying the investigating plasmid 
DNA yields the expected sized PCR product, if the recombinant has the correct 
orientation. Recombinant plasmids with a positive PCR result were propagated in 
E. coli. The recombinant plasmids were extracted and the sequence confirmed by 
DNA sequencing with universal T7 primers. 
 
The sequencing results of the long truncated (BPSL3022_2) clone showed that 
there were two nucleotides that were different from the reference genome of B. 
pseudomallei strain K96243, resulting in one amino acid alteration at residue 79 
(A to V) (Figure 4.8). On the other hand, the BPSL3022_1 short truncated 
construct could not be successfully cloned, since the plasmid sequencing indicated 
that these clones contained the long truncated insert. This may be due to an 
inappropriate primer design.     
 
 
Figure 4.8 DNA sequencing of BPSL3022_2 in the pETBlue-1 clone: The translated 
protein sequence of the recombinant truncated BPSL3022 (first line) was aligned with the 
full length protein sequence of FtsQ in B. pseudomallei strain K96243 (second line), 
showing one amino acid alteration highlighted in red (Ala to Val). This figure was 
created using Boxshade (Hofmann & Baron). 
BPSL3022_24        1 --------------------------------------MREIRIDGDTEHINAPTVRAGV
gi_53720632_ref    1 MWNNVRQLNLAASALYALLLLVLAAAGCYWLIQRPAFALREIRIDGDTEHINAPTVRAGV
consensus          1 mwnnvrqlnlaasalyallllvlaaagcywliqrpafamREIRIDGDTEHINAPTVRAGV
BPSL3022_24       23 VGRLKGNFFTVDLDLARVVFEQMPWVRHASVRRVWPNALAVTLEEYKPLGTWGNDQLVSV
gi_53720632_ref   61 VGRLKGNFFTVDLDLARVAFEQMPWVRHASVRRVWPNALAVTLEEYKPLGTWGNDQLVSV
consensus         61 VGRLKGNFFTVDLDLARV-FEQMPWVRHASVRRVWPNALAVTLEEYKPLGTWGNDQLVSV
BPSL3022_24       83 DGELFTANQGELDAELPSFDGPEGSAKEVVARYRDFAKWFAPIHATPEEVTLSPRYAWTV
gi_53720632_ref  121 DGELFTANQGELDAELPSFDGPEGSAKEVVARYRDFAKWFAPIHATPEEVTLSPRYAWTV
consensus        121 DGELFTANQGELDAELPSFDGPEGSAKEVVARYRDFAKWFAPIHATPEEVTLSPRYAWTV
BPSL3022_24      143 KLSNGMQVELGRERNSDTLPDRIQRLVAAWPSVTQRWGGDIEYADLRYPNGFAIRAAGMR
gi_53720632_ref  181 KLSNGMQVELGRERNSDTLPDRIQRLVAAWPSVTQRWGGDIEYADLRYPNGFAIRAAGMR
consensus        181 KLSNGMQVELGRERNSDTLPDRIQRLVAAWPSVTQRWGGDIEYADLRYPNGFAIRAAGMR
BPSL3022_24      203 FLTDTDKGKK
gi_53720632_ref  241 FLTDTDKGKK
consensus        241 FLTDTDKGKK
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4.3.3. Protein expression 
Expression of the truncated BPSL3022_2 in pETBlue-1 was carried out in E. coli 
TunerTM (DE3), with 1mM IPTG induction at 37°C for 4 hours after growing to 
mid log phase (OD600 ~ 0.6). After harvesting and disrupting the bacterial cells, 
the protein expression profiles were analysed by SDS PAGE. The expected 
molecular weight of this construct is 23.9 kDa (ProtParam, ExPASy server). 
There was an intense band between 21.5 and 31 kDa on the SDS PAGE gel 
(Figure 4.9). In the host expression system, E. coli TunerTM also produces 
chloramphenicol acetyl transferase (CAT) which is 25.7 kDa in size. Therefore, it 
was uncertain whether the band visualised on the gel was the target protein or the 
CAT protein. It was quite difficult to separate these two proteins with their similar 
pI (BPSL3022_2 pI 5.7, CAT pI 5.9) as there was no affinity tag on the target 
protein.  
 
 
 
Figure 4.9 SDS PAGE BPSL3022_2 in pETBlue-1 expressed in E. coli Tuner 
(DE3) pLacI cells: lane 1 Mark12TM; lane 2 pre-induction; lane 3 soluble fraction 
at 37°C induction for 4 hours; lane 4 insoluble fraction at 37°C induction for 4 
hours 
 
 
 
 
 
 
              1           2          3         4             
 kDa 
 
31 
 
 
21.5 
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As overexpression of the CAT protein often occurs in the pETBlue-1 expression 
system, a different construct, BPSL3022_3, was thus designed in order to clone 
into the pET24-a vector system using the restriction enzyme strategy. This 
construct provides a C-terminal His-tag to the protein in order to ease protein 
purification. The forward primer (5’-GCGTTCCATATGCGGGAAATC-3’) and 
the reverse primer (5’- GTCCTCGAGCTTCTTGCCCT-3’) were used to amplify 
the truncated periplasmic FtsQ of B. pseudomallei (residue 40-250). The PCR 
reaction for this truncated BPSL3022 required the addition of 2% DMSO at an 
annealing temperature of 58°C. The expected size of the PCR product was 
approximately 600 base pairs on a 1% agarose gel.  
 
The cloning of the BPSL3022_3 construct using restriction enzymes was carried 
out by ligating the compatible overhangs of the digested PCR product and a 
linearised pET24-a vector. The PCR product was digested with the restriction 
enzymes, NdeI and XhoI to provide the overhangs 5’…-CA^TATG…-3’ and 5’-
…C^TCGAG…3’, respectively. The pET24-a vector was also digested with these 
restriction enzymes to linearise the vector with compatible ends. Then, the 
ligation was performed using T4 ligase to join the compatible ends of the insert 
and the vector, and this ligated vector was transformed into E. coli DH5α cells for 
screening on kanamycin agar plates. The recombinant clones were confirmed by 
plasmid DNA sequencing using universal T7 primers. There was one nucleotide 
different from the reference sequence based on the B. pseudomallei strain K96243 
genome, but the protein sequence remained unchanged (Figure 4.10). 
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a)  
b)  
Figure 4.10 DNA sequencing of the truncated FtsQ with a C-terminal His tag 
(BPSL3022_3): a) The recombinant plasmid DNA was sequenced using the universal T7 
forward and reverse primers and the insert was identified by sequence alignment of the 
recombinant clone (read from T7 forward primer-first line, read from T7 reverse primer-
second line) against the reference gene sequence (third line);  b) The protein sequence of 
the recombinant truncated BPSL3022 (first line) was identical to the reference FtsQ 
protein sequence of B. pseudomallei strain K96243 (second line), highlighted in green. 
This figure was created using Boxshade (Hofmann & Baron).    
 
ftsqh1f            1 TATACATATGCGGGAAATCCGCATCGACGGGGACACCGAGCACATCAACGCGCCGACCGT
ftsqh1r            1 TATACATATGCGGGAAATCCGCATCGACGGGGACACCGAGCACATCAACGCGCCGACCGT
BPSL3022____cel    1 -------ATGCGGGAAATCCGCATCGACGGGGACACCGAGCACATCAACGCGCCGACCGT
consensus          1 tatacatATGCGGGAAATCCGCATCGACGGGGACACCGAGCACATCAACGCGCCGACCGT
ftsqh1f           61 GCGCGCGGGCGTCGTCGGGCGGCTGAAGGGCAACTTCTTCACCGTCGATCTCGACCTCGC
ftsqh1r           61 GCGCGCGGGCGTCGTCGGGCGGCTGAAGGGCAACTTCTTCACCGTCGATCTCGACCTCGC
BPSL3022____cel   54 GCGCGCGGGCGTCGTCGGGCGGCTGAAGGGCAACTTCTTCACCGTCGATCTCGACCTCGC
consensus         61 GCGCGCGGGCGTCGTCGGGCGGCTGAAGGGCAACTTCTTCACCGTCGATCTCGACCTCGC
ftsqh1f          121 GCGCGTCGCGTTCGAGCAGATGCCGTGGGTGCGCCACGCGAGCGTGCGCCGGGTGTGGCC
ftsqh1r          121 GCGCGTCGCGTTCGAGCAGATGCCGTGGGTGCGCCACGCGAGCGTGCGCCGGGTGTGGCC
BPSL3022____cel  114 GCGCGTCGCGTTCGAGCAGATGCCGTGGGTGCGCCACGCGAGCGTGCGCCGGGTGTGGCC
consensus        121 GCGCGTCGCGTTCGAGCAGATGCCGTGGGTGCGCCACGCGAGCGTGCGCCGGGTGTGGCC
ftsqh1f          181 GAACGCGCTCGCCGTGACGCTCGAAGAGTACAAGCCGCTCGGCACGTGGGGCAACGATCA
ftsqh1r          181 GAACGCGCTCGCCGTGACGCTCGAAGAGTACAAGCCGCTCGGCACGTGGGGCAACGATCA
BPSL3022____cel  174 GAACGCGCTCGCCGTGACGCTCGAAGAGTACAAGCCGCTCGGCACGTGGGGCAACGATCA
consensus        181 GAACGCGCTCGCCGTGACGCTCGAAGAGTACAAGCCGCTCGGCACGTGGGGCAACGATCA
ftsqh1f          241 GCTCGTGAGCGTCGACGGCGAGCTCTTCACCGCGAACCAGGGCGAACTCGATGCGGAGCT
ftsqh1r          241 GCTCGTGAGCGTCGACGGCGAGCTCTTCACCGCGAACCAGGGCGAACTCGATGCGGAGCT
BPSL3022____cel  234 GCTCGTGAGCGTCGACGGCGAGCTCTTCACCGCGAACCAGGGCGAGCTCGATGCGGAGCT
consensus        241 GCTCGTGAGCGTCGACGGCGAGCTCTTCACCGCGAACCAGGGCGAaCTCGATGCGGAGCT
ftsqh1f          301 GCCGTCGTTCGACGGCCCGGAGGGCAGCGCGAAGGAGGTCGTCGCGCGCTATCGCGACTT
ftsqh1r          301 GCCGTCGTTCGACGGCCCGGAGGGCAGCGCGAAGGAGGTCGTCGCGCGCTATCGCGACTT
BPSL3022____cel  294 GCCGTCGTTCGACGGCCCGGAGGGCAGCGCGAAGGAGGTCGTCGCGCGCTATCGCGACTT
consensus        301 GCCGTCGTTCGACGGCCCGGAGGGCAGCGCGAAGGAGGTCGTCGCGCGCTATCGCGACTT
ftsqh1f          361 CGCGAAATGGTTTGCGCCGATCCACGCGACGCCTGAGGAGGTGACGCTGTCGCCGCGCTA
ftsqh1r          361 CGCGAAATGGTTTGCGCCGATCCACGCGACGCCTGAGGAGGTGACGCTGTCGCCGCGCTA
BPSL3022____cel  354 CGCGAAATGGTTTGCGCCGATCCACGCGACGCCTGAGGAGGTGACGCTGTCGCCGCGCTA
consensus        361 CGCGAAATGGTTTGCGCCGATCCACGCGACGCCTGAGGAGGTGACGCTGTCGCCGCGCTA
ftsqh1f          421 CGCGTGGACGGTGAAGCTGTCGAACGGCATGCAGGTCGAGCTCGGCCGCGAGCGCAACAG
ftsqh1r          421 CGCGTGGACGGTGAAGCTGTCGAACGGCATGCAGGTCGAGCTCGGCCGCGAGCGCAACAG
BPSL3022____cel  414 CGCGTGGACGGTGAAGCTGTCGAACGGCATGCAGGTCGAGCTCGGCCGCGAGCGCAACAG
consensus        421 CGCGTGGACGGTGAAGCTGTCGAACGGCATGCAGGTCGAGCTCGGCCGCGAGCGCAACAG
ftsqh1f          481 CGACACGCTGCCCGACCGGATCCAGCGCCTCGTCGCCGCATGGCCGTCGGTCACGCAGCG
ftsqh1r          481 CGACACGCTGCCCGACCGGATCCAGCGCCTCGTCGCCGCATGGCCGTCGGTCACGCAGCG
BPSL3022____cel  474 CGACACGCTGCCCGACCGGATCCAGCGCCTCGTCGCCGCATGGCCGTCGGTCACGCAGCG
consensus        481 CGACACGCTGCCCGACCGGATCCAGCGCCTCGTCGCCGCATGGCCGTCGGTCACGCAGCG
ftsqh1f          541 CTGGGGCGGCGACATCGAGTACGCGGATCTTCGCTATCCGAACGGATTCGCGATTCGCGC
ftsqh1r          541 CTGGGGCGGCGACATCGAGTACGCGGATCTTCGCTATCCGAACGGATTCGCGATTCGCGC
BPSL3022____cel  534 CTGGGGCGGCGACATCGAGTACGCGGATCTTCGCTATCCGAACGGATTCGCGATTCGCGC
consensus        541 CTGGGGCGGCGACATCGAGTACGCGGATCTTCGCTATCCGAACGGATTCGCGATTCGCGC
ftsqh1f          601 GGCGGGCATGCGGTTCCTGACCGATACCGACAAGGGCAAGAAGCTCGAGCACCACCACCA
ftsqh1r          601 GGCGGGCATGCGGTTCCTGACCGATACCGACAAGGGCAAGAAGCTCGAGCACCACCACCA
BPSL3022____cel  594 GGCGGGCATGCGGTTCCTGACCGATACCGACAAGGGCAAGAAGTAA--------------
consensus        601 GGCGGGCATGCGGTTCCTGACCGATACCGACAAGGGCAAGAAGctcgagcaccaccacca
ftsqh1f          661 CCACCACTGA
ftsqh1r          661 CCACCACTGA
BPSL3022____cel      ----------
consensus        661 ccaccactga
ftsqh1             1 --------------------------------------MREIRIDGDTEHINAPTVRAGV
B._pseudomallei    1 MWNNVRQLNLAASALYALLLLVLAAAGCYWLIQRPAFALREIRIDGDTEHINAPTVRAGV
consensus          1 mwnnvrqlnlaasalyallllvlaaagcywliqrpafamREIRIDGDTEHINAPTVRAGV
ftsqh1            23 VGRLKGNFFTVDLDLARVAFEQMPWVRHASVRRVWPNALAVTLEEYKPLGTWGNDQLVSV
B._pseudomallei   61 VGRLKGNFFTVDLDLARVAFEQMPWVRHASVRRVWPNALAVTLEEYKPLGTWGNDQLVSV
consensus         61 VGRLKGNFFTVDLDLARVAFEQMPWVRHASVRRVWPNALAVTLEEYKPLGTWGNDQLVSV
ftsqh1            83 DGELFTANQGELDAELPSFDGPEGSAKEVVARYRDFAKWFAPIHATPEEVTLSPRYAWTV
B._pseudomallei  121 DGELFTANQGELDAELPSFDGPEGSAKEVVARYRDFAKWFAPIHATPEEVTLSPRYAWTV
consensus        121 DGELFTANQGELDAELPSFDGPEGSAKEVVARYRDFAKWFAPIHATPEEVTLSPRYAWTV
ftsqh1           143 KLSNGMQVELGRERNSDTLPDRIQRLVAAWPSVTQRWGGDIEYADLRYPNGFAIRAAGMR
B._pseudomallei  181 KLSNGMQVELGRERNSDTLPDRIQRLVAAWPSVTQRWGGDIEYADLRYPNGFAIRAAGMR
consensus        181 KLSNGMQVELGRERNSDTLPDRIQRLVAAWPSVTQRWGGDIEYADLRYPNGFAIRAAGMR
ftsqh1           203 FLTDTDKGKKLEHHHHHH
B._pseudomallei  241 FLTDTDKGKK--------
consensus        241 FLTDTDKGKKlehhhhhh
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BPSL3022_3 with a C-terminal His tag was expressed in E. coli BL21 (DE3) 
using 1 mM IPTG induction at 37°C for 4 hours. There was a highly expressed 
protein band between 21.5 and 31 kDa on the SDS PAGE gel, but only in the 
insoluble fraction. In order to increase the soluble form of the protein, the 
induction temperature was decreased to 20°C but at this temperature there was no 
expression of the target protein (Figure 4.11). 
 
   
  
 
Figure 4.11 SDS PAGE of BPSL3022_3 with C-terminal His tag in pET24-a 
expressed in E. coli BL21 (DE3). lane 1 Mark12TM; lane 2 pre-induction; lane 3 
soluble fraction at 37°C induction for 4 hours; lane 4 insoluble fraction at 37°C 
induction for 4 hours; lane 5 soluble fraction at 20 °C induction 4 hours; lane 6 
insoluble fraction at 20°C induction 4 hours; lane 7 soluble fraction at 20°C 
induction overnight; lane 8 insoluble fraction at 20°C induction overnight. 
 
 
The constructs of short and long truncated FtsQ (BPSL3022_1 and BPSL3022_2) 
without an affinity tag were also designed and cloned into pET24-a with the 
restriction enzymes NdeI and BamHI. The forward primer used to amplify these 
truncated genes was the same as the truncated BPSL3022 with the C-terminal His 
tag construct, but the reverse primers were different due to the use of different 
restriction enzymes and the gene fragment length. The resultant recombinant 
clones were confirmed by DNA sequencing and the sequence of BPSL3022_1 
was identical to the reference genome in amino acid level while one amino acid 
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! 84!
was altered in BPSL3022_2 at residue 175 (R to H). This change could be due to 
the different genomic strain in the database or perhaps resulted from the use of 
additional DMSO in the PCR. Protein expression tests were carried out using E. 
coli BL21 (DE3) with 1mM IPTG induction at 37°C for 4 hours. There was no 
expression of either target protein on SDS PAGE. Even if the expression tests 
were carried out in a different expression host E. coli C43 (DE3), which is able to 
prevent cell death associated with recombinant protein expression, but there was 
still no protein expression of truncated BPSL3022.    
 
As further experiments to promote soluble expression of B. pseudomallei FtsQ 
were likely to be time consuming, this project was terminated. 
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4.4. BPSS0945-Subfamily M23B unassigned peptidase 
 
The gene encoding BPSS0945 is located in chromosome 1 of the B. pseudomallei 
strain K96243 genome according to the Burkholderia genome. This gene consists 
of 948 nucleotides, encoding a 315-amino acid protein that has been annotated as 
a member of the subfamily M23B unassigned peptidases (Winsor et al, 2008). 
 
Preliminary analysis of the BPSS0945 protein sequence was performed using 
ProtParam (ExPASy server) and the protein characteristics are described in Figure 
4.12. BPSS0945 has a molecular weight of 32 kDa and a theoretical pI of 9.78. 
 
 
Figure 4.12 Analysis of BPSS0945 protein sequence: The characterization of 
BPSS0945 revealed its molecular weight, theoretical pI, amino acid composition 
and extinction coefficients by ProtParam. 
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The hydrophobicity of BPSS0945 was also characterised by hydropathy plot 
(http://www.vivo.colostate.edu/molkit/hydropathy/index.html). Kyte-Doolittle 
scale plot of BPSS0945 showed the protein is rich in hydrophobic residues at the 
N-terminal region (Figure 4.13). It is unlikely to be a transmembrane protein but 
this hydrophobic region could possibly be a signal peptide. 
 
 
Figure 4.13 A hydropathy plot of BPSS0945: The N-terminal region of the protein 
contains hydrophobic residues. This figure was produced using the hydropathy 
plot server (http://www.vivo.colostate.edu/molkit/hydropathy/index.html). 
 
To predict whether a signal peptide sequence was present in BPSS0945, the 
protein sequence was analysed using the SignalP 4.0 server (Petersen et al, 2011). 
According to the scores, it was likely that residues 1-23 are probably a signal 
peptide, but this annotation is not certain.   
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Figure 4.14 Signal peptide prediction of BPSS0945: There is no predicted signal 
peptide in BPSS0945 using the score cut-off at 0.57. This figure was produced 
using the SignalP 4.0 server (Petersen et al, 2011).  
 
 
4.4.1. Protein structure prediction 
Protein structure prediction for fold recognition and secondary structure for 
BPSS0945 was performed using the PSIPRED Protein Structure Prediction Server 
(McGuffin et al, 2000). BPSS0945 was matched to three proteins in the PDB, 
with more than 99% confidence level. These proteins were a lysostaphin 
peptidase from Vibrio cholerae, a peptidoglycan hydrolase from Staphylococcus 
aureus and an M23 family peptidase from Pseudomonas aeruginosa (Table 4.4). 
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Table 4.4 A list of similar protein structures to the predicted BPSS0945 structure   
PDB 
ID 
Protein Organism % Sequence 
identity to 
BPSS0945  
Crystallisation 
condition 
2gu1 Lysostaphin 
peptidase 
V. cholerae 36 0.2M NH2(SO4), 
20% PEG 4000,  
0.1 Tris pH 8.5, 
25°C 
1qwy Peptidoglycan 
hydrolase, 
LytM 
S. aureus 32 0.17M NH2(SO4), 
25.5%(w/v)PEG 
8K, 15% (v/v) 
glycerol, 21°C 
 
2hsi M23 peptidase P. aeruginosa 30 0.1M HEPES,  
0.2M 
CH3COONH4, 
25% PEG 3350, 
10% glycerol, 
pH 6.5, 17°C 
 
 
The protein sequences of BPSS0945 and the identified homologue proteins were 
aligned and the key residues were identified. As the signature-conserved 
sequences commonly found in these lysostaphin-type like enzymes, which are 
metallopeptidases, have been described, the motifs involved in metal ligand 
binding were considered in this case. The motifs HX(3,6)D and HXH have been 
reported in which the ligand binding occurs. The residues that chelate the metal, 
which are H and D in the HX(3,6)D motif and the first H in the HXH motif are 
conserved in space in all LytM crystal forms, and found in the Zn2+ binding site in 
peptidoglycan amidases (Firczuk et al, 2005). The sequence alignment shows that, 
despite high sequence similarity, BPSS0945 lacks these two conserved motifs 
relating to Zn2+ binding (Figure 4.15). It is possible that BPSS0945 either does not 
bind metal or uses a different constellation of residues than those seen in LytM-
like proteins. 
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Figure 4.15 Protein sequence alignment of BPSS0945 (third line) and proteins 
with known structure; peptidoglycan hydrolase (LytM) from S. aureus (first line), 
Lysostaphin peptidase from V. cholerae (second line) and M23 peptidase from P. 
aeruginosa (fourth line): Identical residues are displayed in green boxes. Metal 
ligand binding motifs are shown with a red border. This figure was created using 
Boxshade (Hofmann & Baron). 
 
 
4.4.2. Gene amplification and cloning 
To clone the BPSS0945 protein, oligonucleotide primers were designed according 
to the open reading frame of the BPSS0945 coding gene, subject to being cloned 
into a pETBlue-1 vector. The forward primer 5’-ATGAGCAAGAGCGAGAT 
CGA-3’ and the reverse primer 5’- CTAGCCCTGCTGCCGGC-3’ were used 
together with the genomic DNA of B. pseudomallei strain D286 to amplify the 
gene fragment by PCR. The PCR product was obtained with the addition of 5% 
DMSO at an annealing temperature of 56°C. Analysis on 1% agarose gel 
electrophoresis showed that the PCR product was about 1,000 base pairs in size, 
and was likely to be BPSS0945 which consists of 948 base pairs (Figure 4.16). 
 
1QWY_A_PDBID_CH    1 --------------AETTNTQQAHT------QMSTQSQDVSYGTYYTIDSNGDYHHTPD-
2GU1_A_PDBID_CH    1 MSLQPKRIHYMVKVGDTLSGIFAQLGVPYSILQKILSVDLDHLQLDMIQPGEELELMMDD
BPSS0945_gi_522    1 --MSKSEIDRSVAWLSGVAAAFVVAG--CATTSPVTPTDTLAAAASSASAAQPAAAPPGD
M23_Pseudomonas    1 -------MPRTLAFVSTLLLAAFCA-------LPAQADSFIMRLLNKPVPGGVAVVDLGE
consensus          1 --l----i-rsvaw-stl-gafa-ag------mpiqs-dvl-g-l-ti-pggda-l-p-d
1QWY_A_PDBID_CH   40 -GNWNQAMFDNKEYSYTFVDAQGHTHYFYNCYPKN-------ANANGSGQTYVNPATAGD
2GU1_A_PDBID_CH   61 MGQLSRLIYHMSIVEKAIYTRENDGSFSYDFQEISGEWREILFSGEINGSFSVSARRVGL
BPSS0945_gi_522   57 AAQHPEHAAAPAPIATRYVVRRGDT--LSAIAQANGCTVRELQAWNRMGRRTRIGIGQVL
M23_Pseudomonas   47 EGPPPRAFYQGK---PVLVVRE-------------------------EGRRWIAVVGIPL
consensus         61 -gq-pramy--k-v----vvregdt-y-y-----ng-----l--an--Grr-v-aigvgl
1QWY_A_PDBID_CH   92 NNDYTASQSQQHINQYGYQSNVGPDASYYSHSNNNQAYNSHDGNGKVNYP----------
2GU1_A_PDBID_CH  121 TSSQVANITQVMKDKIDFSRSLRAGDRFDILVKQQYLGEHNTGNSEIKAISFKLAKGDVS
BPSS0945_gi_522  115 RIAPPGAENAVASEAADGVGATRAAGNAAGAARAADPASGAGGAPVADAP----------
M23_Pseudomonas   79 STKPGPQKLEVRAATGNHEERFSVGSKHYREQRITLKNKRQVNPLPEDLKRIER------
consensus        121 ts-p-an-sqv--d-ady---vragaryy---rnn--g--n-gn--vdap----------
1QWY_A_PDBID_CH  142 -----NGTSNQNGGSASKATASGHAKDASWLTSRKQLQPYGQYHGGG---AHYGVDYAMP
2GU1_A_PDBID_CH  181 AFLAEDGRFYDRAGNSLERAFNRYPVDKAYRQITSGFNPKRKHPVTGRVVPHNGTDFATP
BPSS0945_gi_522  165 ----QPASAPESAADRAADHRVVQETKRHAQSIALAWPAKGAVVETFQPGRNRGIRIVGR
M23_Pseudomonas  133 ----ELAEQTAAYRRFSPGLPSNLMLDKPVDGPLSSPFGLRRFFNGEERNPHSGLDFAVP
consensus        181 ----e-gt--d-ag--s-a--s---vdk-w-ti-sgfqpk-ky---g---ph-Gvdfamp
1QWY_A_PDBID_CH  194 ENSPVYSLTDGTVVQAGWSNYGGGNQVTIKEANSNNYQWYMHNNRLTVSAGDKVKAGDQI
2GU1_A_PDBID_CH  241 IGAPVYSTGDGKVIVVRKHPYAG--NYLVIEHNSVYKTRYLHLDKILVKKGQLVKRGQKI
BPSS0945_gi_522  221 AGDPVRAAASGRVMYAGTG-LNGYGTLILVQHNADFLTAYAHNRKVLVKTGDVVQQGEQI
M23_Pseudomonas  189 AGTPIKAPAAGKVILIGDYFFNG--KTVFVDHGQGFISMFCHLSKIDVKLGQQVPRGGVL
consensus        241 agsPvy--adGkVivag---ynG--qvlivehns-flt-ymH--kilVk-G-lVkrGdqi
1QWY_A_PDBID_CH  254 AYSGSTGNSTAPHVHFQRMSGG-----------IGNQYAVDPTSYLQSR-----------
2GU1_A_PDBID_CH  299 ALAGATGRLTGPHLHFEVLVRNRPVDAMKADLPIAKSLSSNQKTSFLARVSEFDHEGHHH
BPSS0945_gi_522  280 AEMG-TGDSTRAGMLFEVRRDG---------------KPVNPMPYLASRQQG--------
M23_Pseudomonas  247 GKVGATGRATGPHMHWNVSLND---------------ARVDPAIFIGAFQP---------
consensus        301 a-mGaTGrsTgphmhfevmv-g-----------ig----v-p-syla-rq----------
1QWY_A_PDBID_CH      ---
2GU1_A_PDBID_CH  359 HHH
BPSS0945_gi_522      ---
M23_Pseudomonas      ---
consensus        361 ---
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Figure 4.16 Amplification of BPSS0945 coding gene: A 1% agarose gel showing 
that PCR product has approximately 1000 base pairs, corresponding to BPSS0945 
in size (948 base pairs). 
 
The PCR product of BPSS0945 was cloned into the pETBlue-1 vector using the 
TA cloning strategy. After transformation of E. coli NovaBlue, which facilitates 
blue/white screening, the white colonies were selected and verified for correctly 
oriented insert using colony PCR, prior to DNA sequencing. The DNA 
sequencing results of BPSS0945 recombinant clones showed there were three 
nucleotides different from the B. pseudomallei K96243 genome sequence. As a 
result of these nucleotide differences, 2 amino acids were different in the protein 
sequence, residue 133 (V to A) and residue 177 (A to V) (Figure 4.17). In the 
sequences of orthologous proteins from different strains of other completely 
sequenced genomes of B. pseudomallei, the equivalent residues of the altered 
residue 133 are all valine, whereas those of the residue 177 are either alanine or 
valine. These observations could possibly be due to a result of a mutation in the 
PCR process or a real strain variation. A further clarification of the sequence 
differences is required. 
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a)  
b)  
Figure 4.17 DNA sequencing of the BPSS0945 recombinant clone: The recombinant 
plasmid DNA was sequenced and the insert was identified; a) Nucleotide sequence 
alignment of BPSS0945 (second line) and positive clone sequenced using T7 forward 
primer (third line) and T7 reverse primer (first line) shows three nucleotides in the 
recombinant gene which had been amplified from B. pseudomallei strain D286 were 
different from the reference sequence of B. pseudomallei strain K96243; b) Protein 
sequence alignment of the reference sequence of BPSS0945 (first line) and the identified 
insert sequence from positive clone (second line) shows two amino acid residues altered 
(colored in red) from the reference sequence of B. pseudomallei strain K96243. 
0945r        1 --------------------------NNNNNNTTTGTTNAACTTTANGNNGGAGATATAGATTATGAGCAAGAGCGAGAT
BPSS0945     1 ---------------------------------------------------------------ATGAGCAAGAGCGAGAT
0945f        1 NNNNNNNNNNNNNTNNTTGNCTAGCAGATAATTTTGTTTAACTTTAAGAAGGAGATATAGATTATGAGCAAGAGCGAGAT
consensus    1 --------------------------------tttgtt-aacttta-g--ggagatatagattATGAGCAAGAGCGAGAT
0945r       55 CGACCGCAGTGTCGCATGGTTGTCCGGCGTGGCGGCCGCGTTCGTCGTCGCGGGCTGCGCAACCACGTCGCCCGTCACGC
BPSS0945    18 CGACCGCAGTGTCGCATGGTTGTCCGGCGTGGCGGCCGCGTTCGTCGTCGCGGGCTGCGCAACCACGTCGCCCGTCACGC
0945f       81 CGACCGCAGTGTCGCATGGTTGTCCGGCGTGGCGGCCGCGTTCGTCGTCGCGGGCTGCGCAACCACGTCGCCCGTCACGC
consensus   81 CGACCGCAGTGTCGCATGGTTGTCCGGCGTGGCGGCCGCGTTCGTCGTCGCGGGCTGCGCAACCACGTCGCCCGTCACGC
0945r      135 CGACTGATACGCTCGCGGCCGCCGCGTCTTCGGCGAGCGCCGCGCAGCCCGCGGCCGCGCCGCCGGGCGACGCGGCGCAG
BPSS0945    98 CGACTGATACGCTCGCGGCCGCCGCGTCTTCGGCGAGCGCCGCGCAGCCCGCGGCCGCGCCGCCGGGCGACGCGGCGCAG
0945f      161 CGACTGATACGCTCGCGGCCGCCGCGTCTTCGGCGAGCGCCGCGCAGCCCGCGGCCGCGCCGCCGGGCGACGCGGCGCAG
consensus  161 CGACTGATACGCTCGCGGCCGCCGCGTCTTCGGCGAGCGCCGCGCAGCCCGCGGCCGCGCCGCCGGGCGACGCGGCGCAG
0945r      215 CATCCGGAGCACGCCGCCGCGCCGGCGCCGATCGCGACACGCTACGTCGTGAGGCGCGGCGATACGCTGTCGGCGATCGC
BPSS0945   178 CATCCGGAGCACGCCGCCGCGCCGGCGCCGATCGCGACACGCTACGTCGTGAGGCGCGGCGATACGCTGTCGGCGATCGC
0945f      241 CATCCGGAGCACGCCGCCGCGCCGGCGCCGATCGCGACACGCTACGTCGTGAGGCGCGGCGATACGCTGTCGGCGATCGC
consensus  241 CATCCGGAGCACGCCGCCGCGCCGGCGCCGATCGCGACACGCTACGTCGTGAGGCGCGGCGATACGCTGTCGGCGATCGC
0945r      295 GCAAGCGAACGGCTGCACCGTGCGCGAGCTGCAGGCCTGGAACCGGATGGGCCGGCGCACCCGGATCGGCATCGGCCAGG
BPSS0945   258 GCAAGCGAACGGCTGCACCGTGCGCGAGCTGCAGGCTTGGAACCGGATGGGCCGGCGCACCCGGATCGGCATCGGCCAGG
0945f      321 GCAAGCGAACGGCTGCACCGTGCGCGAGCTGCAGGCCTGGAACCGGATGGGCCGGCGCACCCGGATCGGCATCGGCCAGG
consensus  321 GCAAGCGAACGGCTGCACCGTGCGCGAGCTGCAGGCcTGGAACCGGATGGGCCGGCGCACCCGGATCGGCATCGGCCAGG
0945r      375 TATTGCGGATCGCGCCGCCGGGTGCGGAAAACGCGGTCGCCTCCGAGGCGGCGGATGGCGCGGGCGCGACCCGCGCGGCC
BPSS0945   338 TATTGCGGATCGCGCCGCCGGGTGCGGAAAACGCGGTCGCCTCCGAGGCGGCGGATGGCGTGGGCGCGACCCGCGCGGCC
0945f      401 TATTGCGGATCGCGCCGCCGGGTGCGGAAAACGCGGTCGCCTCCGAGGCGGCGGATGGCGCGGGCGCGACCCGCGCGGCC
consensus  401 TATTGCGGATCGCGCCGCCGGGTGCGGAAAACGCGGTCGCCTCCGAGGCGGCGGATGGCGcGGGCGCGACCCGCGCGGCC
0945r      455 GGCAATGCAGCCGGCGCCGCGCGCGCGGCCGATCCGGCGAGCGGCGCGGGCGGGGCGCCTGTCGCCGATGCGCCGCAGCC
BPSS0945   418 GGCAATGCAGCCGGCGCCGCGCGCGCGGCCGATCCGGCGAGCGGCGCGGGCGGGGCGCCTGTCGCCGATGCGCCGCAGCC
0945f      481 GGCAATGCAGCCGGCGCCGCGCGCGCGGCCGATCCGGCGAGCGGCGCGGGCGGGGCGCCTGTCGCCGATGCGCCGCAGCC
consensus  481 GGCAATGCAGCCGGCGCCGCGCGCGCGGCCGATCCGGCGAGCGGCGCGGGCGGGGCGCCTGTCGCCGATGCGCCGCAGCC
0945r      535 TGCATCGGCGCCCGAAAGCGCCGCGGACCGGGTGGCGGACCATCGGGTCGTCCAGGAAACGAAGCGGCACGCGCAATCGA
BPSS0945   498 TGCATCGGCGCCCGAAAGCGCCGCGGACCGGGCGGCGGACCATCGGGTCGTCCAGGAAACGAAGCGGCACGCGCAATCGA
0945f      561 TGCATCGGCGCCCGAAAGCGCCGCGGACCGGGTGGCGGACCATCGGGTCGTCCAGGAAACGAAGCGGCACGCGCAATCGA
consensus  561 TGCATCGGCGCCCGAAAGCGCCGCGGACCGGGtGGCGGACCATCGGGTCGTCCAGGAAACGAAGCGGCACGCGCAATCGA
0945r      615 TCGCGCTCGCGTGGCCGGCGAAGGGCGCGGTCGTCGAAACGTTCCAGCCCGGCCGCAATCGCGGCATCCGGATCGTCGGG
BPSS0945   578 TCGCGCTCGCGTGGCCGGCGAAGGGCGCGGTCGTCGAAACGTTCCAGCCCGGCCGCAATCGCGGCATCCGGATCGTCGGG
0945f      641 TCGCGCTCGCGTGGCCGGCGAAGGGCGCGGTCGTCGAAACGTTCCAGCCCGGCCGCAATCGCGGCATCCGGATCGTCGGG
consensus  641 TCGCGCTCGCGTGGCCGGCGAAGGGCGCGGTCGTCGAAACGTTCCAGCCCGGCCGCAATCGCGGCATCCGGATCGTCGGG
0945r      695 CGCGCGGGCGATCCGGTGCGTGCCGCGGCGTCCGGCCGGGTGATGTACGCGGGCACGGG-CCTGAACGGGTACGGCACGC
BPSS0945   658 CGCGCGGGCGATCCGGTGCGTGCCGCGGCGTCCGGCCGGGTGATGTACGCGGGCACGGG-CCTGAACGGGTACGGCACGC
0945f      721 CGCGCGGGCGATCCGGTGCGTGCCGCGGCGTCCGGCCGGGTGATGTACGCGGGCACGGGCCTGAACGGGTACGGCACGCT
consensus  721 CGCGCGGGCGATCCGGTGCGTGCCGCGGCGTCCGGCCGGGTGATGTACGCGGGCACGGG-CctgAacGGgtacGgcacgc
0945r      774 TGATCCTGGTCCAGCACAACGCGGATTTTCTGACCGCTTACGCGCACAACCG--CAAGGTGCTCGTGAAGACGGGCGACG
BPSS0945   737 TGATCCTGGTCCAGCACAACGCGGATTTTCTGACCGCTTACGCGCACAACCG--CAAGGTGCTCGTGAAGACGGGCGACG
0945f      801 GATCCTGGTCCAGCACAACGCGGATTTTCTGACCGCTTACGCGCACAACCGCAAGGTGCTCGTGAAGACGGGCGACGTCG
consensus  801 tgatCctGgtCcagcacAacgcGgaTTTtctgaCcgcTtacgcgcacAaCcg--caaGgTgcTcgtGAaGacgGgCGaCG
0945r      852 TCGTTCAGC-AGGGCGAACAGATCGCCGAGATGGGCACCGGCGACAGCACGCGCGCCGGCATGCTGTTCGAGGTGCGGCG
BPSS0945   815 TCGTTCAGC-AGGGCGAACAGATCGCCGAGATGGGCACCGGCGACAGCACGCGCGCCGGCATGCTGTTCGAGGTGCGGCG
0945f      881 TTCAAGCAGGGCGAACAGATCNCCCAGATGGGCACCGGC-----------------------------------------
consensus  881 Tcgttcagc-agGgcgAacagatCgccgaGatgggCacCggcgacagcacgcgcgccggcatgctgttcgaggtgcggcg
0945r      931 CGACGGCAAGCCCGTCAATCCGATGCCGTATCTGGCGAGCCGGCAGCAGGGCTAGAATCGAATTCCTGCCCGGGCGTGTA
BPSS0945   894 CGACGGCAAGCCCGTCAATCCGATGCCGTATCTGGCGAGCCGGCAGCAGGGCTAG-------------------------
0945f          --------------------------------------------------------------------------------
consensus  961 cgacggcaagcccgtcaatccgatgccgtatctggcgagccggcagcagggctag-------------------------
0945r     1011 ATCANNNTNNNNNNNNNNNNNN
BPSS0945       ----------------------
0945f          ------------------    
consensus 1041 ----------------------BPSS0945  MSKSEIDRSVAWLSGVAAAFVVAGCATTSPVTPTDTLAAAASSASAAQPAAAPPGDAAQH
25_0945   MSKSEIDRSVAWLSGVAAAFVVAGCATTSPVTPTDTLAAAASSASAAQPAAAPPGDAAQH
consensus MSKSEIDRSVAWLSGVAAAFVVAGCATTSPVTPTDTLAAAASSASAAQPAAAPPGDAAQH
BPSS0945  PEHAAAPAPIATRYVVRRGDTLSAIAQANGCTVRELQAWNRMGRRTRIGIGQVLRIAPPG
25_0945   PEHAAAPAPIATRYVVRRGDTLSAIAQANGCTVRELQAWNRMGRRTRIGIGQVLRIAPPG
consensus PEHAAAPAPIATRYVVRRGDTLSAIAQANGCTVRELQAWNRMGRRTRIGIGQVLRIAPPG
BPSS0945  AENAVASEAADGVGATRAAGNAAGAARAADPASGAGGAPVADAPQPASAPESAADRAADH
25_0945   AENAVASEAADGAGATRAAGNAAGAARAADPASGAGGAPVADAPQPASAPESAADRVADH
consensus AENAVASEAADG-GATRAAGNAAGAARAADPASGAGGAPVADAPQPASAPESAADR-ADH
BPSS0945  RVVQETKRHAQSIALAWPAKGAVVETFQPGRNRGIRIVGRAGDPVRAAASGRVMYAGTGL
25_0945   RVVQETKRHAQSIALAWPAKGAVVETFQPGRNRGIRIVGRAGDPVRAAASGRVMYAGTGL
consensus RVVQETKRHAQSIALAWPAKGAVVETFQPGRNRGIRIVGRAGDPVRAAASGRVMYAGTGL
BPSS0945  NGYGTLILVQHNADFLTAYAHNRKVLVKTGDVVQQGEQIAEMGTGDSTRAGMLFEVRRDG
25_0945   NGYGTLILVQHNADFLTAYAHNRKVLVKTGDVVQQGEQIAEMGTGDSTRAGMLFEVRRDG
consensus NGYGTLILVQHNADFLTAYAHNRKVLVKTGDVVQQGEQIAEMGTGDSTRAGMLFEVRRDG
BPSS0945  KPVNPMPYLASRQQG
25_0945   KPVNPMPYLASRQQG
consensus KPVNPMPYLASRQQG
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4.4.3. Protein expression 
To produce recombinant protein of BPSS0945, E. coli TunerTM (DE3) cells were 
used to express the gene encoding BPSS0945, which had been inserted in a 
pETBlue-1 vector. The recombinant protein was over-produced by adding 1mM 
IPTG. After induction at 37°C for 4 hours, SDS PAGE showed that there were 
obvious bands around 36.5 kDa in both the soluble and insoluble fractions, 
indicative of the target protein, which has the approximate molecular weight of 32 
kDa (Figure 4.18). Reducing the expression temperature to 25°C did not increase 
the soluble protein expression and at 20°C there was no expression of the target 
protein. 
 
 
 
Figure 4.18 Overexpression of BPSS0945: SDS PAGE of BPSS0945 expressed in 
E.coli TunerTM (DE3) pLacI on 12% resolving gel; lane 1 a protein marker 
Mark12TM; lane 2 pre-induction; lane 3 soluble fraction at 37°C induction for 4 
hours; lane 4 insoluble fraction at 37°C induction for 4 hours.  
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4.4.4. Protein purification 
About 9 g of cell paste were resuspended in 50 mM HEPES pH 7.5 and the cells 
were disrupted by ultra-sonication on ice for 2-3 cycles of 20 seconds. Crude 
protein was extracted and separated by centrifugation at 24500 rpm for               
10 minutes. Approximately 56 ml of crude extract was loaded onto a 5 ml SP-HP 
cation exchange column (GE Healthcare), which was pre-equilibrated with         
50 mM HEPES pH 7.5. The protein was eluted with a gradient of 0-1 M NaCl in 
50 mM HEPES pH 7.5. 3 ml fractions were collected and monitored by UV 
absorbance. The protein concentration of fractions corresponding to the UV peak 
was determined by the Bradford assay and the fraction profile was analysed by 
SDS PAGE. The fractions containing BPSS0945 (32 kDa) were combined. 
Ammonium sulphate precipitation was subsequently performed by adding 4 M 
ammonium sulphate to make a final concentration of 1.5 M ammonium sulphate. 
The protein precipitate was recovered by centrifugation at 24500 rpm for            
5-10 minutes and resuspended with 50 mM HEPES pH 7.5 prior to the next 
purification step using gel filtration. The protein sample was loaded onto 
SuperdexTM 200 (GE Healthcare). The protein was eluted using 50 mM Tris-HCl 
pH 8 plus 0.5 M NaCl. 2 ml fractions were collected and monitored by UV 
absorbance. The protein concentration of fractions corresponding to the UV peak 
was determined by the Bradford assay and the fraction profile was analysed by 
SDS PAGE. The fractions containing the purified BPSS0945 protein were pooled 
together (Figure 4.19) and the protein was concentrated to approximately 10 
mg/ml in 10 mM HEPES pH 7.5 with 50 mM NaCl using a 10 kDa MWCO 
VivaspinTM centrifugal concentrator (Vivascience). The average yield of protein 
purification was about 3 mg purified protein obtained from three litres of 
recombinant E. coli culture.         
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Figure 4.19 Purification of BPSS0945: SDS PAGE gel shows the recovery of the 
target protein BPSS0945 in each step of protein purification. Fraction 6, 7 and 8 
in the gel filtration step were collected and the protein was concentrated prior to 
crystallisation trials.  
 
 
           
 
Figure 4.20 Stability of BPSS0945: SDS PAGE gel shows the BPSS0945 protein 
degradation after purification and stored at 4 °C for up to 7 days.  
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4.4.5. Crystallisation trials 
The purified protein was concentrated to approximately 10 mg/ml and then put 
into crystallisation trials. Initial crystallisation screening was performed using 
commercially available NeXtal crystallisation screens (QIAGEN) by the sitting 
drop vapour diffusion technique. 9.5 mg/ml purified protein in 50 mM HEPES  
pH 7 were screened using a Hydra II Plus 1 robot against JCSG, PACT and 
Classic screens. No crystals were observed and most drops were clear, indicating 
a high solubility. Therefore, the protein concentration was increased to 14.5 
mg/ml protein and used against the same screens. Yet again, no crystals were 
obtained.  
 
 
4.4.6. Unstable BPSS0945 
Due to the crystallisation failure, the stability of BPSS0945 was analysed after 
purification. SDS PAGE showed the degradation of protein occurs over time, 
possibly due to its peptidase activity (Figure 4.20). The full-length protein 
completely disappeared within 7 days. This non-homogenous protein solution 
could easily cause failure in the crystallisation step.  
 
The same autolytic phenomenon also occurred in the production of the related 
peptidase LytM, a unique autolysin from Staphylococcus aureus (Ramadurai & 
Jayaswal, 1997). The autolytic activity bands of degraded products of LytM were 
19 and 22 kDa. This protein was further characterised and it may possibly be a 
glycylglycine endopeptidase, based on the biochemical analysis of LytM-cleaved 
peptidoglycan fragments (Ramadurai et al, 1999). BPSS0945 shares 32% 
sequence identity with LytM and it is possible that a similar autolysis to LytM is 
seen for BPSS0945.    
 
As the sequence alignments showed that BPSS0945 is possibly an M23B metal-
dependent peptidase family member, attempts were made to inactivate its 
peptidase function by the addition of 4 mM EDTA, to act as a chelating agent for 
the metal ion.  
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Purified protein at 21 mg/ml with EDTA treatment was again put into screening 
crystallisation trials but there were still no crystals. The protein treated with 
EDTA was analysed on SDS gel showing that the degradation of BPSS0945 still 
occurred (Figure 4.21). However, as the Zn2+ binding motif present in the LytM 
family cannot be found in the sequence of BPSS0945, it is possible that the 
peptidase function of this protein does not require metal, and hence EDTA 
treatment would be ineffective. 
 
 
Figure 4.21 BPSS0945 treated with EDTA: In order to inactivate the activity of 
BPSS0945, EDTA was added to the protein after purified. It seems that 
BPSS0945 still has activity to cleave itself, resulting in non-homogenous solution, 
which may cause crystallisation failure. 
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4.5. BPSS0238 and BPSS1416 
4.5.1. BPSS0238 Penicillin-binding protein 
The gene encoding BPSS0238 is located in chromosome 2 of B. pseudomallei 
strain K96243. This gene consists of 2163 nucleotides, encoding a 720-amino acid 
protein. According to the Burkholderia genome database, it has been annotated as 
a putative penicillin-binding protein (Winsor et al, 2008). The protein sequence of 
BPSS0238 was analysed by ProtParam (ExPasy server). This protein has a 
molecular weight of approximately 77 kDa with a theoretical pI of 9.4 (Figure 
4.22).  
 
 
Figure 4.22 Analysis of BPSS0238 sequence: Molecular weight, pI, amino acid 
and atomic composition and extinction coefficient of BPSS0238 were 
characterised by ProtParam (ExPasy server). 
MPTKDFDMTD HTPHSSPPAS PTPPQGPAPK RRRYFRTLAG LVLGAAIAGG 
AVGTWTLHRI WTALPSVEPL AVYRPALPLR IFSREGELLA EYGVERREFV 
PLDRIPPLVR HALLAAEDAQ FYTHGVVDIG GLARATVANV VTGQPGQGGS 
TITMQVARNF FLTREKVLSR KLAEILMSYK LERAYSKDKL LELYMNEIYL 
GERAYGFAAA ASVYFGKPLD ALTPGEAAVL AGLPKAPSAF NPVVNPARAT 
MRRNYVLGRM RALGYLDEAA YRQAADAPIA LATTPPPGIL AAPYVAERAR  
RMMVERFHDD AYTLGLDVTT TIAMREQRAA DAALARGLAQ VGRRDAKDAL 
EGALVSIDAA TGDILALVGG ADFSHNVFDH ALQAYRQPGS SFKPFVYSAA 
LEKGMFPGVL IDDTQRTLSR DETGANPWRP RNFGNHYEGF IPVRRGLMRS 
KNLVAVSLMQ VARPDFVQQH AARFGFEPLR NPASLPLALG AGSATPLEVA 
SAYGVFANGG VRMEPRLIES VRQRHGGALF DAQPAPGVRV ISARNAFVMD 
SMLRDVVAHG TARRAVALKR ADAAGKTGTS NGSKDVWFAG YSSGVVSVVW  
MGYDAPRSLG RATGSSAALP VWVDYMKTAV DGRGAIERTP PADVALVDGD 
FVYAEYANGD KCAPSLPPFV RSPFACGAAR GAPADGGAPA SAAGAAGAPT 
PAAVDAAERA RVLELFRTED  
 
Number of amino acids: 720 Molecular weight: 76876.7 Theoretical pI: 9.40 
 
Amino acid composition:  
Ala (A) 118  16.4% 
Arg (R)  63   8.8% 
Asn (N)  16   2.2% 
Asp (D)  39   5.4% 
Cys (C)   2   0.3% 
Gln (Q)  16   2.2% 
Glu (E)  31   4.3% 
Gly (G)  65   9.0% 
His (H)  12   1.7% 
Ile (I)  18   2.5% 
Leu (L)  63   8.8% 
Lys (K)  18   2.5% 
Met (M)  18   2.5% 
Phe (F)  29   4.0% 
Pro (P)  54   7.5% 
Ser (S)  36   5.0% 
Thr (T)  35   4.9% 
Trp (W)   6   0.8% 
Tyr (Y)  24   3.3% 
Val (V)  57   7.9% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
 (B)   0   0.0% 
 (Z)   0   0.0% 
 (X)   0   0.0% 
 
 
Total number of negatively charged residues (Asp + Glu): 70 
Total number of positively charged residues (Arg + Lys): 81 
 
Atomic composition: 
Carbon      C       3425 
Hydrogen    H       5395 
Nitrogen    N        989 
Oxygen      O        988 
Sulfur      S         20 
 
Formula: C3425H5395N989O988S20 
Total number of atoms: 10817 
 
Extinction coefficients: 
 
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in water. 
 
Ext. coefficient    68885 
Abs 0.1% (=1 g/l)   0.896, assuming all pairs of Cys residues form cystines 
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The hydrophobicity of BPSS0238 was analysed using hydropathy plot 
(http://www.vivo.colostate.edu/molkit/hydropathy/index.html). The Kyte-
Doolittle scale plot revealed it is unlikely to be a transmembrane protein (Figure 
4.23). 
 
 
Figure 4.23 A hydropathy plot of BPSS0238: There was no significant feature of 
transmembrane spanning domain. This figure was produced using the hydropathy 
plot server (http://www.vivo.colostate.edu/molkit/hydropathy/index.html). 
 
4.5.1.1. Gene amplification and cloning 
The oligonuclotide primers (5’-ATGCCAACGAAGGATTTCGAC-3’ and 5’-
TCAGTCTTCGGTGCGAAACA-3’) were used to amplify the gene encoding 
BPSS0238 by PCR. The PCR product was obtained using an annealing 
temperature of 56°C with the addition of 10% DMSO. 
 
 
Figure 4.24 PCR product of BPSS0238: The DNA band on a 1% agarose gel 
corresponds to BPSS0238 with a size of approximately 2000 base pairs.  
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The PCR product was then cloned using the pETBlue-1 cloning system. Plasmid 
DNA sequencing of the recombinant clones revealed that the insert was not the 
BPSS0238 gene. This may be due to the size of this target gene, which is about 2 
kb and possibly not suitable for cloning with the pETBlue-1 vector.  
 
Attempts were made to make a new construct using the pET24-a cloning strategy. 
A new pair of oligonucleotide primers (5’-GTACGCCGCATATGCCAAC-3’ and 
5’-!GGATCCCCGCTCAGTCTTC-3’) were used to amplify the BPSS0238 gene. 
The PCR product was obtained with the expected size of approximately 2000 base 
pairs and was then cloned into the pET24-a plasmid. The recombinant clone was 
confirmed by plasmid DNA sequencing. Analysis of the sequencing results 
showed the identified insert was not the whole target gene of BPSS0238 and was 
truncated at position 239/240 from the open reading frame of this gene. The 
BPSS0238 gene contains the sequence G^GATCT, which is similar to the 
restriction site of BamHI (G^GATCC) that was used in the cloning, resulting in 
shortening of the insert.  
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4.5.2. BPSS1416 Uncharacterised protein 
The gene encoding BPSS1416, a hypothetical protein in B. pseudomallei strain 
K96243, is located in chromosome 2 and the coding nucleotide sequence consists 
of 1,404 base pairs encoding a 467-amino acid protein according to the 
Burkholderia genome database (Winsor et al, 2008). The protein sequence of 
BPSS1416 was analysed using ProtParam (ExPasy server), showing its molecular 
weight of 47.7 kDa with a theoretical pI of 5.5  (Figure 4.25). 
 
 
Figure 4.25 Analysis of BPSS1416 sequence: Amino acid composition of 
BPSS1416 was characterised by ProtParam (Expasy server). 
 
 
MPASMSTDQA LRPLLGCIAD DFTGATDLAN MLVKSGMRTV QTIGVPAAGA 
AVPADAIVVA LKSRTIPAAD AVAQSLAALD WLRAQGCRQF FFKYCSTFDS 
TDAGNIGPVA DALLDALGGE RAFTIACPAF PENGRTVYRG HLFVGDALLG 
ESGMENHPLT PMKDANLVRV LQRQTPSKVG LIRHDAIALG TCAVRETIDT 
LRREGVRIAI ADALTDRDLY VLGEACADLP LITGGSGVAL GLPSNFRLGG 
LLPERGDAAA LPAIGGASAV LAGSASKATH AQVAAWRAER PALRIDPFAA  
ARGEPVVDQA LAFARAHLPQ PVLIYASAAP DEVKQVQQAL GIEAAGHLVE 
ATLAAIARGL REMGVRKFVV AGGETSGAVV QALGVKALRI GAQIDPGVPA 
TATTEGSPCG TTEGSPCGTT EGSPCGATEG SPRGTPDAQP LGLALKSGNF 
GSVDFFEKAL RALEGAA  
 
Number of amino acids: 467  Molecular weight: 47724.5  Theoretical pI: 5.51 
 
Amino acid composition:  
Ala (A)  82  17.6% 
Arg (R)  29   6.2% 
Asn (N)   7   1.5% 
Asp (D)  26   5.6% 
Cys (C)   9   1.9% 
Gln (Q)  16   3.4% 
Glu (E)  21   4.5% 
Gly (G)  52  11.1% 
His (H)   6   1.3% 
Ile (I)  19   4.1% 
Leu (L)  48  10.3% 
Lys (K)  11   2.4% 
Met (M)   7   1.5% 
Phe (F)  15   3.2% 
Pro (P)  29   6.2% 
Ser (S)  22   4.7% 
Thr (T)  29   6.2% 
Trp (W)   2   0.4% 
Tyr (Y)   4   0.9% 
Val (V)  33   7.1% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
 (B)   0   0.0% 
 (Z)   0   0.0% 
 (X)   0   0.0% 
 
 
Total number of negatively charged residues (Asp + Glu): 47 
Total number of positively charged residues (Arg + Lys): 40 
 
Atomic composition: 
Carbon      C       2092 
Hydrogen    H       3386 
Nitrogen    N        602 
Oxygen      O        640 
Sulfur      S         16 
 
Formula: C2092H3386N602O640S16 
Total number of atoms: 6736 
 
Extinction coefficients: 
 
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in water. 
 
Ext. coefficient    17460 
Abs 0.1% (=1 g/l)   0.366, assuming all pairs of Cys residues form cystines 
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Analysis of the hydrophobicity of BPSS1416 using hydropathy plot in the Kyte-
Doolittle scale (http://www.vivo.colostate.edu/molkit/hydropathy/index.html) 
indicated it is unlikely to be a transmembrane protein (Figure 4.26).  
 
 
Figure 4.26 A hydropathy plot of BPSS1416: There was no significant 
hydrophobic region found, and the protein is unlikely to be a membrane spanning 
protein. This figure was produced using the website (http://www.vivo.colostate. 
edu/molkit/hydropathy/index.html). 
 
4.5.2.1. Gene amplification and cloning 
The gene encoding BPSS1416 was amplified using the oligonucleotide primers 
(5’- ATGCCTGCCTCCATGAGC-3’ and 5’- TCATGCGGCGCCCTCCA-3’) by 
PCR. The PCR product for the target gene fragment was obtained using an 
annealing temperature of 56°C with the addition of 5% DMSO (Figure 4.27).  
 
The PCR product was then cloned into a pETBlue-1 vector and the recombinant 
clones were selected using similar procedures before. DNA sequencing of the 
recombinant plasmids revealed that they were not successfully cloned as the insert 
was not the target gene. The cloning was repeated but still failed. This may be due 
to the size of this target gene which is about 1.4 kb and is probably not suitable 
for cloning with the pETBlue-1 vector.  
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Figure 4.27 PCR product of BPSS1416: The DNA band with approximately 1400 
base pairs on a 1% agarose gel corresponds to the gene encoding BPSS1416 
(1404 base pairs).  
 
 
A new construct was thus made of this gene to clone into the pET24-a plasmid 
using a restriction enzyme cloning strategy. A new pair of oligonucleotide primers 
(5’-CCGCATATGCCTGCCTCCAT-3’ and 5’-AGGATCCTCATGCGGCG 
CCC-3’) were used to amplify the target gene with a number of different PCR 
conditions but a PCR product that corresponded to the size of the BPSS1416 gene 
(1404 base pairs) was not obtained.   
 
As it was time-consuming process to achieve the cloning of these two genes, these 
projects were terminated. 
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4.6. Other uncharacterised proteins 
4.6.1. BPSS0603 
The gene encoding BPSS0603 in B. pseudomallei strain K96243 is located in 
chromosome 2 and the coding nucleotide sequence consists of 303 base pairs 
encoding 100 amino acids according to the Burkholderia genome database 
(Winsor et al, 2008). 
 
The protein sequence of BPSS0603 was analysed by ProtParam (ExPASy server). 
The amino acid composition of BPSS0603 was described, with an approximate 
molecular weight of 11 kDa, a theoretical pI of 6.55 and an extinction coefficient 
of 24980 M-1cm-1 (Figure 4.28).  
 
 
Figure 4.28 Analysis of BPSS0603 sequence: The characterization of BPSS0603 
revealed its molecular weight, theoretical pI, amino acid composition and 
extinction coefficients by ProtParam. 
 
BPSS 0603 
 
MIMEASMLNW ISRWALRYAP TPEKSATSML VTARMELFAA EQRVIDAKLQ ADYWCTRVSF 
LEVVQKQGID PWVNAQAQKA DDAPAAAVHG AAGPRLAAST 
 
Number of amino acids: 100 Molecular weight: 10992.6  Theoretical pI: 6.55 
 
Amino acid composition:  
Ala (A)  20  20.0% 
Arg (R)   6   6.0% 
Asn (N)   2   2.0% 
Asp (D)   5   5.0% 
Cys (C)   1   1.0% 
Gln (Q)   6   6.0% 
Glu (E)   5   5.0% 
Gly (G)   3   3.0% 
His (H)   1   1.0% 
Ile (I)   4   4.0% 
Leu (L)   7   7.0% 
Lys (K)   4   4.0% 
Met (M)   5   5.0% 
Phe (F)   2   2.0% 
Pro (P)   5   5.0% 
Ser (S)   6   6.0% 
Thr (T)   5   5.0% 
Trp (W)   4   4.0% 
Tyr (Y)   2   2.0% 
Val (V)   7   7.0% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
 (B)   0   0.0% 
 (Z)   0   0.0% 
 (X)   0   0.0%
 
Total number of negatively charged residues (Asp + Glu): 10 
Total number of positively charged residues (Arg + Lys): 10 
 
Atomic composition: 
Carbon      C        487 
Hydrogen    H        768 
Nitrogen    N        136 
Oxygen      O        142 
Sulfur      S          6 
   Formula: C487H768N136O142S6 Total number of atoms: 1539 
 
Extinction coefficients: 
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in water. 
Ext. coefficient    24980 
Abs 0.1% (=1 g/l)   2.272, assuming ALL Cys residues appear as half cystines 
Ext. coefficient    24980 
Abs 0.1% (=1 g/l)   2.272, assuming NO Cys residues appear as half cystines 
 
 
Estimated half-life: 
The N-terminal o  the sequence conside ed is M (Met). 
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro). 
                            >20 hours (yeast, in vivo). 
                            >10 hours (Escherichia coli, in vivo). 
 
Instability index: 
The instability index (II) is computed to be 27.82 
This classifies the protein as stable. 
 
Aliphatic index: 83.20 
Grand average of hydropathicity (GRAVY): -0.049 
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The hydrophobicity of BPSS0603 was characterised using hydropathy plot, and it 
can be seen that there were no hydrophobic membrane-spanning regions present 
in the BPSS0603 sequence (Figure 4.29). 
 
 
Figure 4.29 A hydropathy plot of BPSS0603, showing that it is unlikely to be a 
transmembrane protein. This figure was produced using the hydropathy plot 
server (http://www.vivo.colostate.edu/molkit/hydropathy/index.html). 
  
 
4.6.1.1. Gene amplification and cloning 
The oligonucleotide primers (5’- ATGATAATGGAGGCAAGCATGT-3’ and 5’- 
GTTACGTGCTCGCCGC -3’) were used to amplify the target gene using 
standard PCR. The PCR product was obtained using an annealing temperature of 
53°C. The expected size of a 300-base pair band was seen on a 1% agarose gel 
(Figure 4.30). Due to other non-specific products obtained during PCR, the 
expected band was cut from the gel and gel extraction was performed to recover 
the gene fragment prior to cloning.   
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Figure 4.30 PCR product of BPSS0603: The 300 bp band on a 1% agarose gel 
was cut and the gene fragment was extracted from the gel. 
 
 
The PCR product was then cloned into a pETBlue-1 vector and the recombinant 
clones in E.coli NovaBlue were selected by the blue/white colony method. White 
colonies were further screened by colony PCR for the correctly oriented insert 
clones. The positive clones were confirmed by DNA sequencing. The DNA 
sequencing results showed that the insert was BPSS0603 but with one amino acid 
alteration (residue 64 V to E) compared to the reference B.pseudomallei strain 
K96243 genome (Figure 4.31). In comparison to the orthologous proteins from 
different strains of other completely sequenced genomes of B. pseudomallei, the 
equivalent residues of residue 64 are all valine. The V to E change in this residue 
may therefore have occurred as a result of a mutation during PCR. Alternatively, 
it could be a real strain variation. This needs to be clarified.  
 
 
 
Figure 4.31 DNA sequencing of the recombinant BPSS0603 clone showed there 
is one amino acid (colored in red) different from the reference genome (first line). 
 
 
BPSS0603     1 MIMEASMLNWISRWALRYAPTPEKSATSMLVTARMELFAAEQRVIDAKLQADYWCTRVSF
0603_2       1 MIMEASMLNWISRWALRYAPTPEKSATSMLVTARMELFAAEQRVIDAKLQADYWCTRVSF
consensus    1 MIMEASMLNWISRWALRYAPTPEKSATSMLVTARMELFAAEQRVIDAKLQADYWCTRVSF
BPSS0603    61 LEVVQKQGIDPWVNAQAQKADDAPAAAVHGAAGPRLAAST
0603_2      61 LEVEQKQGIDPWVNAQAQKADDAPAAAVHGAAGPRLAAST
consensus   61 LEV-QKQGIDPWVNAQAQKADDAPAAAVHGAAGPRLAAST
 bp 
 
300 
 
200 
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4.6.1.2. Protein expression 
BPSS0603 was over expressed in E. coli TunerTM (DE3) cells with 1mM IPTG 
added to induce the protein production at 37°C for 4 hours. Analysis on SDS 
PAGE showed that the target protein (11 kDa) forms inclusion bodies and is in 
the insoluble fraction (Figure 4.32). An attempt to enhance the solubility of the 
target protein was carried out with the use of different IPTG concentrations (0.1 
mM, 0.25 mM, 0.5 mM and 1mM IPTG) during induction at 37°C, because as the 
protein synthesis decreases, the protein may be found more in the soluble form. 
The results showed the protein was still in the insoluble fraction in all conditions. 
Decreasing the expression temperature to 30°C, still resulted in protein production 
but it was still insoluble. However, when the over-expression tests were carried 
out at 20°C, no expression of the target protein was seen.  
 
The alteration of the residue 64 from valine (hydrophobic) to glutamic acid 
(polar) may have possibly caused the misfolding of the protein, resulting in its 
presence in the inclusion bodies. 
 
 
 1 2 3 4 
 
Figure 4.32 Overexpression of BPSS0603: SDS PAGE of BPSS0603 expressed in 
E.coli TunerTM (DE3) pLacI on a 15% resolving gel; lane 1 a protein marker 
Mark12TM; lane 2 pre-induction; lane 3 soluble fraction at 37°C induction for 4 
hours; lane 4 insoluble fraction at 37°C induction for 4 hours. 
 
 
 
kDa 
 
 
 
14 
 
 
6 
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4.6.2. BPSS0683 
According to the Burkholderia genome database, the BPSS0683 encoding gene in 
B. pseudomallei strain K96243 is located in chromosome 2 and the coding 
nucleotide sequence consists of 357 base pairs encoding 118 amino acids (Winsor 
et al, 2008). 
 
The protein sequence of BPSS0683 was analysed by ProtParam (ExPASy server). 
The amino acid composition of BPSS0683 was described with an approximate 
molecular weight of 13 kDa, a theoretical pI of 5.09 and an extinction coefficient 
of 22125 M-1cm-1 (Figure 4.33).  
 
 
Figure 4.33 ProtParam of BPSS0683: The protein sequence was analysed and the 
characterization of BPSS0683 was displayed. 
 
The hydropathicity of BPSS0683 was analysed by hydropathy plot. The 
hydropathy plot of BPSS0683 revealed that it is unlikely to be a membrane 
protein (Figure 4.34). 
BPSS 0683 
 
MRLTIRINGS DAPAQQFAVL WLDTDEQLWS REAHQGIDLP AWGKVKDVEG AVALCSADSG  
EALCRLQGLS FSNVRRLSED EEHGNAVLGG KNPQGAWRLQ AVDSASIQPE HREFTIVR 
 
Number of amino acids: 118 Molecular weight: 12994.5 Theoretical pI: 5.09
Amino acid composition:  
Ala (A)  13  11.0% 
Arg (R)   9   7.6% 
Asn (N)   4   3.4% 
Asp (D)   8   6.8% 
Cys (C)   2   1.7% 
Gln (Q)   8   6.8% 
Glu (E)   9   7.6% 
Gly (G)  10   8.5% 
His (H)   3   2.5% 
Ile (I)   5   4.2% 
Leu (L)  12  10.2% 
Lys (K)   3   2.5% 
Met (M)   1   0.8% 
Phe (F)   3   2.5% 
Pro (P)   4   3.4% 
Ser (S)   9   7.6% 
Thr (T)   3   2.5% 
Trp (W)   4   3.4% 
Tyr (Y)   0   0.0% 
Val (V)   8   6.8% 
Pyl (O)   0   0.0% 
Sec (U)   0   0.0% 
 
 (B)   0   0.0% 
 (Z)   0   0.0% 
 (X)   0   0.0% 
 
Total number of negatively charged residues (Asp + Glu): 17 
Total number of positively charged residues (Arg + Lys): 12 
 
Atomic composition: 
Carbon      C        565 
Hydrogen    H        892 
Nitrogen    N        170 
Oxygen      O        177 
Sulfur      S          3 
 
Formula: C565H892N170O177S3 Total number of atoms: 1807 
 
Extinction coefficients:  
Extinction coefficients are in units of  M-1 cm-1, at 280 nm measured in water. 
Ext. coefficient    22125 
Abs 0.1% (=1 g/l)   1.703, assuming ALL Cys residues appear as half cystines 
 
Ext. coefficient    22000 
Abs 0.1% (=1 g/l)   1.693, assuming NO Cys residues appear as half cystines 
 
Estimated half-life: 
The N-terminal of the sequence considered is M (Met). 
The estimated half-life is: 30 hours (mammalian reticulocytes, in vitro). 
                            >20 hours (yeast, in vivo). 
                            >10 hours (Escherichia coli, in vivo). 
 
Instability index: 
The instability index (II) is computed to be 35.40 
This classifies the protein as stable. 
 
Aliphatic index: 86.86 
Grand average of hydropathicity (GRAVY): -0.392 
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Figure 4.34 A hydropathy plot of BPSS0683 showing that strongly hydrophobic 
region is not found along the sequence. This figure was produced using the 
hydropathy plot server (http://www.vivo.colostate.edu/molkit/hydropathy/ 
index.html). 
 
 
4.6.2.1. Gene amplification and cloning 
The gene encoding BPSS0683 was amplified from the genomic DNA of 
B.pseudomallei using the primers 5’-ATGCGCCTCACCATTCGAAT-3’ and 5’- 
TCAGCGCACGATGGTGAAT-3’. The PCR product was obtained using an 
annealing temperature of 60 °C with an expected PCR product size of about 300 
base pairs (Figure 4.35). 
 
  
Figure 4.35 PCR product of BPSS0683: An approximately 300 bp band on 1% 
agarose gel was suspected to be the BPSS0683 gene fragment.  
 bp 
300 
 
200 
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The PCR product was cloned into a pETBlue-1 vector and the recombinant clones 
were screened by the blue-white colony method and colony PCR. The 
recombinant clone with the correctly oriented insert was confirmed by DNA 
sequencing and the results showed that the insert was identical to the reference 
genome of  B.pseudomallei strain K96243. 
 
 
4.6.2.2. Protein expression 
The recombinant BPSS0683 was over expressed in E.coli TunerTM (DE3) with 
1mM IPTG added to induce the protein production at 37°C for 4 hours but it was 
found to be insoluble (Figure 4.36). There were no expression of the target protein 
when the induction temperature was decreased to either 30°C or 20°C. 
 
 1         2        3    4 
 
Figure 4.36 Overexpression of BPSS0683: SDS PAGE of BPSS0683 expressed in 
E.coli TunerTM (DE3) pLacI on a 15% resolving gel; lane 1 a protein marker 
Mark12TM; lane 2 pre-induction; lane 3 soluble fraction at 37°C induction for 4 
hours; lane 4 insoluble fraction at 37°C induction for 4 hours. 
 
 
 
 
 
 
kDa 
 
 
 
14 
 
 
 
6 
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4.6.3. BPSL0606 
 
According to the Burkholderia genome database, the gene encoding BPSL0606 in 
the B. pseudomallei strain K96243 is located on chromosome 1 and the coding 
nucleotide sequence consists of 651 base pairs, encoding 216 amino acids 
(Winsor et al, 2008).  
 
A preliminary analysis of BPSL0606 protein sequence was performed using the 
ProtParam (ExPASy) server. An amino acid composition of BPSL0606 was 
described with the molecular weight of 23.5 kDa, with a theoretical pI of 6.24 and 
an extinction coefficient of 20065 M-1cm-1 (Figure 4.37).  
 
 
 
Figure 4.37 The characterization of BPSL0606 sequence by ProtParam (ExPasy 
server) revealed its amino acid composition, molecular weight, pI and extinction 
coefficient. 
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The protein sequence of BPSL0606 was also compared to other proteins in the 
non-redundant database using BlastP (NCBI). The search showed a hit to the 
ElaA family protein, which is predicted as a transferase with an acyl-CoA N-
acyltransferase domain from Burkholderia species and an N-acetyltransferase 
from other bacteria. 
 
In addition, a domain of the Acyl-CoA N-acetyltransferase superfamily (NAT) 
has been found at the N-terminal region of the BPSL0606 protein (residues 1-152) 
using a Superfamily search, the HMM library and a genome assignment server 
(Gough et al, 2001). In comparison to orthologous proteins, BPSL0606 has a C-
terminal sequence extension apart from the NAT domain-containing region 
(Figure 4.38). 
 
Residue 1            152             216 
 
Figure 4.38 Schematic of BPSL0606 domain: A NAT domain (residues 1-152) was 
identified in BPSL0606, with a C-terminal extension not seen in orthologous proteins.  
 
The hydrophobicity of BPSL0606 was characterised using the hydropathy 
programme (http://www.vivo.colostate.edu/molkit/hydropathy/index.html), which 
showed that BPSL0606 is not likely to have a transmembrane component (Figure 
4.39). 
 
 
Figure 4.39 A Kyte-Doolittle hydropathy plot of BPSL0606 showed the protein is 
unlikely to contain a membrane spanning domain. This figure was produced using the 
hydropathy plot server (http://www.vivo.colostate.edu/molkit/hydropathy/ index.html). 
NAT domain 
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4.6.3.1. Gene amplification and cloning 
Oligonucleotide primers were designed for amplifying the full length of             
the BPSL0606 coding gene according to an open reading frame of this gene in  
the B. pseudomallei strain K96243. The forward primer (5’-GAATCTCCCAT 
ATGGACTGG-3’) and the reverse primer (5’-GGATCCTCATCGGTTCA   
TTC-3’) containing NdeI and BamHI restriction sites (underlined) were used in 
PCR with the genomic DNA of B. pseudomallei strain D286.  
 
For amplification of the gene encoding BPSL0606, the PCR product was obtained 
by adding 2%(v/v) DMSO, resulting in an approximately 600 bp DNA fragment 
(Figure 4.40).  
 
 
Figure 4.40 Analysis of PCR product of BPSL0606 on a 1% agarose gel 
electrophoresis: The PCR product has approximate 600 base pairs in length, 
which corresponds to BPSL0606 (651 base pairs). 
 
The gene fragment of BPSL0606 was inserted into the pET-24a plasmid. 
Restriction enzyme digestion of the PCR product and the pET-24a vector were 
carried out to obtain the insert with NdeI and BamHI overhangs, and the NdeI-
BamHI linearised vector, respectively.  The insert was then ligated into the vector 
at the restriction cloning sites using T4 ligase. Recombinant plasmids were 
transformed into E. coli DH5α cells, and screening for positive clones was 
achieved using the kanamycin selective marker in pET-24a. The transformants 
were then propagated in a 10 ml culture to isolate plasmid DNA from candidate 
recombinants for verification.     
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a)  
 
b)  
Figure 4.41 DNA sequencing of the recombinant BPSL0606 clone: The gene 
insert in the recombinant pET24-a was identified; a) Nucleotide sequence 
alignment of BPSL0606 (second line) and positive clone sequenced using T7 
forward primer (first line) and T7 reverse primer (third line) shows the alteration 
of nucleotides in the clone compared to the reference sequence of B. pseudomallei 
strain K96243; b) Protein sequence alignment of BPSL0606 (first line) and the 
identified insert from positive clone (second line) indicates one amino acid of the 
clone altered (colored in red) compared to the reference sequence of B. 
pseudomallei strain K96243. 
BPSL0606     1 MDWTCCEFRHLSSNELYMILRTRNAVLVVEDAHTHLDIDGKDEFAIHVFATDKRGEQPAI
06061/2      1 MDWTCCEFRHLSSNELYMILRTRNAVLVVEDAHTHLDIDGKDEFAIHVFATDKRGEQPAI
consensus    1 MDWTCCEFRHLSSNELYMILRTRNAVLVVEDAHTHLDIDGKDEFAIHVFATDKRGEQPAI
BPSL0606    61 AAYARLLPGDDIDPETTIDKILTSAAHRDDRTIDALIEHVLAAAHARWPDAPVRVQAPAP
06061/2     61 AAYARLLPGDDIDPETTIDKILTSAAHRDDRTIDALIEHVLAAAHARWPDAPVRVQAPAP
consensus   61 AAYARLLPGDDIDPETTIDKILTSAAHRDDRTIDALIEHVLAAAHARWPDAPVRVQAPAP
BPSL0606   121 REGFYNRFGFRKVDGPYLEHGAPYVGMLRAASAPSKAVRNLLDLVGNATGANPGTSAGAV
06061/2    121 REGFYNRFGFRKVDGPYLEHGAPYVGMLRAASAPSKAVRNLLDLVGNATGANPGTSAGAV
consensus  121 REGFYNRFGFRKVDGPYLEHGAPYVGMLRAASAPSKAVRNLLDLVGNATGANPGTSAGAV
BPSL0606   181 PASAARKPRKANAESTTEGERYAFAGRLPADSGMNR
06061/2    181 PASAARKPRKANAESTTEGERYTFAGRLPADSGMNR
consensus  181 PASAARKPRKANAESTTEGERY-FAGRLPADSGMNR
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The positive clone was confirmed by DNA sequencing, which showed there are 
two different nucleotides in comparison to the B. pseudomallei strain K96243 
genome sequence, resulting in 1 amino acid change at residue 203 (A to T) 
(Figure 4.41). This sequence difference could be a result of a mutation in the 
PCR, as this residue in orthologous proteins from different strains of B. 
pseudomallei is always an alanine. Alternatively, it could possibly be a variation 
between the strains of B. pseudomallei. This needs to be clarified.  
 
4.6.3.2. Protein expression 
The recombinant protein of BPSL0606 was over produced in E. coli BL21 (DE3) 
cells, with 1 mM IPTG induction at 37°C for 4 hours. The protein expression 
profile was analysed by SDS PAGE and a large amount of soluble protein was 
present on the gel between 21.5 and 31 kDa, which was expected as the molecular 
weight of the target protein is approximately 23.5 kDa. Reducing the temperature 
to 20 °C during induction did not show a significant increase in the soluble 
protein yield (Figure 4.42).  
 
 
 
 Figure 4.42 BPSL0606 expression profile: lane 1 Mark12TM; lane 2 pre-
induction; lane 3 soluble fraction at 37°C induction for 4 hours; lane 4 insoluble 
fraction at 37°C induction for 4 hours; lane 5 soluble fraction at 20°C induction 4 
hours; lane 6 insoluble fraction at 20°C induction 4 hours; lane 7 soluble fraction 
at 20°C induction overnight; lane 8 insoluble fraction at 20°C induction overnight. 
    1       2        3        4       5        6        7        8 
 kDa 
 
31 
 
 
 
 
21.5 
!
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Selenomethionine incorporated protein was also produced for BPSL0606. After 
growing the bacterial cells to mid-log phase, the use of minimal media with 
supplements including selenomethionine (described in section 3.3.4) was used in 
order to allow the production of selenomethionine incorporated protein during 
induction by IPTG (Stols et al, 2004). The supplements added inhibit methionine 
biosynthesis in the cells and the additional selenomethionine is provided as an 
external amino acid source for incorporation into the cellular proteins. The 
overexpression of selenomethionine substituted BPSL0606 was performed using 
1 mM IPTG induction at 37°C for 4 hours in a similar manner to the native 
protein production. 
 
 
4.6.3.3. Protein purification 
Approximately 2 g of cell paste was resuspended in 50 mM Tris-HCl pH 8 and 
the cells were disrupted by ultra-sonication on ice for 2-3 cycles of 20 seconds. 
About 20 ml crude extract was obtained after the cell debris was removed by 
centrifugation. The protein solution was loaded onto a 5 ml Heparin HP column 
(GE Healthcare) which was pre-equilibrated with 50 mM Tris-HCl pH 8 and the 
protein was eluted with a gradient of 0-1 M NaCl in 50 mM Tris-HCl pH 8. 2.5 
ml fractions were collected and monitored by UV absorbance. The fractions 
corresponding to the UV peak were analysed using the Bradford assay (Bradford, 
1976) and SDS PAGE in order to select the fractions containing the target protein. 
The second purification step was anion exchange chromatography using a 
ResourceTM Q column (GE Healthcare). The diluted sample was applied to this 
column, pre-equilibrated with 50 mM Tris-HCl pH 8 and the protein was eluted 
with a gradient of 0-1 M NaCl in 50 mM Tris-HCl pH 8. 3 ml fractions were 
collected. The Bio-Rad assay and SDS PAGE were carried out for the fractions 
corresponding to the UV peak. The fractions containing the purified protein 
BPSL0606 (23.5 kDa) were pooled together and the protein was concentrated to 
approximately 10 mg/ml using a 10 kDa MWCO VivaspinTM centrifugal 
concentrator (Vivascience). 
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In the purification steps, BPSL0606, which has its theoretical pI 6.24 predicted by 
ProtParam (ExPASy server) has a net negative charge in the buffer at pH 8 and 
binds to the anion exchange column. The purity of BPSL0606 obtained was 
greater than 95%, which is suitable for subsequent crystallisation trials (Figure 
4.43). The average yield of protein purification was approximately 5 mg protein 
obtained from one litre of recombinant E. coli culture. 
 
 
Figure 4.43 Analysis of BPSL0606 protein purification by 12% SDS-PAGE: 
Lane1 Mark12; Lane2 Cell debris; Lane3 Crude extract; Lane4 Unbound fraction 
from Heparin HP column; Lane5 Heparin HP column-bound fraction and Lane6 
the purified BPSL0606 (23.5 KDa) after Resource Q column. 
   
For the selenomethionine-substituted protein, the same purification protocols were 
employed. Analysis of molecular weight of the purified protein was carried out by 
mass spectrometry. The results provided the molecular mass of native BPSL0606 
and Se-Met substituted protein (Figure 4.44). The difference between the 
molecular weights of sulphur-methionine protein and selenium-methionine 
protein indicate the incorporation of selenium into the methionine residues. As the 
difference of atomic weights between selenium and sulphur atoms is 78.96-32.06 
= 46.9 and BPSL0606 contains 4 methionine residues, the molecular mass of the 
Se-Met protein would be 187.6 greater than the native protein if selenium is fully 
incorporated in all 4 methionines. The difference of molecular mass between the 
Se-Met protein and the native protein obtained from mass spectrometry was 
calculated to be 189. Thus, BPSL0606 was produced with 100% Se incorporation 
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of the methionine residues and was thus suitable for subsequent structure 
determination.  
 
a)  
b)  
Figure 4.44 Analysis of purified BPSL0606 by mass spectrometry: a) Mass 
spectrum of native BPSL0606 with its molecular weight of 23517 Da; b) Mass 
spectrum of Se-Met incorporated protein with its molecular weight of 23706 Da. 
The difference of molecular weights is approximately the difference between 
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atomic weights of sulphur and selenium in 4 methionine residues in BPSL0606, 
indicating the full incorporation of selenium in the Se-Met protein. 
  
 
4.7. Chapter summary 
In summary, from seven selected target genes, five genes including BPSL3022, 
BPSS0945, BPSS0603, BPSS0683 and BPSL0606 were successfully cloned. 
Within these five, two proteins, BPSS0945 and BPSL0606, were expressed in a 
soluble form. These results showed that soluble protein expression remains the 
bottleneck of protein production, to be used in crystallographic studies. 
BPSS0945 was unstable and did not crystallise. BPSL0606 was the only protein 
that was successfully crystallised and whose structure was determined. The 
crystallisation and structure determination of BPSL0606 is described in the 
following chapter. The summary of this work is shown in Table 4.5. 
 
Table 4.5 Summary of target proteins studied in this project. 
 
 
Possible future experiments for those targets that have not led to structures 
include: 
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-BPSL3022: Different constructs of periplasmic FtsQ could be made in order to 
achieve soluble protein expression and crystallisation. Once the structure of B. 
pseudomallei FtsQ is determined, it could be compared to known structures of 
FtsQ from other organisms. This could be useful for understanding aspects of cell 
division in B. pseudomallei. 
 
-BPSS0945: Truncated constructs without residues 1-23, which are probably a 
signal peptide, could be made and the mature protein could be further 
investigated. Attempts to obtain protein crystals and a structure would provide the 
structural information and its biological function.  
 
-BPSS0603: A new clone without sequence difference could be made and the 
soluble protein expression could be observed.  
 
-BPSS0683: To improve the soluble expression of these proteins, co-expression of 
molecular chaperones such as GroES-GroEL, DnaK-DnaJ-GrpE and ClpB could 
be helpful for in vivo protein folding.  
 
-BPSS0238 and BPSS1416: Different cloning systems could be used for 
producing the recombinant proteins. As BPSS0238 is a large protein, choosing 
smaller fragments would perhaps be alternative for cloning this gene and 
producing the soluble protein. 
  
Sequence differences between the clones and the genomes 
All the proteins studied in this thesis have been cloned using genomic DNA from 
B. pseudomallei strain D286. As there was no genome sequence for this strain, the 
sequences of the successfully cloned genes were compared to the sequences of the 
genome of B. pseudomallei strain K96423, the only B. pseudomallei genome 
sequence available. Problems of assignment thus occur if the sequence of the 
cloned gene differs from the genome sequence. These differences could either be 
due to real differences between the strains, or to errors introduced in the PCR 
process. It is thus important to repeat the cloning of any genes where differences 
are seen, to identify any potential PCR errors that may result in incorrect folding, 
solubilisation problems or low yields of the recombinant protein. 
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For BPSL3022, different sequence changes are seen in the different constructs, 
with BPSL3022_2 having an A79V change; BPSL3022_3 having one nucleotide 
difference (no change in protein sequence); BPSL3022_2 having a R175H 
difference and BPSL3022_1 having the same sequence as that seen in the 
genome. As the sequence changes are different between these constructs, these 
differences are thus most likely to be from the PCR reaction. 
 
For BPSS0945, BPSS0603 and BPSL0606, differences are also seen between the 
cloned gene and the genome sequence. In each of these cases the residue present 
in the K96423 strain of B. pseudomallei in also present in the genes from other B. 
pseudomallei strains, indicating again that an error may have been introduced 
during the PCR process, alternatively, these sequence differences could be a real 
strain variation. 
 
For each of these genes the cloning process should be repeated and a number of 
different clones sequenced, to clarify differences in sequence due to PCR errors 
from differences due to genetic drift between strains. This may well result in 
proteins with increased stability, solubility and even an increased chance of 
crystallisation. However, until a full genome sequence is determined for the D286 
strain of B. pseudomallei, the cause of these differences in sequence cannot be 
certain.  
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Chapter 5: Crystallisation, Analysis of 
X-ray Diffraction and Structure 
Determination of BPSL0606 
 
This chapter details the crystallisation of BPSL0606 and the determination of the 
BPSL0606 crystal structure. Preliminary analysis of the X-ray diffraction data is 
included. 
 
5.1. Crystallisation of BPSL0606 
Freshly purified BPSL0606 protein in 10 mM Tris-HCl pH 8, 0.1 M NaCl was 
concentrated to approximately 10 mg/ml using a 10 kDa MWCO vivaspin 
concentrator (Vivascience), prior to crystallisation trials.  
 
Automated crystallisation screening was initially performed using a Hydra II Plus 
One robot and commercially available screening kits (QIAGEN), including the 
PACT, JCSG, PEG, pH clear and Classics screens. The experiment was carried 
out using the sitting-drop vapour-diffusion method, in a 96-well crystallisation 
plate with each well containing 200 nl of protein mixed with an equal amount of 
different crystallisation solutions, which consisted of precipitants, buffers and/or 
salts. All crystallisation trays were sealed using a clear tape and stored at 17°C.  
 
Only a single hit condition from the robot screens was found. BPSL0606 protein 
crystallised in 20 % (w/v) PEG3350, 0.1 M Bis-Tris propane pH 6.5 and 0.2 M 
potassium thiocyanate. The crystals of BPSL0606 obtained from the initial robot 
screening were of a rod morphology, grouped in clusters (Figure 5.1). 
 
To obtain larger crystals, the crystallisation condition for BPSL0606 was further 
optimised by varying the precipitant concentration, buffer pH and the ratio of 
protein and reservoir solution using the hanging drop vapour diffusion technique. 
The optimization of crystallisation included varying the precipitant concentration 
(14%-24% PEG 3350), the pH (0.1 M Bis-Tris Propane pH 6.3, 6.5 and 7) and the 
ratio of protein and reservoir solution (1:1, 1:2 and 2:1). 
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Figure 5.1 Crystals of BPSL0606 observed in the drop F4 in the robot PACT 
screen. The crystals grew in a solution of 20% (w/v) PEG3350, 0.1 M Bis-Tris 
propane pH 6.5 and 0.2 M potassium thiocyanate at 270 K. 
 
Single long rod-like crystals were obtained from 16% (w/v) PEG3350, 0.1 M Bis-
Tris propane pH 6.3 and 0.2 M potassium thiocyanate, with approximate 
dimensions of 400 µm x 25 µm x 25 µm. 
 
Prior to mounting on the diffractometer, the protein crystals were mounted in a 
fibre loop and washed through a cryoprotectant solution, which consisted of the 
mother liquor they grew from and 25% ethylene glycol. They were then flash 
cooled to 100 K with an Oxford Cryosystems Cryostream 700 for X-ray 
diffraction experiments.   
 
The crystals were tested using an ‘in house’ Rigaku MM007 copper rotating 
anode generator and a MAR345 Research image plate. Two test images of 1 
degree rotation and 5 minutes exposure were taken and the X-ray diffraction 
patterns were analysed using the autoindexing routine in Mosflm (Leslie & 
Powell, 2007). The native and Se-M incorporated BPSL0606 protein crystals both 
belonged to the monoclinic crystal system with the Laue group P2/m and 
approximate cell dimensions of a=60.6Å, b=81.4Å, c=78.2Å, α=90°, β=100° and 
γ=90°. 
100 µm 
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a)  
 
b)  
Figure 5.2 Data collection of the native BPSL0606 crystal: a) The sulphur-
methionine BPSL0606 crystal was mounted in a fibre loop and was exposed to a 
100 µm X-ray beam b) A diffraction image of the BPSL0606 crystal: Diffraction 
data were collected to a resolution of 2.2 Å on the ADSC Q315 CCD detector at 
the beamline I03 of the Diamond synchrotron source. The BPSL0606 crystal 
diffracted the X-rays beyond the resolution of 2.35 Å (blue circle). 
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5.2. X-ray data collection 
Single crystals of BPSL0606 were mounted and cryoprotected with 25% ethylene 
glycol with their mother liquor prior to cryocooling using an Oxford Cryosystems 
Cryostream 700 at 100 K. An X-ray diffraction test was carried out using an in-
house Rigaku MicroMax 007 micro-focus copper rotating anode generator 
running at 40kV, 20mA with a MarResearch MAR345 image plate detector 
system. Each crystal was exposed for 5-15 minutes and a few test images were 
observed at a starting angle and 90 degree apart to assess the resolution limit and 
diffraction quality. These images were pre-analysed for its unit cell dimensions, 
mosaicity and Laue group determination using Mosflm (Leslie & Powell, 2007). 
Well diffracting crystals were kept in vials in a liquid nitrogen Dewar and they 
were later transferred to universal pucks for data collection at the Diamond 
Synchrotron.   
 
High-resolution data sets were collected at the macromolecular crystallography 
beamlines of the Diamond Synchrotron. DNA software (http://www.dna.ac.uk/) 
and Mosflm (Leslie & Powell, 2007) were employed for data collection strategies. 
 
The first native data set was collected at beamline I03 of the Diamond 
Synchrotron source. A total of 360 images with a 0.5° rotation per image were 
collected to a resolution of 2.2 Å at the edge of the detector. 
 
 
5.3. Data processing 
For the native data set, diffraction images were initially analysed using the 
autoindexing routine in Mosflm (Leslie & Powell, 2007). Autoindexing was 
performed to estimate the cell dimensions, crystal system, space group and 
mosaicity. The possible solution with low penalty indicated the crystal belonged 
to the monoclinic crystal system in the Laue group P2/m with the cell dimensions 
of a = 60.61 Å, b = 81.39 Å, c = 78.18 Å, α=90°, β=99.99° and γ=90°, with an 
estimated mosaicity of 0.63°. The diffraction data were subsequently integrated 
using Mosflm, resulting in an .mtz file that included the reflection intensities and 
indices. 
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To determine the space group, the POINTLESS program (Evans, 2006) in the 
CCP4 suite was employed. Analysis of systematic absences indicated the presence 
of 21 screw axis along b (0k0; k = 2n), therefore it was likely that the BPSL0606 
crystal belonged to space group P21 (P 1 21 1). 
 
Data reduction was performed using the CCP4 package. The data were scaled by 
the SCALA program (Evans, 2006) and the scaling showed the data were good 
beyond the resolution of 2.5 Å. Between the resolution of 2.6 Å and 2.4 Å, I/σ fell 
from 2.3 to 1.4, which is in the range of a typical signal to noise threshold value 
for a resolution cut-off (1 < I/σ(I) < 2) (Evans, 2011). The data were therefore cut 
to a resolution of 2.35 Å. 
 
The unit cell contents were analysed using Matthews_coef program (Kantardjieff 
& Rupp, 2003; Matthews, 1968) in the CCP4 suite. The unit cell volume was 
calculated to 3.8 x 105 Å3, resulting in the Matthews coefficient values of 2.71 and 
2.03 Å3 Da-1 for 3 and 4 molecules in asymmetric unit with 54.6% and 39.5% 
solvent content, respectively, based on the molecular weight of the full length 
protein of 23.5 kDa.  
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Table 5.1 Data collection statistics of the native, sulphur-methonine BPSL0606 
crystal 
 
Dataset 
Spacegroup P 1 21 1 
Unit cell parameters 
(Å) 
 
a  60.61  
b 81.39  
c 78.18  
α 90.00 ° 
β 99.99 ° 
γ 90.00 ° 
Temperature (K) 100 
X-ray Source DIAMOND I03 
Detector ADSC Q315 CCD 
Resolution (Å)1 29.77-2.35 
(2.41-2.35) 
Energy (keV) 12.800 
Unique observations1 30688 (2254) 
Rmerge 1,2 0.074 (0.583) 
Rpim1 0.055 (0.434) 
Completeness (%)1 98.4 (98.8) 
Multiplicity1 3.7 (3.6) 
Mean((I)/sd(I))1 10.6 (2.2) 
1Numbers in parentheses indicate values for the highest resolution shell 
2 Rmerge = Σhkl Σi |Ii(hkl) – 〈I(hkl)〉|/ Σhkl Σi Ii(hkl), where 〈I(hkl)〉 is the mean intensity of the 
reflection 
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5.4. Analysis of self-rotation function and self-Patterson function 
A self-rotation function, using the X-ray data between 20-6 Å, shows a peak of 
87.3% of the origin at ω = 90.0°, ϕ = 11.7°, κ = 180.0° using an orthogonalization 
matrix of c along x, a* along y and b* along z. This peak decreases to 85.1% of 
the origin using 20-3 Å data, and the position changes to ω = 90.0°, ϕ = 10.1°, κ = 
180.0°. This gives clear evidence for a non-crystallographic 2-fold axis lying in 
the ac plane, and approximately 10° away from the c axis (Figure 5.3).  Inspection 
of the self-rotation function showed no significant peaks at κ = 90.0° or κ = 
120.0°, indicating that non-crystallographic 4-fold or 3-fold axes are unlikely. 
 
Analysis of self-Patterson using 20-6 Å data shows a peak of 11.5% of the origin 
at (0, 0.44, 0.47) which decreases to 5.1% of the origin using 20-3 Å data. This 
perhaps indicates the presence of non-crystallographic translational symmetry. 
 
Figure 5.3 Analysis of the self-rotation function using data from 20-6 Å: A peak 
of 87.3% of the origin can be seen at ω = 90.0°, ϕ = 11.7°, κ = 180.0°, indicating 
the presence of a non crystallographic 2-fold axis in the ac plane and 11.7° away 
from the c axis. This figure was generated using Polarrfn in the CCP4 suite 
(Collaborative Computational Project, 1994). 
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5.5. Structure determination 
As BPSL0606 shares sequence homology with the acyl coA N-acetyltransferase 
family (Section 4.6.3), then initial attempts were made to determine the structure 
using molecular replacement. The protein with the highest sequence similarity and 
known structure to BPSL0606 is an acyl coA N-acetyltransferase from P. 
aeruginosa (PDB ID: 1XEB). These two proteins share 34.9% sequence identity 
for the N-terminal 150 residues, but the BPSL0606 C-terminal extension of 66 
residues is not present in the P. aeruginosa protein (Figure 5.4).  
 
Therefore, the coordinates of the crystal structure of the Acyl CoA N-
acetyltransferase from P. aeruginosa were used as a search model, together with 
the native BPSL0606 X-ray data for determining BPSL0606 structure by 
molecular replacement, using the program Phaser (McCoy et al, 2007) in the 
CCP4 package. 
 
 
 
Figure 5.4 Fold recognition and secondary structure prediction of BPSL0606:  
The predicted fold recognition and secondary structure of BPSL0606 showed the 
similarity to acyl coA N-acetyltransferase from P. aeruginosa (PDB ID: 1XEB) 
with 35% sequence identity. This figure was produced using mGenTHREADER 
(McGuffin et al, 2000). 
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The best solution from the molecular replacement was obtained with a log-
likelihood gain (LLG) of 647 and a translation function Z-score of 10.5. This 
molecular replacement solution contained four copies of the P. aeruginosa model 
each with 149 residues. Although the packing of the four chains in the crystal 
appeared reasonable  (Figure 5.5), electron density maps calculated using this 
solution did not show any density for the 67 C-terminal residues present in 
BPSL0606 (Figure 5.6).  
 
 
Figure 5.5 Crystal packing for 4 copies of BPSL0606. The 4 molecules in the 
asymmetric unit pack well in the lattice, and there was no clash between them. 
Molecules colored in yellow, blue, pink and green represent 4 copies of 
BPSL0606 and those colored in grey are symmetry related molecules. This figure 
was produced using Coot (Emsley et al, 2010). 
 
 
Furthermore, the molecular replacement map contained bias against the model, 
with inconclusive electron density for many of the sequence changes between the 
1XEB model and BPSL0606. For example, as can be seen in Figure 5.7, the 
electron density did not fit the side chain of Ile 93 in BPSL0606 but agreed with 
the amino acid Gly 93 in the 1XEB search model.  
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Attempts were made to improve the molecular replacement solution by screening 
more crystals for better data quality, but no improvement on the quality or 
resolution of the data could be made. 
 
As the molecular replacement map was not of a very high quality, and because 
none the C-terminal 65 residues were visible in the map, doubts remained as to 
whether the molecular replacement result was a correct solution. Therefore, 
seleno-methionine (Se-Met) incorporated protein was produced to allow 
independent, unbiased structure determination using the multiwavelength 
anomalous dispersive (MAD) method.    
 
 
 
Figure 5.6 The C-terminal 65 residues of BPSL0606 were missing: There was no 
electron density beyond the residue 151 of BPSL0606. The skeleton of BPSL0606 
is shown in violet and the structure of 1XEB, used as a model, is shown in yellow. 
The electron density map, contoured at 1 σ is shown in blue. This figure was 
produced using Coot (Emsley et al, 2010).    
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Figure 5.7 Biased structure determination by molecular replacement: The 
molecular replacement map did not agree in places with the sequence of 
BPSL0606. The skeleton of BPSL0606 is shown in violet and the structure of 
1XEB, used as a model, is shown in yellow. The electron density map, contoured 
at 1 σ is shown in blue. This figure was produced using Coot (Emsley et al, 2010).    
 
 
5.6. Se-methionine protein 
The Se-methionine protein was purified and crystallised in the same conditions as 
the S-methionine protein, with large rod shaped crystals growing from solutions 
of 16% (w/v) PEG3350, 0.1 M Bis-Tris propane pH 6.3 and 0.2 M potassium 
thiocyanate with approximate dimensions of 400 µm x 25 µm x 25 µm (Figure 
5.8). 
 
Figure 5.8 Crystals of the Se-Met protein of BPSL0606 grew in solutions of 16% 
(w/v) PEG3350, 0.1 M Bis-Tris propane pH 6.3 and 0.2 M potassium thiocyanate.  
500 µm 
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For multi wavelength anomalous dispersion (MAD) experiments, an X-ray 
fluorescence scan was carried out in order to determine appropriate wavelengths 
for collecting MAD data using CHOOCH (Evans & Pettifer, 2001). 
 
MAD data were collected at the beamline I04 of the Diamond Synchrotron 
source. Three wavelengths were selected on a basis of a fluorescence scan at the 
absorption K-edge of selenium (Figure 5.9). A peak data set was collected at the 
wavelength λ1 (λ1 = 0.9795 equivalent to E = 12657.9 eV) where the f” 
component is maximised, whereas the inflection data were collected at the 
wavelength λ2 (λ2 = 0.9797 equivalent to E = 12655.4 eV) where the f’ component 
is minimised. The remote data were collected at the wavelength λ3 (λ3 = 0.9763 
equivalent to E = 12700 eV) in which the dispersive difference is maximised. A 
total of 180 images with a 1° rotation per image were collected to a resolution of 
2.0 Å at the edge of the detector for each wavelength. As the crystals were of a 
rod morphology, the crystal was translated through the beam while collecting the 
different data sets to minimise radiation damage (Figure 5.10).  
 
 
Figure 5.9 A fluorescence absorption spectrum of the Se-Met BPSL0606 crystal 
near to the absorption K-edge of Se: The absorption signal f” (above) and 
dispersive signal f’ (below) suggested the suitable wavelengths for collecting 
MAD data sets. This figure was produced using CHOOCH (Evans & Pettifer, 
2001). 
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a)  
b)  
Figure 5.10 MAD data collection: a) A photograph of the BPSL0606 crystal 
mounted in a fibre loop showed the crystal was being shot by the X-ray beam of 
50 µm x 50 µm (red box) and whilst collecting the different data sets, the Se-Met 
crystal was translated through the beam to minimise radiation damage. b) A 
diffraction image was collected to a resolution of 2.0 Å at the edge of the ADSC 
Q315 CCD detector at the beamline I02 of the Diamond synchrotron source. The 
crystal diffracted the X-rays beyond a resolution of 2.2 Å (blue circle) 
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For the MAD data, all data sets were indexed, integrated and scaled similarly to 
the native by the automated program xia2 (Winter, 2010) using the 3dr mode with 
the XDS and XSCALE programs (Kabsch, 2010), provided at the beamline. 
Statistics for data collection of the Se-Met protein crystal of BPSL0606 are shown 
in Table 5.2. 
 
Table 5.2 Data collection statistics of the Se-Met protein crystal of BPSL0606 
Datasets Se-Met 
Inflection Remote Peak 
Spacegroup P 1 21 1 P 1 21 1 P 1 21 1 
Unit cell parameters     
a  60.55 60.60 60.62 
b 82.10 82.24 82.25 
c 78.05 77.98 77.98 
α 90.00 90.00 90.00 
β 100.14 100.22 100.21 
γ 90.00 90.00 90.00 
Temperature (K) 100 100 100 
X-ray Source DIAMOND I02 DIAMOND I02 DIAMOND I02 
Detector ADSC Q315 CCD ADSC Q315 CCD ADSC Q315 CCD 
Resolution (Å)1 56.12-2.39 
(2.45-2.39) 
56.11-2.29 
(2.35-2.29) 
51.76-2.18 
(2.23-2.18) 
Energy (keV) 12.6554 12.700 12.6579 
Unique observations1 29786 (2193) 33910 (2473) 39151 (2829) 
Rmerge 1,2 0.084 (0.712) 0.089 (0.602) 0.081 (0.639) 
Rpim1 0.065 (0.487) 0.069 (0.42) 0.068 (0.454) 
Completeness (%)1 99.2 (99.3) 99.2 (98.7) 99.1 (98.6) 
Anomalous completeness (%)1 95.4 (96.2) 96.0 (95.3) 95.9 (95.3) 
Multiplicity1 3.7 (3.8) 3.7 (3.8) 3.7 (3.8) 
Anomalous multiplicity1 1.8 (1.8) 1.9 (1.8) 1.8 (1.8) 
Mean((I)/sd(I))1 12.5 (1.9) 9.6 (2.2) 10.2 (2.1) 
1Numbers in parentheses indicate values for the highest resolution shell 
2 Rmerge = Σhkl Σi |Ii(hkl) – 〈I(hkl)〉|/ Σhkl Σi Ii(hkl), where 〈I(hkl)〉 is the mean intensity of the reflection 
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The three-wavelength MAD data sets were input into the automated structure 
determination program Phenix (Adams et al, 2010). The substructure solution 
from Phenix had 12 selenium sites in total, with a figure of merit 0.43 and overall 
Z-score 41.6. As the BPSL0606 sequence contains 4 methionines at positions 1, 
18, 147 and 214, this substructure is consistent with 3 full-length copies in the 
asymmetric unit or alternatively, four copies with either the N-terminal 
methionine or the C-terminal extension missing. Furthermore, Phenix had 
automatically built 476 residues in 4 chains as an initial model. Clear electron 
density was visible for the selenium atoms at the position 1, 18 and 147, which 
accounted for all the peaks in the substructure solution (Figure 5.11). Statistics for 
all selenium atoms found are shown in Table 5.3. 
 
 
Table 5.3 Statistics of the selenium sites identified by experimental phasing  
Selenium site Occupancy B-factor 
Se1 1.21 46.20 
Se2 1.07 51.70 
Se3 0.88 39.40 
Se4 1.04 44.60 
Se5 1.1 60.00 
Se6 1.01 60.00 
Se7 0.69 33.10 
Se8 0.77 53.30 
Se9 0.45 54.50 
Se10 0.50 50.90 
Se11 0.59 52.10 
Se12 0.56 51.60 
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a) b)
c)  
Figure 5.11 Selenium atom location: The initial MAD electron density map, 
contoured at 1 σ, centered around the selenium atoms in residue 1 (a), 18 (b) and 
147 (c). Clear density can be seen to these residues. This figure was produced 
using Pymol (Schrodinger, 2010). 
 
The initial model was inspected for each residue one by one, to modify residues if 
appropriate and to join the fragments together. Rebuilding the model to fit the 
electron density map was performed in COOT (Emsley et al, 2010). During the 
model building task, the model was frequently validated using the validation tools 
in COOT in order to analyse the geometry, incorrect chiral volumes, peptide 
omega, rotamers, density fit as well as unidentified blobs and questionable waters 
throughout the model.  
 
A number of cycles of model refinement and rebuilding were run through the 
program REFMAC5 in the CCP4 suite (Murshudov et al, 2011). Each round of 
running REFMAC5, the modified model was refined against the peak wavelength 
data set at 2.18 Å resolution, to avoid bias from any electron density modification 
from cycle to cycle. The R-factor and R-free were monitored during the 
refinement tasks (Figure 5.12). 
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a)  
 
b)  
Figure 5.12 A portion of the electron density map of BPSL0606. The model was 
built and fitted to the electron density map derived from the 2.18 Å resolution 
data, contoured at 1 σ; a) initial solution, b) final model. This figure was produced 
using Pymol (Schrodinger, 2010). 
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5.7. Structure validation 
After a number of refinement cycles were performed, the model of BPSL0606 
was analysed using the validation tools in the CCP4 suite such as PROCHECK 
(Laskowski et al, 1993) and RAMPAGE (Lovell et al, 2003). The refinement 
parameters are summarised in Table 5.4. The final model had an R-factor and R-
free of 0.196 and 0.25, respectively, which are acceptable at this resolution. 
Ramachandran plots indicated that 97% of residues were in the favoured region 
and 0.3% of residues, specifically residues His 140 of chain C and D, were in the 
outlier region (Figure 5.13). These residues were unfavorable due to poor electron 
density fit.  
 
 Table 5.4 Data refinement statistics of BPSL0606 structure model 
  
Resolution range (Å) 51.76  - 2.18 (2.25  - 2.18) 
Space group P 1 21 1 
Unit cell dimensions (Å) a=60.62, b=82.25, c=77.98 
α=90° β=100.21° γ=90° 
Unique reflections 39131 (3853) 
Completeness (%) 98.90 (98.52) 
Mean I/sigma(I) 10.19 (2.17) 
Wilson B-factor 32.49 
Number of molecules in asymmetric unit 4 
R-factor 0.1957 (0.2684) 
R-free 0.2500 (0.3404) 
Number of atoms 5088 
  macromolecules 4794 
  water 270 
Protein residues 605 
RMS(bonds) 0.015 
RMS(angles) 1.77 
Ramachandran favored (%) 97 
Ramachandran outliers (%) 0.34 
Clashscore 10.11 
Average B-factor 38.00 
  macromolecules 37.80 
  solvent 39.20 
NB: Statistics for the highest-resolution shell are shown in parentheses. 
 
! 139!
 
a) 
-180
0
180
-180 0 180
q
s
B140  HIS
D140  HIS
General/Pre-Pro/Proline Favoured General/Pre-Pro/Proline Allowed
Glycine Favoured Glycine Allowed
Number of residues in favoured region (~98.0% expected) :  580  (97.2%)
Number of residues in allowed region (~2.0% expected) :  15  (2.5%)
Number of residues in outlier region :  2  (0.3%)
RAMPAGE by Paul de Bakker and Simon Lovell available at http://www-cryst.bioc.cam.ac.uk/rampage/ 
Please cite: S.C. Lovell, I.W. Davis, W.B. Arendall III, P.I.W. de Bakker, J.M. Word, M.G. Prisant, J.S. Richardson & D.C. Richardson (2002)
Structure validation by C_ geometry: q/s and C` deviation. Proteins: Structure, Function & Genetics. 50: 437-450
! 140!
 
b) 
Figure 5.13 Ramachandran plots for the BPSL0606 structure. a) A Ramachandran 
plot showed the protein backbone torsion angle distribution in general including 
β-region, right- and left- handed helical regions b) 97% of all residues were in 
favoured region whereas 2.5% were in the allowed region. Residues His 140 in 
chain C and D were in the outlier region. This figure was produced using 
RAMPAGE (Lovell et al, 2003). 
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5.8. Structure description 
The final BPSL0606 structure contained 4 copies of the protein, each running 
from the N-terminal methionine to residue 151 of the full-length sequence. No 
density was present for the 65 C-terminal residues.  
 
A subunit of the BPSL0606 crystal structure consists of eight β-strands and three 
α-helices. From the N-terminal region, a short β-strand is connected to the first α-
helix (α1) via a helical loop. Following the long helix, three antiparallel strands 
(β2, β3 and β4) are formed and precede the second long α-helix (α2), which is laid 
underneath the β-sheet. A β-strand (β5) is linked to the helix α2 and followed by a 
short α-helix α3, turning back behind the strand β5. Two β strands (β6 and β 7) are 
connected and followed by the last strand β8, parallel to the strand β5 (Figure 
5.14). 
 
In the β-sheets, there is an opening between the strands β4 and β5, like a V-cleft. 
This has the effect of making a groove in structure at the C-terminal ends of the 
strands β4 and β5, which perhaps could be the active site.    
   
 
Figure 5.14 The cartoon representation of the secondary structure of BPSL0606 
subunit colored from N-terminal (blue) to C-terminal (red). This figure was 
produced using Pymol (Schrodinger, 2010). 
β1 
β2 
β3 
α2 
α1 
α3 
β4 
β5 β6 
β7 
β8 
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No density was visible for the remaining 65 C-terminal residues, which perhaps 
indicates that these residues are disordered. Using the RONN server (Yang et al, 
2005) to predict potential disordered regions of the protein, based on its sequence, 
there is a high probability of a disordered region from residue 152 to the end, 
which corresponds to the missing residues in the crystal structure (Figure 5.15). 
 
 
Figure 5.15 Protein disorder prediction: The C-terminal part of the BPSL0606 
sequence shows a clear propensity to be a disordered region. This figure was 
produced using RONN server (Yang et al, 2005).  
 
Alternatively, these C-terminal residues may have been cleaved prior to 
crystallisation. If this were the case, then the 151-residue fragment would have an 
approximate molecular weight of 17 kDa. Using this value in a cell content 
analysis, four chains would have a solvent content of 56.3% and Matthews 
coefficient Vm of 2.81 Å3 Da-1. In comparison, four copies of the full-length 
protein packed in asymmetric unit would have a Vm of 2.03 Å3 Da-1, 
corresponding to 39.5% solvent content. It is therefore possible that there is space 
in the crystal lattice for the remaining 65 C-terminal residues (Figure 5.16). 
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Figure 5.16 Available space in the crystal lattice beyond residue 151: There is 
room for the missing 65 C-terminal residues.  This figure was produced using 
Coot (Emsley et al, 2010). 
 
To investigate whether the crystals were grown from the full-length expressed 
protein or whether it had been truncated during crystallisation, the remaining 
crystals in the crystallisation tray were picked out and dissolved in water, prior to 
analysis using SDS PAGE. A single band from the crystallised protein on the SDS 
gel lay between 21.5 and 14.4 kDa, indicating that the crystals were not the full-
length protein of 23.5 kDa (Figure 5.17). It is therefore likely that after 
crystallisation was set up with the full-length expressed protein, proteolysis 
occurred during crystallisation process, resulting cleaved protein being 
crystallised. 
 
As an analysis of the crystallised protein by mass spectrometry could not be 
achieved, the same batch of purified protein that had been stored at 4°C for a few 
months was sent for mass spectrometry instead. The spectrum of the protein mass 
showed the majority of degraded products were in the range of 17 kDa (Figure 
5.18), which corresponds to the obviously intense band of lane 4 on the SDS gel 
(Figure 5.17). This could explain why the structural model of BPSL0606 was 
built up to 151 residues instead of the full-length 216 residues.   
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Figure 5.17 SDS PAGE of the BPSL0606 crystals: Lane1 Mark12 ladder, Lane 2 
and 3 crystallised protein, Lane 4 the same purified batch protein as crystallised 
protein kept in the fridge for a few months.    
 
 
Figure 5.18 Mass spectrometry of the remaining purified protein: From the SDS 
gel, the remaining protein was degraded from 32 kDa to 17 kDa during a few 
months storage at 4°C. 
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Attempts were made to crystallise the remaining protein in the same 
crystallisation condition that the crystal had grown before but it was not 
successful. The stored protein was thus analysed further. 
 
 
5.9. Crystallisation and structure determination of the truncated 
BPSL0606 
Another batch of purified protein BPSL0606 that had been stored in a 4°C 
refrigerator for 2 months after purification was analysed by mass spectrometry 
and the spectrum showed the remaining protein was 17.776 kDa, which 
corresponds to a truncated protein containing 159 residues from N-terminal region 
(Figure 5.19). 
 
 
Figure 5.19 Mass spectrometry of the old protein used for the crystallisation 
experiment: The purified BPSL0606 protein was characterised after keeping at 4 
°C for a few months. The spectrum indicated the remaining protein had the 
molecular weight of 17.8 kDa.  
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An 8 mg/ml solution of this 17.8 kDa protein was screened for crystallisation by 
the sitting-drop vapour-diffusion method and the Hydra II Plus One robot with 
commercially available screening kits (QIAGEN). Approximately 200 µm long 
single crystals (Figure 5.20) were obtained from the condition H7 in the JCSG 
screen containing 25% PEG3350, 0.1 M Bis-Tris pH5.5 and 0.2 M ammonium 
sulphate.   
 
A protein crystal was mounted and washed through a cryoprotectant solution 
containing 25% ethylene glycol, 25% PEG3350, 0.1 M Bis-Tris pH5.5 and 0.2 M 
ammonium sulphate, prior to cooling down to 100 K with an Oxford Cryosystems 
Cryostream 700 for X-ray diffraction tests using an in house Rigaku MM007 
copper rotating anode generator and a MAR345 Research image plate. A couple 
of test images of a few minutes exposure were taken and the X-ray diffraction 
patterns were analysed using the autoindexing routine in Mosflm (Leslie & 
Powell, 2007). The truncated BPSL0606 protein crystals belonged to the 
orthorhombic crystal system, in Laue group P222, with cell dimensions of 
a=60.94Å, b=75.0 Å, c=78.24Å and α=β= γ=90°. 
 
 
 
Figure 5.20 A photograph of a cryoprotected crystal of the truncated BPSL0606 
mounted by a 0.25 µm loop: The crystal was shot by an X-ray beam of 100 µm x 
100 µm (red box) at the Diamond Synchrotron source for data collection. 
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5.9.1. Data collection and processing 
A data set from the truncated protein crystal was collected at the beamline I04 of 
the Diamond Synchrotron source. A total of 90 images with a 1° rotation per 
image were collected to a resolution of 2 Å. Statistics of the data collection are 
shown in Table 5.5. 
 
Table 5.5 Data collection statistics of the truncated BPSL0606 crystal 
Data set  
Spacegroup P 21 21 21 
Unit cell parameters  
a  60.94 
b 75.00 
c 78.24 
α 90.00 
β 90.00 
γ 90.00 
Temperature (K) 100 
X-ray Source DIAMOND I04 
Detector ADSC Q315 CCD 
Resolution (Å)1 48.08-2.18 (2.24-2.18) 
Energy (keV) 12.649 
Unique observations1 19172 (1397) 
Rmerge 1,2 0.089 (0.547) 
Rpim1 0.066 (0.41) 
Completeness (%)1 99.2 (99.9) 
Multiplicity1 3.5 (3.6) 
Mean((I)/sd(I))1 10.3 (2.0) 
1 Numbers in parentheses indicate values for the highest resolution shell 
2 Rmerge = Σhkl Σi |Ii(hkl) – 〈I(hkl)〉|/ Σhkl Σi Ii(hkl), where 〈I(hkl)〉 is the mean intensity of the 
reflection 
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The space group of the truncated BPSL0606 crystal was determined by the 
POINTLESS program (Evans, 2006). From the analysis of systematic absences, it 
showed high probability of the presence of the 21 screw along all three axes. 
Therefore, the space group P 212121 was chosen. 
 
Analysis of unit cell content was performed using Matthews_coef program in the 
CCP4 suite. The unit cell volume was calculated to 3.6 x 105 Å3, resulting in the 
Matthew’s coefficient value of 2.51 Å3 Da-1 for 2 molecules in asymmetric unit 
with 51.1 % solvent content for the given the protein molecular weight of 17776 
Da. 
 
5.9.2. Structure determination 
The structure of the truncated BPSL0606 was determined by molecular 
replacement using the previously determined BPSL0606 structure. The structure 
determination was carried out using AutoMR in the automated Phenix program 
(Adams et al, 2010). The best solution had a log likelihood gain (LLG) value of 
2,232 and the initial model was automatically built by the AutoBuild program and 
contained 2 copies of the BPSL0606 protein molecules, 304 residues in total with 
R-work 0.23 and R-free 0.28. 
 
The model was rebuilt to fit the electron density in COOT (Emsley et al, 2010). 
Several cycles of model refinement against the 2.18 Å data were carried out using 
REFMAC5 (Murshudov et al, 2011). The R-work and R-free of the final model 
were 0.19 and 0.26, respectively. A summary of refinement statistics is shown in 
Table 5.6. A portion of the electron density map with the model is shown in 
Figure 5.21.  
 
In addition to the two protein molecules, a total of 179 water molecules and 9 
ethylene glycol molecules could be placed in the electron density map (Figure 
5.22). 
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Figure 5.21 The final model of the truncated BPSL0606: The model was refined 
against the 2.18 Å data. The electron density map, contoured at 1.5 σ, is shown in 
brown. This figure was produced using Pymol (Schrodinger, 2010). 
 
 
 
Figure 5.22 Example of other molecules found in the crystal structure: Ethylene 
glycol used in crystallisation was present as well as water molecules as solvent. 
The electron density map, contoured at 1.5 σ, is shown in brown. This figure was 
produced using Pymol (Schrodinger, 2010). 
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Table 5.6 Data refinement statistics of the truncated BPSL0606 
  
Resolution range (Å) 48.08  - 2.18 (2.258  - 2.18) 
Space group P 21 21 21 
Unit cell dimensions (Å) a=60.94, b=75, c=78.24 
α=β=γ=90° 
Unique reflections 19127 (1899) 
Completeness (%) 99.11 (99.79) 
Mean I/sigma(I) 10.37 (2.17) 
Wilson B-factor 27.91 
R-factor 0.1894 (0.2538) 
R-free 0.2593 (0.3463) 
Number of atoms 2628 
  macromolecules 2406 
  water 179 
Protein residues 304 
RMS(bonds) 0.014 
RMS(angles) 1.71 
Ramachandran favored (%) 96 
Ramachandran outliers (%) 0.33 
Clashscore 6.83 
Average B-factor 33.00 
  macromolecules 32.50 
  solvent 36.30 
Statistics for the highest-resolution shell are shown in parentheses. 
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Structure validation was performed using PROCHECK (Laskowski et al, 1993) 
and RAMPAGE (Lovell et al, 2003) in the CCP4 suite. Ramachandran plots 
showed that 96% of the total residues were in a favored region and only one 
residue (Glu 56) in chain A, being an outlier (Figure 5.23). This residue was 
unfavorable since it has poor electron density for its side chain.  
 
a)  
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Structure validation by C_ geometry: q/s and C` deviation. Proteins: Structure, Function & Genetics. 50: 437-450
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b)  
Figure 5.23 Ramachandran plots for the truncated BPSL0606 structure: a) A 
Ramachandran plot showed the protein backbone torsion angle distribution in 
general including β-region, right- and left- handed helical regions b) 96% of all 
residues were in favoured region whereas 3.3% were in the allowed region. 
Residue Glu 56 in chain A was in the outlier region. This figure was produced 
using RAMPAGE (Lovell et al, 2003). 
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5.9.3. Structure description 
The topology of the truncated BPSL0606 structure was exactly the same as the 
previously determined structure of BPSL0606. The conformation of the truncated 
BPSL0606 structure was similar to the BPSL0606 subunit that had been 
determined before. In the crystal structure of the truncated BPSL0606, there were 
two molecules in asymmetric unit and each molecule contained 152 residues.  
 
The five residues 153-159, that from the mass spectrometry results were 
presumably present in protein being crystallised were again not visible in the map, 
showing that these residues are either disordered or a further truncation has 
occurred during crystallisation.  
 
Unlike the previously determined BPSL0606 structure, the crystal structure of the 
truncated BPSL0606 was different in space group and number of molecules in 
asymmetric unit. The truncated BPSL0606 crystal belonged to the space group 
P212121 and consisted of two copies of molecule in the asymmetric unit with 
approximate 51% solvent content whereas the BPSL0606 crystal was in P21, 
filled with four molecules in asymmetric unit with 40% solvent content.  
 
 
Analysis of the crystal structures of BPSL0606 and structure comparison will be 
detailed in the next chapters. 
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Chapter 6: Structure of BPSL0606 
 
This chapter details the crystal structures of BPSL0606. Analysis of the individual 
protein subunits and the protein quaternary structure is included. 
 
 
6.1. The crystal structure of BPSL0606 contained 4 molecules in the 
asymmetric unit (P21 crystal form) 
The full-length BPSL0606 protein was put into crystallisation trials and crystals 
containing truncated protein were obtained. The structure built from the electron 
density that was derived from the X-ray diffraction pattern consisted of 151 
residues of each molecule of 4 copies found in the asymmetric unit. The crystal 
structure of BPSL0606 is shown in Figure 6.1. 
 
 
Figure 6.1 Cartoon representation of the crystal structure of BPSL0606 in the 
asymmetric unit, consisting of 4 protein chains which are denoted by A (green), B 
(cyan), C (magenta) and D (yellow). This figure was produced using Pymol 
(Schrodinger, 2010). 
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 Analysis of the 4 subunits was performed by LSQKAB in the CCP4 suite 
(Kabsch, 1976). An average of RMSD of Cα between each subunit was calculated 
in the range between 0.33 Å and 0.41 Å with maximum XYZ displacement of 
1.25-2.26 Å, summarised in Table 6.1. 
 
 
Table 6.1 Analysis of XYZ displacement between 4 subunits in the BPSL0606 
structure by LSQKAB 
Chain XYZ displacement (Å) 
 RMSD Maximum 
A-B 0.382 2.256 
A-C 0.34 1.739 
A-D 0.34 1.246 
B-C 0.41 1.863 
B-D 0.33 1.529 
C-D 0.394 2.023 
 
 
The main chain Cαs of the 4 subunits in the BPSL0606 structure were 
superimposed (Figure 6.2). For the side chain of these subunits, there was a 
slightly different orientation of some residues. These included the residues His 
140 in chain C and D, which had poor electron density.   
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a)  
b)  
 
Figure 6.2 An overlap of the 4 chains of BPSL0606 seen in the crystal structure: 
Chains A, B, C and D are colored in green, cyan, magenta and yellow, 
respectively and shown as sticks (a) and as ribbons (b). This figure was produced 
using Pymol (Schrodinger, 2010). 
 
6.1.1. Molecular surfaces 
To analyse the protein surface, interface and assemblies involving the stability of 
macromolecules in the crystal form, coordinates of the structure model were input 
into the PISA server via http://pdbe.org/pisa/ (Krissinel, 2009; Krissinel & 
Henrick, 2007). The results revealed the structural information of the individual 
protein chains and also of the molecular assemblies. 
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The solvent accessible areas of each of the four subunits ranged from 8740 Å2 to 
8950 Å2 with an average of 8840 Å2, with approximately 140/151 residues 
contributing solvent exposed atoms (Table 6.2). As 100 Å2 is the approximate 
surface area for a single methionine side chain, for example, the surface areas for 
each molecule are very similar.  
 
 
Table 6.2 Analysis of surface areas of each subunit in the BPSL0606 structure 
  
 
 
6.1.2. Dimer interfaces and assemblies 
In the asymmetric unit of the BPSL0606 crystal, two dimer interfaces were found, 
in which chain A formed an interface with chain B, and chain C formed an 
interface with chain D.  
 
Table 6.3 Analysis of dimer interface in the BPSL0606 structure 
 
 
Within the asymmetric unit, the four chains come together to form two dimers A-
B and C-D (Figure 6.1). A superposition of the C-D dimer onto the A-B dimer 
shows a mean Cα RMSD of 0.32 Å2, indicating that these two dimers are very 
similar (Figure 6.3). 
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Figure 6.3 Superposition of the A-B and C-D dimers: The dimer A-B is closely 
related to the dimer C-D. This figure was produced using Pymol (Schrodinger, 
2010). 
 
The dimer interface is constructed from one face of the α-helix α1, and the loop to 
the strand β2 packing against the equivalent residues for the 2-fold related subunit 
(Figure 6.3). As this proposed dimer interface is not particularly extensive, the 
buried surface area on dimer formation was investigated. 
 
The interface involves 25 residues in chain A, interacting with the same residues 
in chain B (Table 6.3), with an average interface area of 960 Å2, which is 
approximately 11% of the subunit surface area. This value is within the range of 
6-29% of buried surface area seen in a survey of dimeric proteins (Jones & 
Thornton, 1995).  The dimer formation in the crystal packing agrees with the gel 
filtration result, which predicted that BPSL0606 is likely to be a dimeric protein, 
not a monomer. 
  
13 potential hydrogen bonds across the interface were identified, as well as a 
number of hydrophobic interactions (Table 6.3). The residues involved in this 
interface in chain A and chain B are shown in Table 6.4 and the interactions made 
by these residues are described in Table 6.5.    
 
A similar analysis was undertaken for the C-D dimer, which is very similar to the 
A-B dimer and shown in Table 6.6 and 6.7. 
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Table 6.4 Analysis of the A-B dimer interfacing residues of the BPSL0606 
structure: Interfacing residues in Chain A (right) and Chain B (left) are 
highlighted in yellow. 
 
 
 
Table 6.5 Interaction of H-bond between Chain A and Chain B of the BPSL0606 
structure: 13 H-bonds were found in the A-B interface. 
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Figure 6.4 Residues forming the interface of the A-B dimer: The dimer interface 
is formed by 25 residues on the α-helix α1 and the loop connected the strand β2 in 
one chain against the equivalent residues in the other. This figure was produced 
using Pymol (Schrodinger, 2010). 
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Table 6.6 Analysis of the C-D dimer interfacing residues of the BPSL0606 
structure: Interfacing residues in Chain C (right) and Chain D (left) are 
highlighted in yellow. 
 
 
 
Table 6.7 Interaction of H-bond between Chain C and Chain D of the BPSL0606 
structure: 15 H-bonds were found in the C-D interface. 
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6.2. The crystal structure of the truncated BPSL0606 contained 2 
molecules in the asymmetric unit (P212121 crystal form) 
 
In the second, P212121 crystal form of BPSL0606, two subunits are present in the 
asymmetric unit, which are also arranged in the same orientation as the dimer 
seen in crystal form one (Figure 6.5).  
 
 
Figure 6.5 Cartoon representation of the crystal structure of the truncated 
BPSL0606 in the asymmetric unit consisting of 2 protein chains, which are 
designated by A (green) and B (cyan). This figure was produced using Pymol 
(Schrodinger, 2010). 
 
A superposition of each subunit shows the average RMSD of Cα was 0.55 Å with 
a maximum XYZ displacement of 2.56 Å, calculated using LSQKAB in the CCP4 
suite (Kabsch, 1976). The main chains Cα of these two subunits in the truncated 
BPSL0606 structure were similarly oriented (Figure 6.6). A slight difference in 
side chain orientation was observed.  Since residue Glu 56 in Chain A has poor 
electron density, its side chain was displaced from the equivalent residue in Chain 
B, resulting in it being in an outlier region of the Ramachandran plot.  
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Figure 6.6 An overlap of 2 subunits in the truncated BPSL0606 structure: Chain A 
is colored in green and chain B is colored in cyan. This figure was produced using 
Pymol (Schrodinger, 2010). 
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The crystal packing between the dimers in the P212121 and P21 forms is similar 
within one layer but quite different in the other layer as can be seen in Figure 6.7. 
 
 
a)  
b)  
Figure 6.7 Crystal packing of BPSL0606 crystals in P21 and P212121: Symmetry 
related molecules of the dimer (a) in the P21 crystal form containing 4 molecules 
in the asymmetric unit and (b) in the P212121 crystal form containing 2 molecules 
in the asymmetric unit. This figure was produced using Pymol (Schrodinger, 
2010). 
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The molecular 2-fold interface in the P212121 crystal form is built for the same 
residues on the α-helix α1 and the loop connected the strand β2 as in the P21 
crystal form with similar interactions being made (Table 6.8, 6.9 and 6.10). 
 
Table 6.8 Analysis of surface areas of each subunit in the truncated BPSL0606 
structure 
 
 
Table 6.9 Analysis of A-B dimer interfacing residues of the truncated BPSL0606 
structure: Interfacing residues in Chain A (right) and Chain B (left) are 
highlighted in yellow. 
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Table 6.10 Interaction of H-bond between Chain A and Chain B of the truncated 
BPSL0606 structure: 11 H-bonds made by interacting residues in Chain A (right) 
and Chain B (left) found. 
 
 
 
6.3. Interface similarity 
To investigate whether the observed BPSL0606 dimer is biologically relevant, the 
dimer structure was searched against known structures to find any similar 
oligomeric assemblies, using the PISA server (Krissinel, 2009; Krissinel & 
Henrick, 2007). The results are shown in Table 6.11 and 6.12.  
 
Table 6.11 Interface similarity of the A-B dimer (a) and the C-D dimer (b) in the 
crystal form P21. 
 
a) A-B interface similarity 
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b) C-D interface similarity 
 
 
 
Table 6.12 Interface similarity of the dimer in the crystal form P212121 
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The top hit from this analysis was the structure 1XEB, an acyl coA-N-
acetyltransferase from P. aeruginosa (Figure 6.8) 
 
 
Figure 6.8 A similar dimer interface to BPSL0606: Superposition of the dimers in 
BPSL0606 (red) and an acyl coA-N-acetyltransferase from P. aeruginosa (PDB 
ID: 1XEB) (blue) shows their dimer interface similarity. This figure was produced 
using Pymol (Schrodinger, 2010). 
 
The second hit was with the structure 3EFA, a putative N-acetyltransferase from 
Lactobacillus plantarum. This protein also forms a dimer using the same 
secondary structure elements as BPSL0606, however the arrangement of these 
elements at the two fold is quite different, with the helix α1 packing in a crossed 
fashion with its symmetry related mate for the other subunit (Figure 6.9). This 
perhaps indicates that this surface can form more than one type of interaction. The 
proteins further down the list; an uncharacterised GCN5-related N-
acetyltransferase from B. subtilis (PDB ID: 1Q2Y), an N-acyl-L-homoserine 
lactone synthase TofI from B. glumae (PDB ID: 3P2H) and a glyphosate N-
acetyltransferase from B. licheniformis (PDB ID: 2JDD), all share the same 
subunit structure as BPSL0606 but appear to be monomers in their respective 
crystal structures. The ribosomal S18 N-α-protein acetyltransferase from S. 
typhimurium (PDB ID: 2CNM) forms a trimer in the crystal (Figure 6.10), 
indicating that different oligomeric assemblies are possible with this protein fold. 
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The top hits in this analysis are all members of the GCN5-related N-
acetyltransferase (GNAT) superfamily, other members in this family occur as 
dimers, but using totally different interface to that seen in BPSL0606, e.g. 
aminoglycoside 6’N-acetyltransferases from S. enteritidis (PDB ID: 1S3Z) and 
from Acinetobacter haemolyticus (PDB ID: 4EVY) (Figure 6.11). As BPSL0606 
shares the same subunit fold as this family, it may also be a GNAT superfamily 
member. This is discussed in the following chapter.   
 
Figure 6.9 A similar dimer interface to BPSL0606 but different orientation: A 
dimer of a putative N-acetyltransferase from L. plantarum (PDB ID: 3EFA) is 
formed by the helix α1, crossed with its symmetry mate. This figure was produced 
using Pymol (Schrodinger, 2010). 
 
Figure 6.10 A different oligomeric assemblies with similar interface to 
BPSL0606: A ribosomal S18 N-α-protein acetyltransferase from S. typhimurium 
(PDB ID: 2CNM) shares a similar subunit structure to BPSL0606, but forms a 
trimer in the crystal. This figure was produced using Pymol (Schrodinger, 2010). 
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a)  
 
 
b)  
Figure 6.11 Different dimer interfaces to BPSL0606: Most of the GNAT members 
form dimers, some have different interfaces to BPSL0606; aminoglycoside 6’N-
acetyltransferases from S. enteritidis (PDB ID: 1S3Z) (a) and from A. 
haemolyticus (PDB ID: 4EVY) (b). This figure was produced using Pymol 
(Schrodinger, 2010). 
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Chapter 7: Structural and functional 
analysis of BPSL0606 
 
This chapter describes the comparison between the BPSL0606 structure and other 
similar known structures. A structure-based function prediction of BPSL0606 is 
included. 
 
7.1. Structure similarity 
As the structure of proteins is more conserved than the sequence, identifying a 
specific fold in a novel structure could assist a structure-based function prediction. 
However, the similarity of proteins at the structural level does not directly imply 
the protein function (Lee et al, 2007). This knowledge-based approach, by 
comparing the protein fold and structural motifs to those that have been 
characterised in the structural databases, is the most important method for 
predicting function from structure. Any structural similarity seen may infer 
possible biochemical and functional information for an uncharacterised protein 
(Thornton et al, 2000).     
 
The coordinates of the BPSL0606 structure were compared against those 
available published in the protein data bank (PDB) using the Dali server (Holm L, 
2010). The results from this analysis showed that BPSL0606 was structurally 
similar to several proteins related to N-acetyltransferases, including members of 
GCN5-related N-acetyltransferase superfamily (GNAT). The top ten similar 
structures to BPSL0606 are shown in Table 7.1. The structural similarity between 
BPSL0606 and the GNAT family may provide clues to the characteristics of 
BPSL0606. 
 
At the protein sequence level, analysis of BPSL0606 using BlastP showed the 
sequence similarity to an ElaA family protein (a predicted transferase with an 
acyl-coA N-acyltransferase domain) of Burkholderia species and an N-
acetyltransferase from other bacteria. For the protein structure level, the most 
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similar structure of characterised proteins to the BPSL0606 structure was the acyl 
homoserine lactone (AHL) synthase (LasI) from P. aeruginosa, which plays a role 
in virulence gene regulation in this opportunistic human pathogen (Gould et al, 
2004). Like BPSL0606, the LasI structure contains the acyl coA N-acyltransferase 
fold as do members of the GNAT family.  
 
Table 7.1 Top-ten hits for matching the BPSL0606 structure by Dali server 
 PDB 
ID 
Z-
score 
RMSD 
(Cα) 
% 
Sequence 
identity 
No. of 
aligned/ 
total 
residues 
Protein Organism 
1 1XEB 24.6 1.0 35 144/149 Hypothetical protein P. aeruginosa 
2 3EFA 19.1 2.0 22 141/146 Putative acetyl 
transferase 
L. plantarum 
3 1Q2Y 18.2 2.0 18 136/140 Uncharacterised 
GCN5-related N 
acetyltransferase 
(GNAT) 
B. subtilis 
4 1RO5 15.6 2.5 10 145/197 Autoinducer 
synthetic protein 
(LasI)  
P. aeruginosa 
5 1CJW 15.6 2.6 9 140/166 Serotonin N-
acetyltransferase 
Ovis aries 
(sheep) 
6 2JDD 15.4 2.4 14 133/145 Glyphosate N-
acetyltransferase 
B. licheniformis 
7 1J4J 15.3 2.7 11 144/170 Tabtoxin resistance 
protein 
P. syringae pv. 
tabaci 
8 2CNM 15.2 2.3 13 134/151 Ribosomal s18 N-
alpha-protein 
acetyltransferase 
(RimI) 
S. typhimurium 
9 1M4I 14.9 2.7 14 138/181 Aminoglycoside 2’ 
acetyltransferase 
Mycobacterium 
tuberculosis 
10 2G0B 14.8 2.5 11 140/184 N-Acyl Amino Acid 
Synthase (FeeM) 
uncultured 
bacterium 
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a)  
b)  
 
Figure 7.1 A superposition of the BPSL0606 structure (rainbow) and similar 
structures (grey): a) The most similar structure to BPSL0606 analysed by Dali 
was a hypothetical protein from P. aeruginosa (PDB ID 1XEB). b) The most 
similar structure with known function to BPSL0606 was an AHL synthase, LasI 
from P. aeruginosa (PDB ID 1RO5). This figure was produced using Pymol 
(Schrodinger, 2010). 
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7.2. Structural fold and motifs of GNAT family members 
Since the BPSL0606 structure was structurally similar to a number of GNAT-fold 
containing proteins, the following section describes the structural fold and motifs 
of the GNAT family. 
    
The GCN5 (general control non-derepressible 5) -related N-acetyltransferases 
(GNAT) belong to a superfamily of enzymes that catalyse the acetylation of 
various substrates by transferring the acetyl group of acetyl coenzyme A to a 
primary amine of the substrate (Dyda et al, 2000). The chemical reaction 
catalysed by GNATs is shown in Figure 7.2. Proteins from this family function in 
a wide variety of different biochemical processes, including the acetylation of 
aminoglycoside antibiotics (Vakulenko & Mobashery, 2003), eukaryotic 
chromatin modification by histone acetylation (Khan & Khan, 2010), the light-
mediated regulation of melatonin production and mammalian circadian rhythm 
(Scheibner et al, 2002), N-α-acetylation of ribosomal proteins (Hu et al, 2010) 
and mycothiol biosynthesis (Vetting et al, 2006). Members of this superfamily 
that have been structurally characterised include aminoglycoside N-
acetyltransferase (Burk et al, 2003; Vetting et al, 2002; Vetting et al, 2004; 
Vetting et al, 2008b; Wolf et al, 1998; Wybenga-Groot et al, 1999), serotonin N-
acetyltransferase (Hickman et al, 1999; Scheibner et al, 2002; Wolf et al, 2002), 
histone N-acetyltransferase (Clements et al, 1999; Dutnall et al, 1998; Poux & 
Marmorstein, 2003; Rojas et al, 1999; Trievel et al, 1999), glucosamine-6-
phosphate N-acetyltransferase (Peneff et al, 2001), mycothiol synthase (Vetting et 
al, 2003; Vetting et al, 2006), protein N-myristoyl-transferase (Bhatnagar et al, 
1999; Brannigan et al, 2010), tabtoxin resistant protein (He et al, 2003), Rim N-α-
acetyltransferase (Vetting et al, 2008a; Vetting et al, 2005a) and glyphosate N-
acetyltransferase (Siehl et al, 2007). 
 
The structures of these proteins have revealed the core GNAT fold (Figure 7.3), 
which consists of two antiparallel N-terminal β-strands (β0, β1) followed by two 
helices (α1, α2) and three further strands (β2-β4) that in turn, preceded a central 
helix (α3). The fold is completed by a further strand (β5), helix (α4) and a final 
strand (β6) (Vetting et al, 2005b). This common topology of the GNAT structural 
fold contains four conserved sequence motifs, called C, D, A and B, in the order 
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where the motifs follow each other in the primary sequences (Neuwald & 
Landsman, 1997).  
 
Figure 7.2 A schematic of the general reaction of GNATs catalysis: a) Acetyl 
coenzyme A is the acetyl group donor. b) The nucleophilic attack of a primary 
amine occurs on the acyl carbon of the acetyl group, resulting in a predicted 
tetrahedral intermediate. This figure was modified from Dyda et al (2000).   
 
7.2.1. Motif C 
The first motif from the N-terminus that has been identified is motif C, which has 
the weakest conservation at the primary sequence level within this superfamily 
compared to other motifs. The residues of this motif lie mostly on helix α1. 
However, as there is some variation in the secondary structure between members 
of the family in this area the motif is not strictly conserved. For example, in a 
histone N-acetyltransferase from yeast (yHat1) (Dutnall et al, 1998), the helix α1 
is present but not the helix α2, which is present in other GNAT members. The 
absence of the second helix in the yHat1 structure is possibly accommodated by a 
shift in the position of the helix α1, compared to the analogue helix in other 
GNAT structures. Interestingly, in the case of a sheep serotonin N-acetyl 
transferase, the observations of the apo-enzyme structure and the complex form 
with a bisubstrate coenzyme A-S-acetyltryptamine analogue have shown 
conformational changes upon the acetyl coenzyme A binding in which the first 
and second helices were extended, facilitating the serotonin binding (Hickman et 
al, 1999).  
a) 
b) 
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7.2.2. Motifs D and A 
Motif D lies on strands β2 and β3 and is adjacent to motif C in the three 
dimensional structure, and these two elements come together to form the first half 
of the molecule. After a short turn between the strands β3 and β4, the polypeptide 
sequence leads into motif A, which is the longest and universally conserved motif 
of this superfamily. This motif has a conserved sequence of Q/RXXGXGXXL. 
Motif A runs from strand β4 to the carboxyl end of the helix α3, which is the 
longest helix in the GNAT family. This motif is involved in acetyl coenzyme A 
binding and also plays an important role in catalysis. From the crystal structures 
of GNAT members in complex with acetyl coenzyme A, the acetyl coenzyme A is 
found in a V shaped cleft between the strands β4 and β5 (Sternglanz & 
Schindelin, 1999). Adjacent to the first turn of the helix α3, the pyrophosphate 
moiety of acetyl coenzyme A interacts with main-chain amides of the protein. 
This binding pocket is made by hydrogen bonds between amides of the N-
terminal residues of the helix α3 and the phosphate oxygen atoms of the acetyl 
coenzyme A molecule. The pantothenate and β-mercaptoethanolamine parts of 
acetyl coenzyme A are placed along the strand β4 and stabilised by a number of 
hydrogen bonds (Figure 7.4). 
 
7.2.3. Motif B     
The final motif in the GNAT family is motif B, lying along strand β5 and ends at 
the C-terminal end of helix α4. This motif is also partly involved in coenzyme 
binding, with hydrophobic residues on helix α4 forming a hydrophobic pocket that 
stabilises the bottom part of the acetyl coenzyme A binding site. There are some 
differences in the structures in this part of the fold between different family 
members, with, for example, a long extension between strand β5 and  helix α4 in 
the structure of an aminoglycoside 6’ N-acetyltransferase from Enterococcus 
faecium (Wybenga-Groot et al, 1999).  
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Figure 7.3 The topology of the GNAT fold represented by the secondary structure 
elements from the N-terminus: motif C-blue, motif D-red, motif A-green and 
motif B-purple.     
 
 
Figure 7.4 The acetyl coenzyme A binding site in the β4-α3-β5 motif: The most 
conserved motif A (QXXGXGXXL) is shown in yellow sticks. Acetyl coenzyme 
A (grey stick) is bound in a histone N-acetyltransferase from yeast (PDB ID: 
1BOB), with H-bonds (violet dashes). This figure was produced using Pymol 
(Schrodinger, 2010). 
! !β0 
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7.3. Structure comparison 
In order to compare the structure of BPSL0606 to members of the GNAT 
superfamily, Cα superposition of the relevant structures were performed. The 
superposition of BPSL0606 and eight GNAT structures, including 
aminoglycoside N-acetyltransferases (PDB ID: 1B87 and 1N71), histone N-
acetyltransferases (PDB ID: 1BOB, 1QSR, 1YGH and 1CM0) and serotonin N-
acetyltransferases (PDB ID:1cjw) revealed that the backbone of BPSL0606 is 
similar to different members of this superfamily from different species (Figure 
7.5). The sequence similarity seen in this family is shown in a structure based 
sequence alignment of BPSL0606 and selected GNAT members from different 
species (Figure 7.6).  
 
 
 
 
Figure 7.5 Superposition of the BPSL0606 structure and GNAT structures: The 
backbone of BPSL0606 colored in black is structurally similar to members of the 
GNAT superfamily (other colours), which have a unique fold responsible for 
acetyl coenzyme A binding (shown in stick). Overlapped structures included PDB 
ID: 1B87, 1N71, 1BOB, 1QSR, 1YGH, 1CM0 and 1CJW. This figure was 
produced using Pymol (Schrodinger, 2010). 
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Figure 7.6 Structure-based alignment of BPSL0606 and GNAT proteins from different 
species. PDB ID: 1YGH (GCN5, yeast), 1QSR (GCN5, protozoa), 1CM0 (PCAF, 
human), 1BOB (HAT1, yeast), 1BO4 (AAC3’, Gram negative bacteria) and 1B87 (AAC 
6’, Gram positive bacteria). Secondary structure elements representing the structure of 
BPSL0606 are shown from the N-terminus (blue) to the C-terminus (red). This figure was 
created using Boxshade (Hofmann & Baron). 
 
To identify conserved residues within the GNAT superfamily, more GNAT 
structures that have been deposited in the protein data bank were taken into 
account. A structure based alignment of the known structures of GNATs and 
BPSL0606 (Figure 7.7) shows conserved residues in the known structures of 
proteins within the superfamily from different species. Using this alignment, 
conserved residues in the GNAT family were identified and plotted in the 
equivalent position in the structure of BPSL0606 (Figure 7.8). Within these 
conserved residues, most of those that are highly conserved are also present in 
BPSL0606. Differences between the GNATs conserved residues and the 
equivalent residues in BPSL0606 were inspected. Residue Ile 93 in BPSL0606 is 
different from the equivalent residue in the GNAT proteins, which is either Gly or 
Ala. As this residue lies under the pyrophosphate of acetyl coenzyme A in the 
binding pocket of the GNAT family, the increased size of isoleucine in the 
BPSL0606 structure may affect the ligand binding. Within the GNAT family, two 
hydrophobic residues form  part of the hydrophobic pocket  which lies underneath 
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Figure 7.7 Structure based sequence alignment among the GNAT members and 
BPSL0606. Conserved residues among the known structures of GNATs were identified 
in box shades. Identical residues were highlighted in yellow and similar residues were 
highlighted in cyan. This figure was created using Boxshade (Hofmann & Baron). 
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PDB:1bob:A       45 KDLIIHLAFDSVTFKPYVNVKYSAKLGDDNIVDVEKKLLSFLPKDDVIVRDEAKWVDCFA
PDB:1b87:A        1 ------------------------------------------------------------
PDB:1qsr:A        1 ------------------------------------------------------------
PDB:2fiw:A        1 ------------------------------------------------------------
PDB:3exn:A        1 ------------------------------------------------------------
PDB:3r1k:A        1 ------------------------------------------------------------
PDB:2vqy:A        1 ------------------------------------------------------------
PDB:1qsm:A        1 ------------------------------------------------------------
PDB:1j4j:A        1 ------------------------------------------------------------
PDB:1m4i:A        1 ------------------------------------------------------------
BPSL0606.pdb:A    1 ------------------------------------------------------------
consensus        61 ------------------------------------------------------------
PDB:1cm0:A        1 ----------------------KVIE-FHV-----V-GNSLNQKPNKKILMWLVGLQNVF
PDB:1cjw:A        1 -------------------HTLPANE-FRC-----L-TPE-----------DAAGVFEIE
PDB:1i1d:A       1 ------------------MSLPDGFY-IRR-----M-EEG-----------DLEQVTETL
PDB:2c27:A      121 VGVRELIQMRRPLRDIPEPTIPDGVV-IRT-----Y-AGT----------SDDAELLRVN
PDB:2i79:A        1 --------------------MEYELL-IRE-----A-EPK-----------DAAELVAFL
PDB:2jdd:A        1 ------------------------IE-VKP-----I-N--------------AEDTYELR
PDB:1s3z:A        1 ----------------------SHMD-IRQ-----M-NKT-----------HLEHWRGLR
PDB:1n71:A        1 ------------------------MI-ISE-----FDRNNP---------VLKDQLSDLL
PDB:1s7l:A        1 ----------------EIIPVSTTLE-LRA-----A-DES-----------HVPALHQLV
PDB:2cnm:A        1 -----------------------MNT-ISI-----L-STT-----------DLPAAWQIE
PDB:2prb:A        1 ------------------------SV-TLR-----L-MTE----------HDLAMLYEWL
PDB:1bob:A      105 EERKTHNLSDVFEKVSEYSLNGEEFV-VYK-----S-SLVD--------DFARRMHRRVQ
PDB:1b87:A        1 ------------------------MI-ISE-----FDRNNP---------VLKDQLSDLL
PDB:1qsr:A      1 ------------------------LD-FDI-----L-TNDGTH----RNMKLLIDLKNIF
PDB:2fiw:A        1 -----------------GHMVMSTPA-LRP-----Y-LPE-----------DAAVTAAIF
PDB:3exn:A        1 -------------------MHVLTLD-LAP-----V-TPK-----------DAPLLHRVF
PDB:3r1k:A        1 ------------------------VT-LCS-----P-TED-----------DWPGMFLLA
PDB:2vqy:A        1 -----------------------DSV-TLR-----L-MTE----------HDLAMLYEWL
PDB:1qsm:A        1 ----------------------DNIT-VRF-----V-TEN-----------DKEGWQRLW
PDB:1j4j:A        1 ------------------------AQ-LRR-----V-TAESF-------AHYRHGLAQLL
PDB:1m4i:A        1 -------------------MHTQVHTARLV-----H-TADLD-------SETRQDIRQMV
BPSL0606.pdb:A    1 ------------------------MD-WTCCEFRHL-SSN-----------ELYMILRTR
consensus       121 ------------------------i--i-------v---------------d---l--v-
32 SH Q L P R M PK EYI TR
24 RE A FI SVS GN C PL NL D
25 K V L T T V GT ITP ES
164 NA-- --FA-----------G-----HPE--- GG---------W----TA-------VQ
23 NR V SL ETDFTSLDG DG I L LT
16 HR I L R PNQPIEAC M F ES
2 KQ L W P G H P DD A
22 RL T W P E E YGD SSA E
27 LK N KAW LQQ SLD WPQ Y VTSQEETRKH
20 QR A H A F P WS E KT
20 NRSHI V EWW GA R PTLADVQ EQ
150 IF S L ----LFI-E A------N----------Y---- --------D-
22 RL T W P E E YGD SSA E
26 SR Q L P K M PK EYI VK
26 VA S IEQLTADDYSEEQQE AW AS AAD DEA K
24 HL SPSY FAL IGME L PTL EDV VR
19 AA S F T D F I GP ES
2 NRSHI V EW WGG AR PTLADVQ EQ
2 KS Y QD FY EV S FP DD L
23 FE T VH GGAS VGF MADLDMQQAYAW CD G
29 TG A F AG D F T E TD
24 NA V LVV EDA HT HL D I D
18
46 LV FDP KH K TLALIK DG RVIGGICFRM
40 EV QH F LTLC PELSLGWFV EG RLVAFIIGSLWD
38 FC KLIKYW NEATVWNDKKIMQYNPMVIVD KRT ETVAATGNIII
18 ---LA--E---R-----RGEAWF-----DPDG ILAF --DSPRERPGRLLGFHWTKV--
43 SEEME IF LN KQASSD NQITLLAFL NG KIAGIVNITADQ
33 D L LR GAF HLGGYYG G KLISIASFHQ
32 HL ADGEEI LQAD HLASFIAMA DG VAIGFADASI
36 EV EE M MNPE RIAVAAVD QD ELVGFIGAIPQY
53 VQ G N ILLHQR GYAKMYLIFC QN EMAGVLSFNAI
32 FF G N QGER YLNLKLTA DD RMAAFAITQV
4 YLPSV L AQES VTPYIAML NG EPIGYAQSYVAL
164 ---E---TDP W-----Q--------------IYWLLNKKTK------ELIGFVTTYKYW
36 EV EE M MNPE RIAVAAVD QD ELVGFIGAIPQY
40 LV FDR HH E SMVILK NK QKVIGGICFRQ
55 FA A RL SGQ LTLIATL QG VPVGFASLKG
46 DL QT L EVDP RRRAFLLFL GQ EPVGYLDAKL
3 A TA WR TLVP TDGAVVVRD GS EVVGMALYMD
43 YLPSV LAQESVT PYIAML NG EPIGYAQSYVAL
36 DD F NFG RFLDPN IKMWAAVAVES SS EKIIGMINFFN
50 L KA D IAAG SLLLWVVAE DD NVLASAQLSL
4 W E HT LGG MHALIWH HG AIIAHAAVIQ
40 G K D EFA IHVFATD KRGE QPAIAAYARLLP
24 lva vigfg
72 FPSQ ----G TEIVFCA T-SNEQV GYGTH NHLKEYHIK
72 EERLTQESLALHRPRGH ------- SAHLHALAVH-RSFRQQGKGSVLLWRYLHHVGA
8 ERKIIH--ELGLCGHIEDIAVN-SKYQGQGLGKLLI QLVTIGFD
219 ---------------H DH------PGLGEVYVLGVD-PAAQRRGLGQMLTSIGIVSLAR
8 R KRVRH ------ GDLFIVI-G-KRYWNNGLGSLLLEE IEW QA
58 AEHSEL QGQKQYQLRGMATL-EGYREQKAGSSLIKHAEEILRK
65 RHDYVNGCDSSPVVFLEGIFVL-PSFRQRGVAKQLIAAVQRW TN
67 GIT -- GW LHPLVVE-SSRRKNQIGTRL NYLEKEVAS
86 EPIN-------- KA YIGYWLD- FQGQGIMSQSLQALMT YAR
60 VLD --- EATLFNIAVD-PDFQRRGLGRMLLEHLIDELET
73 GSGDG WWEEETDPG -- -V GIDQL ANASQLGKGLGTKLVRALVELLFN
93 HY---------ID KFR--------- -A ISQFLIF-PPYQNKGHGSCLYEAIIQSWLE
67 GIT -- GW LHPLVVE-SSRRKNQIGTRL NYLEKEVAS
67 YKPQ --R AEVAFLAVT-ANEQVRGYGTRLMNKFKDHMQK
82 P --------- -DHIDMLYVH- DYVGRDVGTTLI LEKL GA
76 GYPE------AED TLSLLLIR-EDHQGRGLGRQALERFAAGLDG
6 LRLTVPGEV LPTAGLSFVAVA-PTHRRRGLLRAMCAELHRRIAD
75 GSGDG WWEEETDPG --- -V GIDQL ANASQLGKGLGTKLVRALVELLFN
72 HMTTWD --FKDKIYINDLY D- SRVKGAGGKLIQFVYDEADK
79 CQKPN GLNRAEVQKLM L-PSARGRGLGRQLMDEVEQVAVK
67 RRLIYRG-NALRCGYVEGVAVR- WRGQRLVSALLDAVEQVMRG
69 GDDI - PE TIDKILTS-AAHRDDRTIDALI HVLAAAHA
30 - -a i l kglgt lm- l - v-
109 HD IL NFLT YADE Y A GYFKKQ G
1 QPA VR RAVL MCED A VPFYQRF G
1 3 YG CY KIIL DCDE K NVKFYEKCGF
257 RLKTLDP V P A LL YVES N -- --- - A VRTYQS -G
118 SGI LR RLQL TVQ RNQ AAVHLYQKH G
100 RG AD LLWC NART S ASGYYKKL G
109 G CR EMAS DTS ENT ISQKVHQALGF
10 G GI TIYL GTDDLDHGTTLSQTDLYEHTFDKVASIQNLREHPYEFYEKL G
1 2 RGD IR RFVI KCRV DNQ ASNAVAR N H
95 RG VV TLWL EVR SNA AAIALYESL G
119 DPE VT KIQT DPSP SNL RAIRCYEKAGF
232 DKS IT EITVED NE-- A-- - - -FD LRDRN-D
10 G GI TIYL GTDDLDHGTTLSQTDLYEHTFDKVASIQNLREHPYEFYEKL G
104 QN IE YLLT YADN F A GYFKKQ G
114 RG A ILTV DASD N AEFFAKR G
11 V RRLYAV VYGH NP KAKAFFQAQGF
105 SG YP VAAL HASE GG IY GRF G
1 DPE VT KIQT DPSP SNL RAIRCYEKAGF
113 LG TP SVYW CTDE SNH RAQLLYVKV G
119 HK RG LLHL DTEA GS VAEAFYSAL A
110 AY Q LGAL SSS R ARRLYASR G
107 RWP DA PVRV QAPA P REGFYNRF G
36 g i l a yy k g
13 F SKEIKIPKTKYV Y KDYEGA
1 4 HPAGPCAIVVGSLTFTEMHCS
146 S NAGVEMQIRK
2 9 -- - - ------ -------- - TTYSVDTAYA -------
1 4 VIEGSQERGAYIEEGKFIDVY
122 F SEQGEVFDTPPVGPHILMYKR
1 5 E ETERVIFYRKRC
152 Y KIVGVLPNANGWDKPDIWMAK
148 TLEGCMKQA YLNGDYHDVNM
120 F NEATIRRNYYPT QGHEDAII
1 6 E RQ TVTTPDG AV MVQTRQA
256 IQRLRK GY A FQ HSDLSDEFLESSRKSLKLE RQFNRLVEMLLLLNNS---------
152 Y KIVGVLPNANGWDKPDIWMAK
126 F TKEHRMPQE WK Y KDYDGG
136 Y VAKQRNTVSINGEWLANTTMT
138 RYVKDG GPTLTWY VRPL
125 Y GPATTLHELT DRRFARFHAD
1 8 E RQ TVTTPDG AV MVQTRQA
1 8 Y KAPKILYKR GY
143 Y TRVGELPGYCATPDGR HPTA
13 LPWHGPTSVLAPTGPVRTPDD
13 F R VDGPYLEHG P VGM RAA
42 f i
153 TLMGCELNPR --- - ----------------------
166 L --- - -- ---------
 --- --- --- - -- ---------
   ---- - --- - -- ----------
166 LMGKLI --- -- ---------
144 IT -- --- - --------
 ---- --- - -- ---------
174 TIIPRPD --- -- --- ----------
170 YARIIDAD -- --- - -- ---------
142 MALPISMKLH --- - -- ---------
168 FERTRS -- - --- ----------
   -- ------ -- - --- -----------
174 TIIPRPDS --- -- --- ----------
148 TLMECYIHPYVDYGR --- - ----- -------------
158 KSL -- - -- ---------
 - --- - -- ---------
147 APGGGLGGSSVRLVRPTEHRGEFEAIYERWRQQ PGGLLRPQVLWDELLAECKAAPGGDR
1 0 FERTRSDA -- - --- ----------
 -- --- - -- ---------
165 IYFKTL -- --- - ---- -----------
153 DGTVFVLPIDISLDTSAEL CDWR GDVW- - ---- -----------
152 - --------- -- ---------
48 -
Motif C 
Motif D 
Motif A 
Motif B 
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a)  
 
 
b)  
 
Figure 7.8 Conserved residues of BPSL0606: a) Equivalent residues that are 
conserved within the GNAT superfamily are plotted on the structure of 
BPSL0606 (N-terminus-blue, C-terminus-red). b) Stereo representation of a). This 
figure was produced using Pymol (Schrodinger, 2010). 
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the pantotheine arm of acetyl coenzyme A. There is some variability in the 
residues at these two positions in the family, but the two residues seen in 
BPSL0606, Ile 81 and Tyr 125 are both hydrophobic and could provide the same 
function in this protein. 
 
In addition to the analysis described above, the BPSL0606 structure was analysed 
using the Cathedral server (Redfern et al, 2007) for protein structure 
classification. As expected, there were significant structural matches between the 
BPSL0606 structure and the GNAT superfamily members, which have been 
classified into the superfamily 3.40.630.30. According to the CATH database, the 
superfamily 3.40.630.30 is in a class α-β (3) with architecture of 3-layer sandwich 
(40) containing a topology fold of aminopeptidases (630) and unassigned 
homology (30). Transferases form the majority of the members of this 
superfamily (90%) including acyltransferases that transfer groups other than 
amino-acyl groups (EC 2.3.1.xx). The GNAT superfamily has been also 
categorised in this category.  
 
The structural and sequence comparison of BPSL0606 gave strong indications 
that this protein may well have an acetyl transferase activity, perhaps catalyzing 
the transfer of an acetyl group from acetyl coenzyme A to the primary amine of 
the substrate. The next section of this chapter describes attempts to show the 
binding of acetyl coenzyme A to BPSL0606. 
 
7.4. Cocrystallisation of BPSL0606 and acetyl co-enzyme A 
Attempts to crystallise BPSL0606 with acetyl coenzyme A were made. Different 
concentrations of acetyl coenzyme A solution were mixed with freshly purified 
BPSL0606, prior to crystallisation trials. Inspection of the conditions that have 
been used to prepare complexes of various GNAT members with acetyl coenzyme 
A or coenzyme A (Table 7.2), the acetyl coenzyme A concentration used in the 
experiments with BPSL0606 ranged over 0.5 mM, 1 mM and 2 mM, which were 
equivalent to 1-fold, 2-fold and 4-fold molar excess, respectively. A mixture of 10 
mg/ml purified BPSL0606 protein and 2 mM acetyl coenzyme A solution was 
prepared. The hanging-drop based crystallisation was manually set up using a 
reservoir solution, which consisted of 14-24% PEG 3350, 0.1 M Bis-Tris propane 
! 185!
pH 6.3 and 0.2 M potassium thiocyanate, with 1:1, 1:2 and 2:1 ratios of protein 
mixture and reservoir solution. 
 
Table 7.2 Crystallisation conditions for a number of GNAT proteins. 
PDB 
ID 
GNAT proteins Organism Crystallisation conditions References 
Protein 
concentration 
(mg/ml) 
Acetyl 
coenzyme A 
concentration 
1QSR GCN5 related 
proteins 
Tetrahymena 7.5 1.5 mM Rojas et al 
(1999) 
1B87 Aminoglycoside 6’ 
N-acetyltransferase 
E. faecium 7-10 2 mM Wybenga-
Groot et al 
(1999) 
1BO4 Aminoglycoside 3’ 
N-acetyltransferase 
Serratia 
marcescens 
3.5 5 mM 
(coenzyme A) 
Wolf et al 
(1998) 
1BOB Histone  
N-acetyltransferase 
Saccharomyces 
cerevisiae 
10 2-fold molar 
excess 
Dutnall et 
al ( 1998) 
1CM0 PCAF (p300/CBP-
associating factor) 
Human 10 2-fold molar 
excess (sodium 
acetyl 
coenzyme A) 
Clements et 
al (1999) 
 
X-ray data sets from three crystals, one with 0.5 mM acetyl coenzyme A and two 
with 2 mM acetyl coenzyme A, were collected using the Diamond synchrotron 
(Table 7.3). Data processing was in similar manner as mentioned before. The 
structure determination was performed using molecular replacement in Phenix 
(Adams et al, 2010) and the solutions were obtained with LLG 2688.8, 3751.4 and 
3467.5 for the BPSL0606 crystals with 0.5 mM acetyl coenzyme A, and 
BPSL0606 with 2 mM acetyl coenzyme A, respectively. 
 
Models for each structure were rebuilt in Coot and the electron density maps were 
inspected for positive density features in the putative acetyl coenzyme A binding 
site. No electron density was present for acetyl coenzyme A in all three crystals 
(Figure 7.9). The lack of any density for the coenzyme may be because 
BPSL0606 actually does not bind acetyl coenzyme A, or that an intermediate is 
required for binding, or that the crystallisation conditions are not favourable for 
complex formation.  
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Table 7.3 Data collection statistics of crystals from the co-crystallisation 
experiments  
Data set BPSL0606 BPSL0606 BPSL0606 
+0.5 mM AcCoA +2 mM AcCoA +2mM AcCoA 
Spacegroup P 1 21 1 P 1 21 1 P 1 21 1 
Unit cell parameters:    
a (Å) 60.88 60.51 60.71 
b (Å) 81.31 81.08 80.55 
c (Å) 78.46 77.88 77.73 
α (°) 90.00 90.00 90.00 
β (°) 99.14 99.57 98.68 
γ (°) 90.00 90.00 90.00 
Temperature (K) 100 100 100 
X-ray Source DIAMOND I24 DIAMOND I03 DIAMOND I03 
Detector  ADSC Q315 CCD ADSC Q315 CCD 
Resolution (Å)1 36.00-2.81 
(2.89-2.81) 
55.76-2.18 
(2.24-2.18) 
31.97-2.31 
(2.37-2.31) 
Energy (keV) (0.97700) 12.700 12.700 
Unique observations1 18136 (1342) 36560 (2759) 32423 (2392) 
Rmerge 1,2 0.114 (0.897) 0.074 (0.462) 0.082 (0.735) 
Rpim 1 0.092 (0.559) 0.099 (0.433) 0.063 (0.545) 
Completeness (%)1 98.1 (98.7) 94.6 (96.3) 98.9 (98.9) 
Multiplicity1 2.5 (2.6) 2.3 (2.4) 3.3 (3.3) 
Mean((I)/sd(I))1 7.2 (2.0) 8.8 (2.2) 7.8 (1.8) 
1 Numbers in parentheses indicate values for the highest resolution shell 
2 Rmerge = Σhkl Σi |Ii(hkl) – 〈I(hkl)〉|/ Σhkl Σi Ii(hkl), where 〈I(hkl)〉 is the mean intensity of the 
reflection 
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Figure 7.9 No electron density for acetyl coenzyme A: The electron density map, 
contoured at 1σ, around the putative binding site of acetyl coenzyme A in 
BPSL0606 is shown in violet. The modeled position of acetyl coenzyme A seen in 
other GNAT superfamily members is shown in orange, indicating that acetyl 
coenzyme A did not bind to BPSL0606. This figure was produced using Pymol 
(Schrodinger, 2010). 
 
 
Further soaking experiments were carried out in order to increase the amount of 
acetyl coenzyme A and add magnesium chloride, which could provide a divalent 
atom to stabilise the charge on the pyrophosphate of the cofactor, which may be 
required for ligand binding. For crystal soaking, BPSL0606 crystals were 
mounted by a loop and transferred into a drop of solution containing 25% 
ethylene glycol, 22% PEG3350, 0.1 M Bis-Tris Propane pH 6.3, 0.2 M potassium 
thiocyanate, 10 mM magnesium chloride and 2 or 10 mM acetyl coenzyme A. 
The crystals were removed from the solution after soaking for 30-60 minutes.  
X-ray data collection from five crystals, which had been soaked with acetyl 
coenzyme A and magnesium chloride were performed. Statistics for the data 
collection are shown in Table 7.4. Solutions from molecular replacement were 
rebuilt and inspected in Coot. Yet again, there was no electron density for acetyl 
coenzyme A (Figure 7.10).  
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Table 7.4 Data collection statistics of crystals from the soaking experiments  
Data set BPSL0606 BPSL0606 BPSL0606 BPSL0606 BPSL0606 
+ 10 mM 
AcCoA 
1 hr 
+ 2 mM 
AcCoA 
1 hr 
+ 10 mM 
AcCoA 
1 hr 
+ 10 mM 
AcCoA  
O/N 
+ 10 mM 
AcCoA  
O/N 
Spacegroup P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1 P 1 21 1 
Unit cell parameters      
a (Å) 60.40 60.62 60.54 60.49 60.70 
b (Å) 80.51 80.65 80.38 80.75 81.06 
c (Å) 77.48 77.96 77.47 78.11 78.53 
α (°) 90.00 90.00 90.00 90.00 90.00 
β (°) 98.71 98.79 98.74 98.93 99.23 
γ (°) 90.00 90.00 90.00 90.00 90.00 
Temperature (K) 100 100 100 100 100 
X-ray Source DIAMOND 
I03 
DIAMOND 
I03 
DIAMOND 
I03 
DIAMOND 
I03 
DIAMOND 
I03 
Detector ADSC Q315 
CCD 
ADSC Q315 
CCD 
ADSC Q315 
CCD 
ADSC Q315 
CCD 
ADSC Q315 
CCD 
Resolution (Å)1 25.53-2.31 
(2.37-2.31) 
26.58-2.25 
(2.30-2.25) 
44.01-1.89  
(1.94-1.89) 
33.45-2.04 
(2.09-2.04) 
51.58-1.99 
(2.05-1.99) 
Energy (keV) 12.700 12.700 12.700 12.700 12.700 
Unique 
observations1 
32176 (2390) 34516 (2519) 58283 (4245) 45900 (3421) 50747 (3739) 
Rmerge 1,2 0.082 (0.420) 0.067 (0.656) 0.042 (0.593) 0.051 (0.406) 0.044 (0.550) 
Rpim1 0.066 (0.33) 0.061 (0.469) 0.035 (0.446) 0.051 (0.399) 0.036 (0.412) 
Completeness (%)1 99.0 (99.8) 97.4 (97.5) 99.0 (98.0) 97.1 (97.5) 99.0 (99.3) 
Multiplicity1 3.3 (3.4) 3.4 (3.6) 3.4 (3.3) 2.7 (2.6) 3.3 (3.4) 
Mean((I)/sd(I))1 8.6 (2.3) 11.2 (2.0) 14.0 (2.1) 11.7 (2.3) 13.7 (2.2) 
1 Numbers in parentheses indicate values for the highest resolution shell 
2 Rmerge = Σhkl Σi |Ii(hkl) – 〈I(hkl)〉|/ Σhkl Σi Ii(hkl), where 〈I(hkl)〉 is the mean 
intensity of the reflection 
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a)  
b)  
Figure 7.10 No acetyl coenzyme A bound to BPSL0606: Electron density maps, 
contoured at 1σ, derived from BPSL0606 crystals soaking with 10 mM acetyl 
coenzyme A and 10 mM magnesium chloride for 1 hour (a) and over-night (b). 
These results indicated that the acetyl coenzyme A did not bind to BPSL0606. 
This figure was produced using Pymol (Schrodinger, 2010). 
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7.5. Ligand observation by NMR 
One way to identify protein-ligand interactions is ligand observation using the 
nuclear magnetic resonance (NMR) technique (Jahnke & Widmer, 2004). As the 
co-crystallisation and soaking experiments had failed to show any acetyl 
coenzyme A binding to BPSL0606, it was decided to use this method in an 
attempt to show acetyl coenzyme A binding. The principle of this technique lies 
on the detectable changes in atomic resonance properties of the ligand when it is 
bound to a protein and the free ligand molecule. Upon ligand binding, a bound 
ligand temporarily behaves like a large molecule. Unlike the unbound form, 
acting as a small molecule, slower tumbling in the bound ligand is observed and 
this behaviour results in the different NMR properties including faster relaxation, 
slower diffusion and large and negative nuclear Overhauser effects (NOEs). These 
differences can be detected by measuring 1H NMR of ligand spectra with and 
without the target protein. Signals of a small molecule like ligand free in solution 
exhibit sharp line widths (Figure 7.11) whereas the broad line-width spectrum is 
observed if the ligand is bound to the target protein (Stockman & Dalvit, 2002). 
 
 
Figure 7.11 An example of ligand binding observation: Top is an expanded region 
of 1D 800 MHz 1H NMR spectrum of a small molecule bound to the protein, 
which exhibits broad line-widths as seen on protein binding. The lower trace 
shows the sharp line-width NMR spectrum of the free ligand. This illustration was 
taken from Stock and Dalvit (2002).  
! 191!
To investigate the binding of BPSL0606 and acetyl coenzyme A, a 1:1 ratio 
mixture of BPSL0606 and acetyl coenzyme A solution was observed using 1H 
NMR. Prior to the experiment, heavy water (D2O) was added to the sample in 
order to prevent the interference of water solvent signal, resulting in the sharp 
NMR signal of the sample. The results showed that the behavior of the ligand-
protein mixture in comparison to the ligand itself profile did not change (Figure 
7.12). If the acetyl coenzyme A binds to BPSL0606, a broad line width spectrum 
should be recorded. The spectrum difference confirmed that no significant broad 
line widths were detected (Figure 7.13), indicating that BPSL0606 did not bind to 
acetyl coenzyme A. Alternatively, if the binding and release of the coenzyme 
occurred at a very fast rate, then this technique would not be able to detect any 
such binding.  
 
 
 
Figure 7.12 1D 1H NMR spectra at 600 MHz for ligand observation: 1H-NMR 
spectrum of the 1:1 molar ratio of BPSL0606 and acetyl coenzyme A mixture 
(black) shows no significant signal for binding recorded.   
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Figure 7.13 1D 1H NMR spectra at 600 MHz of the acetyl coenzyme A solution: 
Top is an expanded region of the reference spectrum of acetyl coenzyme A in the 
absence of BPSL0606. Bottom is the difference of the spectrum of the mixture of 
acetyl coenzyme A and BPSL0606 when the protein spectrum was subtracted. No 
signal is indicated for the ligand binding. 
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7.6. Analysis of acetyl coenzyme A binding site 
As no direct evidence could be obtained for acetyl coenzyme A binding to 
BPSL0606, an analysis of the coenzyme binding site in the GNAT family was 
undertaken, to see of it would be possible to model acetyl coenzyme A binding to 
BPSL0606. A signature feature of the GNAT superfamily is a β-bulge between β-
strands β4 and β5, where the acetyl coenzyme A or coenzyme A is bound the 
proteins (Dyda et al, 2000). Binary and ternary complex structures of GNAT 
proteins and acetyl coenzyme A/ coenzyme A have revealed the acetyl coenzyme 
A binding site at this opening V-cleft (Figure 7.14).  
 
  
Figure 7.14 Superposition of the acetyl coenzyme A bound GNAT structures: The 
acetyl coenzyme A binding site is between the strands β4 and β5. The acetyl 
group is buried in the cleft and points toward the main chain amine of a residue on 
the strand β4. The structures shown in this figure include aminoglycoside 6’-N-
acetyltransferases from E. coli (PDB ID: 2VQY-orange) and E. faecium (PDB ID: 
1B87-yellow), a glyphosate N-acetyltransferase from B. licheniformis (PDB ID: 
2JDD-pink), a serotonin N-acetyltransferase from sheep (PDB ID: 1CJW-green) 
and a histone N-acetyltransferase from S. cerevisiae (PDB ID: 1BOB-cyan). This 
figure was produced using Pymol (Schrodinger, 2010). 
 
β4!
β5!
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To compare the interactions made by acetyl coenzyme A with GNAT family 
members, the structures of the binary/ternary complexes of acetyl coenzyme A (or 
coenzyme A) with an aminoglycoside 6’-N-acetyltransferase from E.coli (PDB 
ID: 2VQY) and E. faecium (PDB ID: 1B87), a glyphosate N-acetyltransferase 
from B. licheniformis (PDB ID: 2JDD), a serotonin N-acetyltransferase from 
sheep (PDB ID: 1CJW) and a histone N-acetyltransferase from S. cerevisiae 
(PDB ID: 1BOB) were compared. From an analysis of these structures, it can be 
seen that the conformation of the acetyl coenzyme A in the binary complexes with 
various GNAT members is very similar. From the acetyl group to the 
pyrophosphate group the conformation of acetyl coenzyme A is generally 
uniform, with the pantotheine arm lying in the cleft between the strands β4 and 
β5. The carbonyl and amide groups of the pantotheine arm make hydrogen bonds 
to both of these strands, somewhat completing the hydrogen bonding of the 
central beta sheet. As BPSL0606 has a very similar structure to the other family 
members in the region of beta strands 4 and 5, these main chain interactions 
between the protein and the acetyl coenzyme A could still be made in a binary 
complex, despite differences in the amino acid sequence. 
 
In contrast, there are some differences between various GNAT complex structures 
at the 3’ phosphate ADP of the acetyl coenzyme A. In particular, in the structure 
of histone N-acetyltransferase from S. cerevisae (PDB ID: 1BOB), the adenine 
ring is flipped to the other side, compared to other structures (Figure 7.15).    
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Figure 7.15 Different conformations of bound acetyl coenzyme A: The position of 
3’ phosphate ADP of the acetyl coenzyme A bound to GNAT structures has some 
variation. These structures shown in this figure include aminoglycoside 6’-N-
acetyltransferases from E. coli (PDB ID: 2VQY-orange) and E. faecium (PDB ID: 
1B87-yellow), a glyphosate N-acetyltransferase from B. licheniformis (PDB ID: 
2JDD-pink), a serotonin N-acetyltransferase from sheep (PDB ID: 1CJW-green) 
and a histone N-acetyltransferase from S. cerevisiae (PDB ID: 1BOB-cyan). This 
figure was produced using Pymol (Schrodinger, 2010). 
 
 
 
The majority of the contacts made between the family members and the 
pyrophosphate of acetyl coenzyme A are again hydrogen bonds to main chain 
amides. In addition, some members have interactions to side chains, with for 
example the side chains of Ser 88 and Thr 77 in a glyphosate-N-acetyltransferase 
from B. licheniformis (PDB ID: 2JDD), making hydrogen bonds to the 
pyrophosphate oxygens. In addition, the side chain of Arg 82 in an 
aminoglycoside 6’-N-acetyltransferase from S. enteritidis (PDB ID: 1S3Z) is 
close to the pyrophosphate, making stabilizing electrostatic interactions between 
the positively charged side chain and the negatively charged pyrophosphate.  
Although in many GNAT proteins the residue at an equivalent position to Thr 77 
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in the glyphosate-N-acetyltransferase (PDB ID: 2JDD) is a hydrophobic residue 
(Val or Leu) this residue is serine in the acyl coA N-acetyltransferase from P. 
aeruginosa (PDB ID: 1XEB) (Ser 83) and is also a threonine in BPSL0606 (Thr 
83), perhaps indicating that equivalent interactions are made in these two proteins. 
At the Ser 88 position in the glyphosate N-acetyltransferase (PDB ID: 2JDD) 
there is much more variation in sequence, with Arg, Pro, His Lys, Thr and Gly all 
being present at this position, indicating that this residue is not essential for acetyl 
coenzyme A binding. The residue at this position in BPSL0606 is an aspartic acid 
(Asp 94) which at first glance may preclude the close association the negatively 
charged pyrophosphate to this acidic side chain. However, the side chain of this 
residue adopts many different conformations in the wider family, so may well 
point out into the solvent in a binary complex of acetyl coenzyme A with 
BPSL0606. In addition, Arg 121 in BPSL0606 (on the opposite side of the 
pyrophosphate from Asp 94, is in an ideal position to both coordinate and stabilise 
the negatively charged pyrophosphate.   
 
The adenine ring of acetyl coenzyme A lies on the periphery of the protein, 
packing against the protein surface and can adopt a variety of different positions. 
The 3’ phosphate attached to the ribose ring, is also in different positions in the 
various family member structures, however, there is usually one or more 
positively charged side chains in the vicinity, to stabilise this group. For example, 
Lys 120 and Lys 85 in the glyphosate N-acetyltransferase (PDB ID: 2JDD), 
Arg82 in a ribosomal S18 protein RimI in S. typhimurium (PDB ID: 2CNM) and 
Lys94 in the aminoglycoside 6’-N-acetyltransferases from S. enteritidis (PDB ID: 
1S3Z). The equivalent residues to Lys 120 and Lys 85 in 2JDD are Arg 127 and 
Arg 91 in BPSL0606, respectively and could thus stabilise the 3’ phosphate in a 
BPSL0606-acetyl coenzyme A complex. 
 
In the light of the structural and functional similarity between BPSL0606 and the 
GNAT family members in the acetyl coenzyme A binding site, an acetyl 
coenzyme A molecule was modeled into the active site cleft of BPSL0606 (Figure 
7.16). As can be seen, the coenzyme fits the structure well. It must be noted, 
however, that the relative position of helix α4 is slightly different in BPSL0606 
compared to the other family members and perhaps may adjust its position on 
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coenzyme binding as the case in serotonin N-acetyltransferase structures. The 
crystal structure of the bisubstrate analogue bound serotonin N-acetyltransferase 
from sheep (Figure 7.17b) revealed a conformational change in the protein, 
compared to the apo enzyme (Figure 7.17a). When the acetyl coenzyme A 
binding site is occupied, the protein is reordered to allow the ligand access. In this 
case, the α-helix α1 was dramatically extended in length, substituting the short β-
strand and shortening the loop connected to the α-helix, α2, which was also 
extended (Figure 7.17c). 
 
 
To model an acetyl coenzyme A into BPSL0606, the structure of aminoglycoside 
6’-N-acetyltransferase (AAC6’) from E. faecium (PDB ID: 1B87) in complex 
with acetyl coenzyme A was used to compare the active site as the acetylation of 
aminoglycoside contributes to antibiotic resistance in bacteria which may be the 
case in BPSL0606.  
 
 
The main chain interactions made between acetyl coenzyme A and AAC6’, 
include the amines of five residues in the protein, which are H-bonded to the 
phosphates and pantothenic acid in the acetyl coenzyme A (Table 7.5). The α-
phosphate oxygen atoms in acetyl coenzyme A are H-bonded to the amines of Gln 
86 and Thr 89 and the β-phosphate oxygens are H-bonded to the amines of Lys 84 
and Gly 88. Also the oxygen atom in pantothenic acid interacts with the amine of 
Val 78, which is equivalent to Thr 83 in BPSL0606. Since the backbone of this 
region is similar to BPSL0606 with the exception that the peptides are flipped for 
the residues Lys 84 and Gln 86, it is possible that acetyl coenzyme A could 
interact with BPSL0606 in similar manner. Unlike other acetyl coenzyme A 
bound GNATs structures, this complex lacks a H-bond between the acetyl group 
and the main chain (equivalent to residue Phe 220 in histone N-acetyltransferase, 
PDB ID: 1BOB) due to the low positional accuracy of the acetyl group.  
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Table 7.5 The main chain interaction of the acetyl coenzyme A bound to AAC6’ 
Acetyl coenzyme A AAC6’ 
(PDB ID: 1B87) 
BPSL0606 
α-phosphate Gln 86 (NH) Arg 91 (NH) 
 Thr 89 (NH) Asp 94 (NH) 
β-phosphate Lys 84 (NH) Asp 89 (NH) 
 Gly 88 (NH) Ile 93 (NH) 
Pantotheine Val 78 (NH) Thr 83 (NH) 
 
Side chain interactions with acetyl coenzyme A, include both H-bonds made with 
the phosphate groups and hydrophobic contacts with the pantotheine arm and the 
acetyl portion of the acetyl coenzyme A molecule. Side chain residues of the 
AAC6’ involved in the acetyl coenzyme A contacts are listed in Table 7.6. The 
Lys 149 side chain in ACC6’ interacts with the 3’phosphate, this residue is 
equivalent to Arg127 in BPSL0606, which could make a H-bond as can be seen in 
other GNATs. The hydroxyl group of Thr 89 in AAC6’ makes a contact to the α-
phosphate of acetyl coenzyme A, which could also be possible using the 
equivalent residue, Asp 94, in BPSL0606. The pantothenic acid and β-
mercaptoethylamine moieties in the acetyl coenzyme A are directed into a 
hydrophobic pocket made from the side chains of Phe 146, Leu 76, Val 77 in 
AAC6’. The side chain of Tyr 147 can also make an interaction with the thiol 
group of acetyl coenzyme A. Additionally the hydrophobic side chains of Leu 73 
and Leu 109 develop the binding pocket deep enough to accommodate the acetyl 
moiety of the acetyl coenzyme A. In the V-cleft of BPSL0606, the hydrophobic 
pocket could also be used to bind acetyl coenzyme A, as the residues involved are 
similar to those in the AAC6’. 
 
These AAC6’ residues involved in these interactions and the main chain 
conformation in the acetyl coenzyme A binding site are conserved in BPSL0606, 
indicating that BPSL0606 could possibly bind acetyl coenzyme A in similar 
manner (Figure 7.16). 
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Table 7.6 Comparison of residues involved in side chain interaction made 
between AAC6’ and acetyl coenzyme A and equivalent residues in BPSL0606 
Interactions with 
AcCoA 
Residues involved 
AAC6’  
(PDB ID 1B87) 
BPSL0606 
equivalent residue 
3’-phosphate Lys 149 Arg 127 
α-phosphate Thr 89 Asp 94 
hydrophobic 
pocket for 
pantotheine 
Phe 146 Phe 124 
Leu 76 Ile 81 
Val 77 Leu 82 
Tyr 147 Tyr 125 
hydrophobic 
pocket for the 
acetyl 
Tyr 147 Tyr 125 
Leu 73 Ile 78 
Leu 109 Val 115 
  
 
 
Figure 7.16 Superposition of the BPSL0606 and the aminoglycoside 6’ N-
acetyltransferase from E. faecium (PDB ID: 1B87): The structure of BPSL0606 
(rainbow color) is superimposed on an aminoglycoside 6’-N-acetyltransferase 
(grey) with acetyl coenzyme A (purple) with a Cα-RMSD 1.3Å, showing the 
residues involving in the acetyl coenzyme A binding. This figure was produced 
using Pymol (Schrodinger, 2010). 
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a)   
b)  
c)  
Figure 7.17 The conformational change of serotonin N-acetyltransferase: Surface 
electrostatics of a) unbound structure (PDB ID: 1b6b, violet) and b) bisubstrate 
analogue bound structure (PDB ID: 1b87, green), showing the different 
conformation of serotonine N-acetyltransferase when the acetyl coenzyme A 
binding site is occupied. c) Superposition of both structures shows the different 
secondary structure. This figure was produced using Pymol (Schrodinger, 2010). 
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7.7. Analysis of substrate binding of GNATs 
In the N-acetylation reaction catalysed by the GNAT family, there is a direct 
nucleophilic attack of the amino group of the acceptor on the thioacyl carbon, 
leading to breakage of the S-C bond (Dyda et al, 2000). For this to occur, the 
amino group must be deprotonated, and thus there is often a general base close to 
the acetyl group to facilliate this. For example, in M.tuberculosis Rv1347c, His 
130 and Asp 168 lie on opposite sides of the cleft, close to the acetyl group (Card 
et al, 2005). In BPSL0606 these residues are Asp 79 and Gln 116, respectively, 
and the side chain of Asp 79 would be ideally positioned to act as a general base 
to abstract a proton from the acceptor amino group.  
 
Since acceptor substrates of the GNAT superfamily across species are widely 
diverse, it is difficult to predict the substrate of BPSL0606 from the structure 
alone. However, one of the functions of GNAT members from pathogenic 
bacteria, is to acetylate aminoglycoside antibiotics, as part of an antbiotic 
resistance strategy. A number of enzymes in this class were selected to analyse 
the binding of aminoglycoside substrates in order to try to model the substrate-
binding site in BPSL0606. These include crystal structures of aminoglycoside N-
acetyltransferases bound to aminoglycosides in the Gram-negative bacteria.  
 
Aminoglycoside N-acetyltransferases play an important catalytic role in the 
regioselective acetylation of one amine group in amionoglycoside antibiotics, 
which disrupt the bacterial protein synthesis by binding to the A-site of 16S rRNA 
(Vetting et al, 2008b). This enzymatic modification by N-acetylation of the active 
aminoglycosides inhibits antibiotic binding, resulting in difficulties in infectious 
disease treatment regimes. Aminoglycoside 6’ N-acetyltransferase (AAC6’) is the 
most common aminoglycoside-modifying enzyme found in most Gram-negative 
bacteria (Vakulenko & Mobashery, 2003). Crystal structures of AAC6’ bound to 
acetyl coenzyme A or coenzyme A and aminoglycoside substrates in E. coli 
(Vetting et al, 2008b) were chosen as models in an analysis of substrate binding. 
 
Crystal structures of ternary complexes of AAC6’ from E. coli with acetyl 
coenzyme A or coenzyme A and different aminoglycosides; kanamycin (PDB ID: 
1V0C), parmomycin (PDB ID: 2VQY) and ribostamycin (PDB ID: 2BUE), 
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revealed that the aminoglycoside substrate binding site of AAC6’ is in a cavity 
made by the anti-parallel β-sheet; β2, β3, β4 with α-helices; α1, α2 and the loop 
connected between β6 and β7 (Figure 7.18). In aminoglycosides, the 6-amino 
hexose ring, which is the target of 6’ N-acetylation, was buried in the negatively 
charge active site with the 6’ amine group pointing to the acetyl group of the 
acetyl coenzyme A. Asp 115 and Asp 152 are the crucial residues that interact 
with 3’ amine group of the 2-deoxystreptamine ring and 6’ amine group of the 
amino sugar, determining the substrate specificity (Figure 7.19).  
 
The ternary complex of AAC6’ from E. coli with acetyl coenzyme A and 
kanamycin was used to model the substrates into the BPSL0606 structure as both 
these structures share similar surface electrostatics in the active site. (Figure 7.20) 
In the complex structure, interactions are made between the main chain carbonyl 
of Ser 98 in the AAC6’ with 3”NH3 of kanamycin and the side chain of Asp 100 
with 3”NH3 and 4”-OH. This loop region is not displaced in BPSL0606, therefore, 
it is not possible to have these interactions in BPSL0606. However, the crucial 
residues for the binding of aminoglycoside, described above, are present in the 
same position in BPSL0606. The residues involved in substrate binding in AAC6’ 
(Asp 115 and Asp 152) are similar in BPSL0606 which are Asp 79 and Gln 116, 
respectively, and the side chains of these two residues could be H-bonded with the 
3’ amine group of the 2-deoxystreptamine ring and 6’ amine group of the amino 
sugar in the kanamycin, similar to the AAC6’ complex structure (Figure 7.21). 
 
The substrates acetyl coenzyme A and kanamycin were modeled into the 
BPSL0606 structure to propose a putative active site for this protein (Figure 7.22 
and 7.23). Although both acetyl coenzyme A and kanamycin fit in the active site 
groove of BPSL0606, it is by no means certain that these are the actual substrates 
of this protein and further crystallographic and biochemical analyses must be 
carried out to determine the function of BPSL0606. 
 
 
! 203!
a)   
b) c)  
Figure 7.18 Crystal structure of the aminoglycoside 6’ N-acetyltransferase from E. coli 
complexed with acetyl coenzyme A and different aminoglycoside substrates: a) A cartoon 
representation of the structure of AAC6’ colored from N-terminus (blue) to C-terminus 
(red) are displayed with bound substrates. b) Surface electrostatics diagram of AAC6’ 
(negative charge in red and positive charge) shows the active sites within the cavity 
where the substrates were bound to the enzyme. c) Aminoglycoside substrates; 
kanamycin (pink), parmomycin (purple), ribostamycin (orange). This figure was 
produced using Pymol (Schrodinger, 2010). 
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Figure 7.19 The active site of AAC6’: Asp 115 and Asp 152 in the AAC6’ are 
significant determinants for aminoglycoside substrate specificity in the catalysis 
of 6’N-acetylation. This figure was produced using Pymol (Schrodinger, 2010). 
 
 
 
a) b)  
Figure 7.20 Surface electrostatics of the structures of AAC6’ complex with 
substrates (a) and BPSL0606 (b): An opening tunnel in BPSL0606 could possible 
be occupied by the acetyl coenzyme A and kanamycin, similar to the AAC6’. This 
figure was produced using Pymol (Schrodinger, 2010). 
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Figure 7.21 The proposed kanamycin binding site of BPSL0606:  Gln 116 and 
Asp 79 in BPSL0606 could stabilise a substrate such as kanamycin in the active 
site. This figure was produced using Pymol (Schrodinger, 2010). 
 
 
Figure 7.22 The proposed acetyl coenzyme A binding site of BPSL0606: Arg 127 
is H-bonded to the 3’phosphate of the acetyl coenzyme A, and the pantotheine 
and acetyl group lie in the hydrophobic pocket. This figure was produced using 
Pymol (Schrodinger, 2010). 
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Figure 7.23 Model of BPSL0606 complex with acetyl coenzyme A and 
kanamycin: Both acetyl coenzyme A and kanamycin could occupy the cavity, 
which may well be the active site of this protein. This figure was produced using 
Pymol (Schrodinger, 2010). 
 
 
7.8. Chapter summary 
Analysis of the BPSL0606 structure has shown that it is structurally similar to the 
GCN-5 related N-acetyltransferase superfamily, in which these proteins use acetyl 
coenzyme A as a functional group donor. Known structures of these superfamily 
members with acetyl coenzyme A were examined and superposed with the 
BPSL0606 structure. Conserved residues among the GNAT family were 
identified and the equivalent residues in BPSL0606 were shown to be similar. 
Cocrystallisation of BPSL0606 and acetyl coenzyme A were set up, but X-ray 
data sets showed that acetyl coenzyme A did not appear in these crystals. Also, 
ligand observation by 1D 1H NMR suggested that BPSL0606 did not bind to 
acetyl coenzyme A. Despite this, the proposed complex of BPSL0606, acetyl 
coenzyme A and kanamycin can be modeled at the putative binding site in 
BPSL0606. 
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Chapter 8: Conclusions and Future work 
 
This chapter summarises the work that contributed to this PhD research. From the 
results obtained, the findings of this thesis provide some informative data as part 
of a directed structural genomics project of B. pseudomallei. Suggestions for what 
could be further investigated are also included.  
 
8.1. Summary 
Since little is known about molecular mechanisms and virulence in B. 
pseudomallei, the potential targets from previously identified putative essential 
genes and immunogenic proteins were selected for this PhD research in order to 
gain more knowledge and informative data from structural studies. Beginning 
with seven target genes, four full-length genes (BPSS0945, BPSS0603, 
BPSS0683, BPSL0606) and one truncated gene (BPSL3022) were successfully 
cloned. Two of them, BPSS0945 and BPSL0606, were expressed in a soluble 
form, which enabled protein crystallisation trials. BPSS0945, a putative subfamily 
M23 unassigned peptidase was unstable, which resulted in a non-homogenous 
protein sample and thus caused crystallisation failure. Only one protein, 
BPSL0606, crystallised sucessfully which enabled a structure to be determined by 
protein crystallography.  
 
The success rate in each step is illustrated in Figure 8.1. This 14% success rate 
compared fairly favourable with a predicted rate of 10-20% for a straightforward 
a bacterial protein crystal structure determination (Rupp, 2010). Success rates in 
each step of structure determination from large structural genomic consortia over 
the world are ranging from one-third to two-thirds of the time (Terwilliger et al, 
2009). According to published data from worldwide structural genomic centers, 
crystal structures have been obtained approximately 3% of total cloned targets 
(http://targetdb-dev.rutgers.edu/statistics/TargetStatistics.html). Soluble protein 
expression and crystallisation are still challenging tasks to feed crystallographic 
work, despite the fact that 15-20% of less than 50 kDa non membrane proteins are 
likely to be suitable for structural biology (Edwards et al, 2000).  
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Figure 8.1 Pyramid of attrition rate in key steps of the structure determination 
project: From target selection, the molecular cloning has a reasonable success rate 
but soluble protein expression and crystallisation have a major impact on 
crystallographic studies. Numbers of genes/proteins in this project that were 
successful in each step are shown in parentheses.  
 
 
BPSL0606 was successfully cloned, expressed as a full-length protein and 
purified. Analysis of the purified protein by mass spectrometry confirmed the 
presence of full-length protein (23.5 kDa), prior to crystallisation trials. Native 
and selenomethionine substituted protein crystallised in space group P21 from 
solutions of 14-24% PEG3350, 0.1 M Bis-tris propane pH 6.3-6.5 and 0.2 M 
potassium thiocyanate, yielding reasonable size single long rod crystals suitable 
for data collection. The crystal structure of BPSL0606 was determined using 
MAD method, to a resolution of 2.2 Å. The 65 C-terminal residues of the protein 
were not visible in the electron density map and the crystals were investigated to 
see if any proteolysis had occurred. SDS PAGE of dissolved crystals showed that 
the molecular weight had reduced to 17 kDa, indicating some truncation of the 
protein, by an, as yet unknown, mechanism.  
 
Target selection 
(7) 
Gene cloning 
(5) 
Protein expression & 
purification 
(2) 
Crystallization 
(1) 
Structure 
(1) 
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Attempts were made to crystallise the truncated protein, from a protein sample 
that was two months old. The mass spectrometry analysis of this sample showed it 
to have a molecular weight of 17 kDa consistent with it representing residues 1-
159. This sample did not crystallise in the same way as the original “full-length” 
sample, forming crystals both under different conditions (25% PEG3350, 0.1 M 
Bis-tris pH 5.5 and 0.2 M ammonium sulphate) and also in a different space group 
(P212121, a=, 60.9 b=75, c=78.2 Å, α=β=γ=90°). The crystal structure obtained 
from the truncated protein was determined at 2.2 Å resolution by molecular 
replacement using the previous structure.   
 
These two structures of BPSL0606 had a similar conformation but showed 
differences in crystal packing in the different layers. The BPSL0606 P21 crystal 
form had four copies in the asymmetric unit, whereas the P212121 crystal form had 
two molecules in the asymmetric unit.  
 
The crystal structure of BPSL0606 consists of eight β-strands and three α-helices, 
including a turn of 310-helix. Structure comparison to the published known 
structures in the protein data bank revealed that BPSL0606 is structurally similar 
to the GCN5-related N-acetyltransferase (GNAT) superfamily. Structure based 
alignment of BPSL0606 the known GNATs structures showed the conservation of 
residues in four signature motifs of the GNAT superfamily.  
 
The dimer formation in crystal packing agrees with gel filtration analysis, which 
predicted that BPSL0606 is likely to be a dimeric protein, not a monomer. The 
dimer interface in the BPSL0606 structure buries approximately 11% of the 
subunit surface area. Two of the residues of the dimer interface (Leu 11 and Ser 
12) are also conserved among the other similar GNAT dimers. The BPSL0606 
interface is also similar to a number of interfaces that belong to GNAT 
superfamily members.  
 
From structure analysis, binding of acetyl coenzyme A seemed possible for 
BPSL0606, as residues involved in the acetyl coenzyme A binding in GNATs are 
also conserved in BPSL0606. The V-cleft made by strands β4 and β5 in 
BPSL0606 also provides possible tunnel that could accommodate acetyl 
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coenzyme A as is seen in the GNAT family members. However, co-crystallisation 
of BPSL0606 and acetyl coenzyme A suggested that BPSL0606 did not bind to 
the acetyl coenzyme A and there was also no indication of binding by acetyl 
coenzyme A and BPSL0606 from ligand observation by H1NMR. A key residue 
in the acetyl coenzyme A binding in the GNAT family is a glycine or alanine 
lying in the pocket. The equivalent residue in BPSL0606 is an isoleucine, Ile 93, 
and this large side chain may prevent acetyl coenzyme A binding. However, it 
must also be mentioned that binary complexes cannot always be crystallised for 
other GNAT members, for example, Rv1347c, a putative antibiotic resistance 
protein from M. tuberculosis. 
 
Since BPSL0606 may be related to one of the GNAT members, aminoglycoside 
N-acetyltransferases, which are involved in antibiotic resistant mechanisms, 
attempts were made to model acetyl coenzyme A and kanamycin into the 
structure of BPSL0606 and a putative active site in BPSL0606 was proposed. As 
the crucial residues for aminoglycoside binding are conserved in BPSL0606 (Asp 
79 and Gln 116), it is possible that kanamycin could accommodate the putative 
binding site even though there is much less negative charge than the 
aminoglycoside N-acetyltransferase.  
 
 
8.2. Future work 
Although the findings in this thesis, provided useful molecular and structural 
information for B. pseudomallei, there are still fundamental research questions 
awaiting further investigations.  
 
As it has proved difficult to show that BPSL0606 binds to acetyl coenzyme A, 
further investigations could include a structure comparison to the acyl homoserine 
lactone (AHL) synthase (LasI) structure from P. aeruginosa (PDB ID: 1RO5). 
This structure is also similar to BPSL0606, however, LasI catalyses a different 
reaction from other members of the GNAT superfamily. Unlike GNAT members, 
LasI uses S-adenosyl-L-methionine (SAM) and acyl acyl-carrier protein (acyl 
ACP) as substrates (Gould et al, 2004). It is possible, therefore, that BPSL0606 
also uses SAM and acyl ACP as binding partners, and cocrystallisation with 
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different substrates including SAM, acyl-ACP and their analogues would be 
carried out to further characterise the active site of BPSL0606. The ternary 
complex structure of TofI from B. glumae and substrates (Chung et al, 2011) 
could also be useful for analysis of potential substrate binding sites. Superposition 
of these structures on to the BPSL0606 structure would assist an identification of 
putative substrate binding sites in BPSL0606. 
 
In addition, a ligand binding assay may also provide a clue in biological function 
of BPSL0606 and could lead to the rational drug and/or inhibitor design. A 
thermal shift assay can be employed to assist a screening of possible substrates 
that could be bound to BPSL0606 and identify the protein-ligand interaction. 
 
A pull down assay of an affinity tagged BPSL0606 against B. pseudomallei cell 
extract would be done in order to determine whether cellular molecules, for 
example signaling molecules like AHL, could interact with BPSL0606. Due to the 
laboratory safety regulation of the harmful pathogen, BPSL0606 homologues in 
closely non-pathogenic strain such as B. thailandensis and B. cenocepacia can be 
substituted for the biochemical studies. For these studies it may be beneficial to 
clone the equivalent protein to BPSL0606 from the non-pathogenic strains of 
Burkholderia. 
 
To clarify sequence differences seen in BPSL3022, BPSS0945, BPSS0603 and 
BPSL0606 whether these have occurred as a result of a mutation from PCR or a 
real strain variation, the amplification and cloning of these genes should be 
repeated and a number of recombinant clones should be sequenced.    
 
Further work on other target proteins studied in this thesis could involve: 
-BPSL3022 cell division protein FtsQ: Making different constructs and 
optimizing the protein expression condition to obtain the soluble protein for 
crystallisation. 
 
-BPSS0945 subfamily M23B unassigned peptidases: Making different constructs 
without the possible signal peptide region to produce the mature protein which 
may be more stable than the full-length protein. In addition, to inactivate the 
autolysis of the protein, protease inhibitors could be used. 
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-BPSS0603: A new clone without sequence difference could be made and the 
soluble protein expression could possibly be observed. 
 
-BPSS0683: Soluble protein expression could be achieved by co-expression of 
molecular chaperones such as GroES-GroEL, DnaK-DnaJ-GrpE and ClpB, which 
could assist the in vivo protein folding. 
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Appendix 
 
 
 
Figure 3.1 The pETBlue-1 vector map and cloning and expression region. The 
vector contains a pre-digested EcoRV cloning site which provides optimal space 
from the ribosome bind site (RBS) for efficient translation initiation when the 
ligated insert begins with 5’ ATG. The protein expression is driven by a strong T7 
RNA polymerase promoter with an inducible lac apparatus. 
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Figure 3.2 The pET24-a vector map and cloning and expression region. The 
pET24-a vector contains multiple cloning sites (RBS) with a kanamycin selective 
marker and also provides an optional C-terminal His tag fusion. It facilitates 
protein expression driven by a strong T7 RNA polymerase promoter with an 
inducible lac apparatus. 
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